{"id":"remdesivir","rwe":[{"pmid":"41901743","year":"2026","title":"Therapeutic Drug Monitoring of GS-441524 in Cats with Feline Infectious Peritonitis: Pharmacokinetic Variability and Implications for Dose Optimization.","finding":"","journal":"Pathogens (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41893449","year":"2026","title":"Successful Treatment of Persistent and Relapsing COVID-19 with Ensitrelvir in a Patient with Obinutuzumab-Induced Long-Term B-Cell Depletion: A Case Report.","finding":"","journal":"Reports (MDPI)","studyType":"Clinical Study"},{"pmid":"41889454","year":"2026","title":"Outcome of and Risk Factors for Mortality in Pediatric Coronavirus Disease 2019 Encephalitis During the 2022 Omicron Wave in Taiwan: A National Retrospective Study.","finding":"","journal":"Open forum infectious diseases","studyType":"Clinical Study"},{"pmid":"41887113","year":"2026","title":"Discovery of orally bioavailable N-acylated remdesivir derivatives with potent broad-spectrum antiviral activity.","finding":"","journal":"Bioorganic chemistry","studyType":"Clinical Study"},{"pmid":"41876770","year":"2026","title":"In silico evaluation of FDA-approved antivirals and corticosteroids against SARS-CoV-2.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"}],"_fda":{"id":"2399f66f-aacb-4743-8117-b722c91b4bac","set_id":"c0978fa8-53ff-4ca2-82a7-567fd3e958ca","openfda":{"nui":["N0000193948"],"unii":["3QKI37EEHE"],"route":["INTRAVENOUS"],"rxcui":["2284960","2367758","2395502","2395504"],"spl_id":["2399f66f-aacb-4743-8117-b722c91b4bac"],"brand_name":["Veklury"],"spl_set_id":["c0978fa8-53ff-4ca2-82a7-567fd3e958ca"],"package_ndc":["61958-2902-2","61958-2901-2"],"product_ndc":["61958-2901","61958-2902"],"generic_name":["REMDESIVIR"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["REMDESIVIR"],"pharm_class_epc":["SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]"],"manufacturer_name":["Gilead Sciences, Inc."],"application_number":["NDA214787"],"is_original_packager":[true]},"version":"23","pregnancy":["8.1 Pregnancy Risk Summary Available data from a clinical trial (IMPAACT 2032), published reports, the COVID-PR pregnancy exposure registry, and compassionate use of remdesivir in pregnant individuals have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following exposure in the second and third trimester. However, there are insufficient pregnancy data available to evaluate the risk of remdesivir exposure during the first trimester. A study evaluating the pharmacokinetics of remdesivir during pregnancy demonstrated no clinically relevant differences between pregnant and non-pregnant individuals. No dose adjustments are recommended in patients who receive VEKLURY during pregnancy (see Data ) and [see Clinical Pharmacology (12.3) ] . In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryo-fetal development when administered to pregnant animals at systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS-441524) that were 4 times (rats and rabbits) the exposure in humans at the recommended human dose (RHD) (see Data ). There are maternal and fetal risks associated with untreated COVID-19 in pregnancy (see Clinical Considerations ). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo-fetal risk COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death. Data Human Data A non-randomized, open-label clinical study (IMPAACT 2032) evaluated pharmacokinetics and safety of up to 10 days of treatment with VEKLURY in 25 hospitalized pregnant and 28 hospitalized non-pregnant individuals of childbearing potential. Subjects received VEKLURY 200 mg once daily for 1 day followed by VEKLURY 100 mg once daily on subsequent days via intravenous infusion. Subjects were enrolled prior to their fourth VEKLURY infusion. Assessments occurred at the following intervals: Screening; Pre-infusion (defined as 48 hours prior to start of first infusion); each infusion day; 48 hours after the last infusion; 7 days after the last infusion; 4 weeks after the last infusion. Assessments also occurred 24 hours post-delivery in subjects who delivered. Treatment with VEKLURY was stopped in subjects who were discharged from the hospital prior to the completion of 10 days of treatment. Of the 25 pregnant subjects, median age was 33 years (Q1, Q3: 27 years, 37 years); 40% were White, 24% were Black, and 48% were Hispanic or Latino. A total of 9 subjects (36%) were on high-flow oxygen; 12 subjects (48%) were on low-flow oxygen; and 1 subject (4%) was on room air, at baseline. Three subjects (12%) did not have data available on baseline oxygen status. The overall median (Q1, Q3) duration of symptoms prior to hospitalization was 7 (6, 9) days. The overall median (Q1, Q3) duration of symptoms prior to first dose of VEKLURY was 8 (6, 9) days. Of the 25 pregnant subjects, median gestational age was 28 weeks at baseline (range 22 to 33 weeks) and about half of subjects were in each of the second and third trimester of pregnancy. No clinically relevant differences in the pharmacokinetics of remdesivir or its metabolites (GS-704277 and GS-441524) were observed between pregnant (n=21) and non-pregnant (n=22) individuals [see Clinical Pharmacology (12.3) ] . No difference in pharmacokinetics of remdesivir or its metabolites is expected between the first and second/third trimesters. The adverse reactions observed were consistent with those observed in clinical trials of VEKLURY in adults [see Adverse Reactions (6.1) ] . There were no adverse reactions in infants born during the study (n=16). Animal Data Remdesivir was administered via intravenous injection to pregnant rats and rabbits (up to 20 mg/kg/day) on Gestation Days 6 through 17, and 7 through 20, respectively, and also to rats from Gestation Day 6 to Lactation/Post-partum Day 20. No adverse effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed in rats and rabbits at nontoxic doses in pregnant animals. During organogenesis, exposures to the predominant circulating metabolite (GS-441524) were 4 times higher (rats and rabbits) than the exposure in humans at the RHD. In a pre/postnatal development study, exposures to the predominant circulating metabolite of remdesivir (GS-441524) were similar to the human exposures at the RHD."],"overdosage":["10 OVERDOSAGE There is no human experience of acute overdosage with VEKLURY. Treatment of overdose with VEKLURY should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with VEKLURY."],"description":["11 DESCRIPTION VEKLURY contains remdesivir, a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor. The chemical name for remdesivir is 2-ethylbutyl N -{( S )-[2- C -(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-d-altrononitril-6- O -yl]phenoxyphosphoryl}-L-alaninate. It has a molecular formula of C 27 H 35 N 6 O 8 P and a molecular weight of 602.6 g/mol. Remdesivir has the following structural formula: VEKLURY for injection contains 100 mg of remdesivir as a sterile, preservative-free lyophilized white to off-white to yellow powder in a single-dose clear glass vial. It requires reconstitution and then further dilution prior to administration by intravenous infusion [see Dosage and Administration (2.5) ] . The inactive ingredients are 3 g betadex sulfobutyl ether sodium and may include hydrochloric acid and/or sodium hydroxide for pH adjustment. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied VEKLURY for injection, 100 mg (NDC 61958-2901-2) is supplied as a single-dose vial containing a sterile, preservative-free white to off-white to yellow lyophilized powder. It requires reconstitution and further dilution prior to administration by intravenous infusion [see Dosage and Administration (2.5) ] . Discard unused portion. The container closure is not made with natural rubber latex. Storage and Handling These products contain no preservative; therefore, partially used vials should be discarded [see Dosage and Administration (2.6) ] . Store VEKLURY for injection, 100 mg vials below 30°C (below 86°F) until required for use. After reconstitution, use vials immediately to prepare diluted solution. Dilute the reconstituted solution in 0.9% sodium chloride injection, USP within the same day as administration. The diluted VEKLURY solution in the infusion bags can be stored up to 24 hours at room temperature (20°C to 25°C [68°F to 77°F]) prior to administration or 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F])."],"microbiology":["12.4 Microbiology Mechanism of Action Remdesivir is an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), which is essential for viral replication. Remdesivir is an adenosine nucleotide prodrug that distributes into cells where it is metabolized to a nucleoside monophosphate intermediate by carboxyesterase 1 and/or cathepsin A, depending upon the cell type. The nucleoside monophosphate is subsequently phosphorylated by cellular kinases to form the pharmacologically active nucleoside triphosphate metabolite (GS-443902). Remdesivir triphosphate (RDV-TP) acts as an analog of adenosine triphosphate (ATP) and competes with high selectivity (3.65-fold) over the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV-2 RdRp, which results in delayed chain termination (position i+3) during replication of the viral RNA. In a biochemical assay assessing RDV-TP incorporation by the MERS-CoV RdRp complex, RDV-TP inhibited RNA synthesis with an IC 50 value of 0.032 µM. RDV-TP can also inhibit viral RNA synthesis following its incorporation into the template viral RNA as a result of read-through by the viral polymerase that may occur at higher nucleotide concentrations. When remdesivir nucleotide is present in the viral RNA template, the efficiency of incorporation of the complementary natural nucleotide is compromised, thereby inhibiting viral RNA synthesis. Remdesivir triphosphate is a weak inhibitor of mammalian DNA and RNA polymerases, including human mitochondrial RNA polymerase. Antiviral Activity In Cell Culture Remdesivir exhibited cell culture antiviral activity against a clinical isolate of SARS‑CoV‑2 in primary human airway epithelial (HAE) cells with a 50% effective concentration (EC 50 ) of 9.9 nM after 48 hours of treatment. Remdesivir inhibited the replication of SARS-CoV-2 in the continuous human lung epithelial cell lines Calu-3 and A549-hACE2 with EC 50 values of 280 nM after 72 hours of treatment and 115 nM after 48 hours of treatment, respectively. Remdesivir EC 50 values for SARS-CoV-2 in A549-hACE2 cells were not different when combined with chloroquine phosphate or hydroxychloroquine sulfate at concentrations up to 2.5 µM. In a separate study, the antiviral activity of remdesivir was antagonized by chloroquine phosphate in a dose-dependent manner when the two drugs were co-incubated at clinically relevant concentrations in HEp-2 cells infected with respiratory syncytial virus (RSV). Higher remdesivir EC 50 values were observed with increasing concentrations of chloroquine phosphate. Increasing concentrations of chloroquine phosphate or hydroxychloroquine sulfate reduced formation of remdesivir triphosphate in A549-hACE2, HEp-2, and normal human bronchial epithelial cells. Based on cell culture susceptibility testing by virus yield reduction assay and/or N protein ELISA assay, remdesivir retained similar antiviral activity against clinical isolates of SARS-CoV-2 variants compared to an earlier lineage SARS-CoV-2 (lineage A) isolate, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Epsilon (B.1.429), Zeta (P.2), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Omicron variants (including B.1.1.529/BA.1, BA.2, BA.2.12.1, BA.2.75, BA.2.86, BA.4, BA.4.6, BA.5, BF.5, BF.7, BQ.1, BQ.1.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF). For these variants, the EC 50 fold change values ranged between 0.2 and 2.3 compared to an earlier lineage SARS-CoV-2 (lineage A) isolate. Using the SARS-CoV-2 replicon system, remdesivir retained similar antiviral activity against Omicron subvariants JN.1.7, JN.1.18, KP.2, KP.3, LB.1, and XBB.1.9.2 compared to the wildtype reference replicon (lineage B). In Clinical Trials SARS-CoV-2 RNA shedding results from GS-US-540-5776 (ACTT-1) indicate that remdesivir does not significantly reduce the amount of detectable SARS-CoV-2 RNA in oropharyngeal or nasopharyngeal swabs or plasma samples in hospitalized patients compared to placebo, and SARS-CoV-2 RNA shedding results from GS-US-540-9012 indicate that remdesivir does not significantly reduce the amount of detectable SARS-CoV-2 RNA in nasopharyngeal swabs in non-hospitalized patients compared to placebo. Resistance In Cell Culture SARS-CoV-2 isolates with reduced susceptibility to remdesivir have been selected in cell culture. In a selection with GS-441524, the parent nucleoside of remdesivir, virus pools emerged expressing amino acid substitutions at V166A, N198S, S759A, V792I, C799F, and C799R in the viral RdRp (nsp12). When these substitutions were individually introduced into a wild-type recombinant virus by site-directed mutagenesis, 1.7- to 3.5-fold reductions in susceptibility to remdesivir were observed. In a cell culture resistance selection experiment with remdesivir, nsp12 substitution E802D emerged, resulting in a 1.4- to 2.5-fold reduction in susceptibility to remdesivir. In another selection with remdesivir using a SARS-CoV-2 isolate containing the P323L substitution in the viral polymerase, a single amino acid substitution at V166L emerged. Recombinant SARS-CoV-2 with substitutions at P323L alone or P323L+V166L in combination exhibited 1.3- and 1.5-fold reductions in remdesivir susceptibility, respectively. Cell culture resistance profiling of remdesivir using the rodent CoV murine hepatitis virus identified two substitutions (F476L and V553L) in the viral RdRp (nsp12) at residues conserved across CoVs. Introduction of the corresponding substitutions (F480L and V557L) into SARS-CoV resulted in 6-fold reduction in susceptibility to remdesivir in cell culture and attenuated SARS-CoV pathogenesis in a mouse model. When individually introduced into a SARS-CoV-2 recombinant virus, the corresponding substitutions at F480L and V557L each conferred 2-fold reduced susceptibility to remdesivir. In Clinical Studies In a literature publication, the SARS-CoV-2 nsp12 E802D substitution previously identified in a resistance selection experiment emerged in one individual treated with remdesivir. The E802D substitution resulted in a 1.4- to 2.5-fold increase in the remdesivir EC 50 value. In Study CO-US-540-5776 (ACTT-1), among 61 subjects with baseline and post-baseline sequencing data available, the rate of emerging substitutions in the viral RdRp (nsp12) was similar in subjects treated with VEKLURY compared to placebo. Two subjects treated with VEKLURY had an emergent substitution previously identified in resistance selection experiments (nsp12 V792I in one and C799F in the other). These substitutions are associated with 2.2- and 2.5-fold decreases in remdesivir susceptibility, respectively, based on assessments of clinical isolates. In one subject treated with VEKLURY, nsp12 V792F emerged at low frequency and was associated with a 1.8-fold decrease in remdesivir susceptibility. In Study GS-US-540-5773, among 19 subjects treated with VEKLURY with baseline and post-baseline sequencing data available, the V792F substitution in viral RdRp (nsp12) emerged at low frequency in one subject. In Study GS-US-540-9012, among 244 subjects with baseline and post-baseline sequencing data available, the rate of emerging substitutions in the viral RdRp (nsp12) was similar in subjects treated with VEKLURY compared to placebo. In one subject treated with VEKLURY, one substitution in the RdRp (nsp12 A376V) emerged and was associated with a 12.6-fold decrease in remdesivir susceptibility in a subgenomic replicon assay. This subject was not hospitalized and showed alleviation of all baseline symptoms, except loss of taste and smell, prior to or on Day 14. In Study GS-US-540-5912, among 60 subjects with baseline and post-baseline sequencing data available, substitutions in the viral RdRp (nsp12) emerged in 8 subjects treated with VEKLURY. In 4 subjects treated with VEKLURY, three substitutions in the RdRp (nsp12 E136V, M794I, or C799F) emerged and were associated with 2.9-, 2.9-, and 3.4-fold reduced susceptibility to remdesivir in a subgenomic replicon assay. In Study GS-US-540-5823, among pediatric subjects with baseline and post-baseline sequencing data available, treatment-emergent substitutions in the viral RdRp (nsp12) were observed in 3 of 27 subjects treated with VEKLURY and were evaluated for susceptibility to remdesivir. In one subject, two substitutions (nsp12 substitutions V166L and V792I) emerged and were associated with 1.85- and 3.6-fold decreases in remdesivir susceptibility relative to reference, respectively. This subject was hospitalized at baseline, recovered from COVID-19, and was released from the hospital on Day 13. None of the substitutions observed in any of the other genes (nsp9–10, nsp13–14) encoding for proteins of the viral replication-transcription complex have been associated with reduced susceptibility to remdesivir. The relationship between the level of reduced susceptibility to remdesivir observed in subgenomic replicon assays and the inhibition of SARS-CoV-2 replication by remdesivir in humans has not been fully established."],"geriatric_use":["8.5 Geriatric Use Of the 1,062 hospitalized subjects with SARS-CoV-2 infection randomized in ACTT-1, 36% were 65 years or older. Of the 397 hospitalized subjects with SARS-CoV-2 infection randomized in Study GS-US-540-5773, 42% were 65 years or older. Of the 584 hospitalized subjects with SARS-CoV-2 infection randomized in Study GS-US-540-5774, 27% were 65 years or older. Of the 562 non-hospitalized subjects with SARS-CoV-2 infection randomized in Study GS-US-540-9012, 17% were 65 years or older. Reported clinical experience has not identified differences in responses between the elderly and younger patients [see Clinical Studies (14) ] . No dosage adjustment is required in patients over the age of 65 years. In general, appropriate caution should be exercised in the administration of VEKLURY and monitoring of elderly patients, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of VEKLURY for the treatment of COVID-19 have been established in pediatric patients from birth to less than 18 years of age and weighing at least 1.5 kg, who are: Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. Use in this age group is supported by the following: Trials in adults [see Clinical Studies (14.1 , 14.2 , 14.3 , 14.4 , 14.5) ] An open-label trial (Study 5823) in 58 hospitalized pediatric subjects [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14.6) ]. Use of VEKLURY in pediatric patients from birth to less than 18 years of age and weighing at least 1.5 kg is supported by Study 5823 where 58 hospitalized pediatric subjects were treated with weight-based VEKLURY for up to 10 days in the following cohorts: Cohorts 1–4, 8; infants, children, and adolescents: Subjects ≥12 years and weighing ≥40 kg (n=12); subjects <12 years and weighing ≥40 kg (n=5); subjects ≥28 days and weighing ≥20 to <40 kg (n=12); subjects ≥28 days and weighing ≥12 to <20 kg (n=12); and subjects ≥28 days and weighing ≥3 to <12 kg (n=12); Cohorts 5–7; neonates and infants: Subjects 14 to <28 days old, GA >37 weeks, and weighing ≥2.5 kg (n=3); subjects <14 days old, GA >37 weeks, and weighing ≥2.5 kg at birth (n=1); and subjects <56 days old, GA ≤37 weeks, and weighing ≥1.5 kg at birth (n=1). The safety and pharmacokinetic results in pediatric subjects were similar to those in adults [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , Clinical Studies (14.6) ]. Use of VEKLURY in pediatric patients weighing at least 40 kg is further supported by a clinical trial of VEKLURY in non-hospitalized subjects that included 3 pediatric subjects 12 years and older, and by clinical trials in hospitalized subjects that included 30 adult subjects weighing 40 to 50 kg. The safety in this weight group was comparable to adult subjects weighing greater than 50 kg. Thirty-nine pediatric patients 12 years and older and weighing at least 40 kg received VEKLURY in a compassionate use program in hospitalized subjects; the available clinical data from these patients are limited [see Adverse Reactions (6.1) and Clinical Studies (14) ]. Use of VEKLURY in pediatric patients with renal impairment is supported by safety data in adults [see Adverse Reactions (6.1) , Use in Specific Populations (8.6) ]. Limited data are available regarding the safety of VEKLURY in pediatric patients with mild or moderate renal impairment. No data are available regarding the safety of VEKLURY in pediatric patients with severe renal impairment . In adults with severe renal impairment, including those requiring dialysis, exposures of GS-441524 and GS-704277, the metabolites of remdesivir, and betadex sulfobutyl ether sodium (SBECD) are increased [see Clinical Pharmacology (12.3) ] . VEKLURY contains SBECD which, when administered intravenously, is eliminated through glomerular filtration and therefore when administered to pediatric patients with renal immaturity or renal impairment, may result in higher exposure to SBECD. The safety and effectiveness of VEKLURY have not been established in pediatric patients weighing less than 1.5 kg."],"effective_time":"20260212","clinical_studies":["14 CLINICAL STUDIES 14.1 Description of Clinical Trials The efficacy and safety of VEKLURY were evaluated in the trials summarized in Table 21. Table 21 Trials Conducted with VEKLURY in Subjects with COVID-19 Trial Population Trial Arms (N) Timepoint COVID-19: coronavirus disease 2019 NIAID ACTT-1 Randomized, double-blind, placebo-controlled trial. (NCT04280705) Hospitalized with mild/moderate and severe COVID-19 VEKLURY 10 Days (532) Placebo (516) 29 Days after Randomization GS-US-540-5773 Randomized, open-label trial. (NCT04292899) Hospitalized with severe COVID-19 VEKLURY 5 Days (200) VEKLURY 10 Days (197) Day 14 GS-US-540-5774 (NCT04292730) Hospitalized with moderate COVID-19 VEKLURY 5 Days (191) VEKLURY 10 Days (193) Standard of care (200) Day 11 GS-US-540-9012 (NCT04501952) Non-hospitalized with mild-to-moderate COVID-19 and at high risk for progression to severe disease VEKLURY 3 Days (279) Placebo (283) Day 28 GS-US-540-5823 (Cohorts 1–8) Open-label trial, descriptive outcome analyses. (NCT04431453) Hospitalized pediatric subjects from birth to <18 years of age and weighing at least 1.5 kg with COVID-19 VEKLURY up to 10 Days (58) Day 10 14.2 NIAID ACTT-1 Study in Hospitalized Subjects with Mild/Moderate and Severe COVID-19 A randomized, double-blind, placebo-controlled clinical trial (ACTT-1) of hospitalized adult subjects with confirmed SARS-CoV-2 infection and mild, moderate, or severe COVID-19 compared treatment with VEKLURY for 10 days (n=541) with placebo (n=521). Mild/moderate disease was defined as SpO 2 >94% and respiratory rate <24 breaths/minute without supplemental oxygen; severe disease was defined as an SpO 2 ≤94% on room air, a respiratory rate ≥24 breaths/minute, an oxygen requirement, or a requirement for mechanical ventilation. Subjects had to have at least one of the following to be enrolled in the trial: radiographic infiltrates by imaging, SpO 2 ≤94% on room air, a requirement for supplemental oxygen, or a requirement for mechanical ventilation. Subjects treated with VEKLURY received 200 mg on Day 1 and 100 mg once daily on subsequent days, for 10 days of treatment via intravenous infusion. Treatment with VEKLURY was stopped in subjects who were discharged from the hospital prior to the completion of 10 days of treatment. At baseline, mean age was 59 years (with 36% of subjects aged 65 or older); 64% of subjects were male, 53% were White, 21% were Black, and 13% were Asian; 24% were Hispanic or Latino; 105 subjects had mild/moderate disease (10% in both treatment groups); 957 subjects had severe disease (90% in both treatment groups). Subjects in this trial were unvaccinated. A total of 285 subjects (27%) (n=131 received VEKLURY) were on invasive mechanical ventilation or ECMO. The most common comorbidities were hypertension (51%), obesity (45%), and type 2 diabetes mellitus (31%); the distribution of comorbidities was similar between the two treatment groups. The primary clinical endpoint was time to recovery within 29 days after randomization. Recovery was defined as discharged from the hospital without limitations on activities, discharged from the hospital with limitations on activities and/or requiring home oxygen, or hospitalized but not requiring supplemental oxygen and no longer requiring ongoing medical care. The median time to recovery was 10 days in the VEKLURY group compared to 15 days in the placebo group (recovery rate ratio 1.29 [95% CI 1.12 to 1.49], p<0.001). Among subjects with mild/moderate disease at enrollment (n=105), the median time to recovery was 5 days in both the VEKLURY and placebo groups (recovery rate ratio 1.22 [95% CI 0.82 to 1.81]). Among subjects with severe disease at enrollment (n=957), the median time to recovery was 11 days in the VEKLURY group compared to 18 days in the placebo group (recovery rate ratio 1.31 [95% CI 1.12 to 1.52]). A key secondary endpoint was clinical status on Day 15 assessed on an 8-point ordinal scale consisting of the following categories: not hospitalized, no limitations on activities; not hospitalized, limitation on activities and/or requiring home oxygen; hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); hospitalized, requiring supplemental oxygen; hospitalized, on noninvasive ventilation or high-flow oxygen devices; hospitalized, on invasive mechanical ventilation or ECMO; and death. Overall, the odds of improvement in the ordinal scale were higher in the VEKLURY group at Day 15 when compared to the placebo group (odds ratio 1.54 [95% CI 1.25 to 1.91]). Overall, 29-day mortality was 11% for the VEKLURY group vs 15% for the placebo group (hazard ratio 0.73 [95% CI 0.52 to 1.03]). 14.3 Study GS-US-540-5773 in Hospitalized Subjects with Severe COVID-19 A randomized, open-label multi-center clinical trial (Study 5773) in adult subjects with confirmed SARS-CoV-2 infection, an SpO 2 of ≤94% on room air, and radiological evidence of pneumonia compared 200 subjects who received VEKLURY for 5 days with 197 subjects who received VEKLURY for 10 days. Treatment with VEKLURY was stopped in subjects who were discharged from the hospital prior to completion of their protocol-defined duration of treatment. Subjects on mechanical ventilation at screening were excluded. All subjects received 200 mg of VEKLURY on Day 1 and 100 mg once daily on subsequent days via intravenous infusion, plus standard of care. At baseline, the median age of subjects was 61 years (range, 20 to 98 years); 64% were male, 75% were White, 12% were Black, and 12% were Asian; 22% were Hispanic or Latino. More subjects in the 10-day group than the 5-day group required invasive mechanical ventilation or ECMO (5% vs 2%), or high-flow oxygen support (30% vs 25%), at baseline. Subjects in this trial were unvaccinated. Median duration of symptoms and hospitalization prior to first dose of VEKLURY were similar across treatment groups. The primary endpoint was clinical status on Day 14 assessed on a 7-point ordinal scale consisting of the following categories: death; hospitalized, receiving invasive mechanical ventilation or ECMO; hospitalized, receiving noninvasive ventilation or high-flow oxygen devices; hospitalized, requiring low-flow supplemental oxygen; hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to COVID-19); hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol for remdesivir administration); and not hospitalized. Overall, after adjusting for between-group differences at baseline, subjects receiving a 5-day course of VEKLURY had similar clinical status at Day 14 as those receiving a 10-day course (odds ratio for improvement 0.75 [95% CI 0.51 to 1.12]). There were no statistically significant differences in recovery rates or mortality rates in the 5-day and 10-day groups once adjusted for between-group differences at baseline. All-cause mortality at Day 28 was 12% vs 14% in the 5- and 10-day treatment groups, respectively. 14.4 Study GS-US-540-5774 in Hospitalized Subjects with Moderate COVID-19 A randomized, open-label multi-center clinical trial (Study 5774) of hospitalized adult subjects with confirmed SARS-CoV-2 infection, SpO 2 >94% and radiological evidence of pneumonia compared treatment with VEKLURY for 5 days (n=191) and treatment with VEKLURY for 10 days (n=193) with standard of care (n=200). Treatment with VEKLURY was stopped in subjects who were discharged from the hospital prior to completion of their protocol-defined duration of treatment. Subjects treated with VEKLURY received 200 mg on Day 1 and 100 mg once daily on subsequent days via intravenous infusion. At baseline, the median age of subjects was 57 years (range, 12 to 95 years); 61% were male, 61% were White, 19% were Black, and 19% were Asian; 18% were Hispanic or Latino. Subjects in this trial were unvaccinated. Baseline clinical status, oxygen support status, and median duration of symptoms and hospitalization prior to first dose of VEKLURY were similar across treatment groups. The primary endpoint was clinical status on Day 11 assessed on a 7-point ordinal scale consisting of the following categories: death; hospitalized, receiving invasive mechanical ventilation or ECMO; hospitalized, receiving noninvasive ventilation or high-flow oxygen devices; hospitalized, requiring low-flow supplemental oxygen; hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to COVID-19); hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol for remdesivir administration); and not hospitalized. Overall, the odds of improvement in the ordinal scale were higher in the 5-day VEKLURY group at Day 11 when compared to those receiving only standard of care (odds ratio 1.65 [95% CI 1.09 to 2.48], p=0.017). The odds of improvement in clinical status with the 10-day treatment group when compared to those receiving only standard of care were not statistically significant (odds ratio 1.31 [95% CI 0.88 to 1.95]). All-cause mortality at Day 28 was ≤2% in all treatment groups. 14.5 Study GS-US-540-9012 in Non-Hospitalized Subjects with Mild-to-Moderate COVID-19 and at High Risk for Progression to Severe Disease A randomized, double-blind, placebo-controlled, clinical trial (Study 9012) evaluated VEKLURY 200 mg once daily for 1 day followed by VEKLURY 100 mg once daily for 2 days (for a total of 3 days of intravenously administered therapy) in 554 adult and 8 pediatric subjects (12 years of age and older and weighing at least 40 kg) who were non-hospitalized, had mild-to-moderate COVID-19, were symptomatic for COVID-19 for ≤7 days, had confirmed SARS-CoV-2 infection, and had at least one risk factor for progression to hospitalization. Risk factors for progression to hospitalization included age ≥60 years, obesity (BMI ≥30), chronic lung disease, hypertension, cardiovascular or cerebrovascular disease, diabetes mellitus, immunocompromised state, chronic mild or moderate kidney disease, chronic liver disease, current cancer, and sickle cell disease. Subjects who received, required, or were expected to require supplemental oxygen were excluded from the trial. Subjects were randomized in a 1:1 manner, stratified by residence in a skilled nursing facility (yes/no), age (<60 vs ≥60 years), and region (US vs ex-US) to receive VEKLURY (n=279) or placebo (n=283), plus standard of care. At baseline, mean age was 50 years (with 30% of subjects aged 60 or older); 52% were male, 80% were White, 8% were Black, and 2% were Asian; 44% were Hispanic or Latino; median body mass index was 30.7 kg/m 2 . Subjects in this trial were unvaccinated. VEKLURY or placebo was first administered to subjects in outpatient facilities (84%), home healthcare settings (13%), or skilled nursing facilities (3%). The most common comorbidities were diabetes mellitus (62%), obesity (56%), and hypertension (48%). Median (Q1, Q3) duration of symptoms prior to treatment was 5 (3, 6) days; median viral load was 6.3 log 10 copies/mL at baseline. The baseline demographics and disease characteristics were well balanced across the VEKLURY and placebo treatment groups. The primary endpoint was the proportion of subjects with COVID-19 related hospitalization (defined as at least 24 hours of acute care) or all-cause mortality through Day 28. Events occurred in 2 (0.7%) subjects treated with VEKLURY compared to 15 (5.3%) subjects concurrently randomized to placebo (hazard ratio 0.134 [95% CI 0.031 to 0.586]; p=0.0076). No deaths were observed through Day 28. 14.6 Study GS-US-540-5823 in Hospitalized Pediatric Subjects with COVID-19 The primary objectives of this Phase 2/3 single-arm, open-label clinical trial (Study GS-US-540-5823) were to evaluate pharmacokinetics and safety of up to 10 days of treatment with VEKLURY in pediatric subjects. A total of 58 pediatric subjects from birth (including preterm to term infants) to <18 years of age and weighing at least 1.5 kg with confirmed SARS-CoV-2 infection and mild, moderate, or severe COVID-19 was evaluated in eight cohorts: Cohorts 1–4, 8; infants, children, and adolescents: Subjects ≥12 years and weighing ≥40 kg (n=12); subjects <12 years and weighing ≥40 kg (n=5); subjects ≥28 days and weighing ≥20 to <40 kg (n=12); subjects ≥28 days and weighing ≥12 to <20 kg (n=12); and subjects ≥28 days and weighing ≥3 to <12 kg (n=12). Subjects weighing ≥40 kg received 200 mg of VEKLURY on Day 1 followed by VEKLURY 100 mg once daily on subsequent days; subjects weighing ≥3 kg to <40 kg received VEKLURY 5 mg/kg on Day 1 followed by VEKLURY 2.5 mg/kg once daily on subsequent days; Cohorts 5–7; neonates and infants: Subjects 14 to <28 days old, GA >37 weeks, and weighing ≥2.5 kg (n=3); subjects <14 days old, GA >37 weeks, and weighing ≥2.5 kg at birth (n=1); and subjects <56 days old, GA ≤37 weeks, and weighing ≥1.5 kg at birth (n=1). Subjects 14 to <28 days old, GA >37 weeks, and weighing ≥2.5 kg received VEKLURY 5 mg/kg on Day 1 followed by VEKLURY 2.5 mg/kg once daily on subsequent days. Subjects <14 days old, GA >37 weeks, and weighing at least 2.5 kg at birth, and subjects <56 days old, GA ≤37 weeks, and weighing ≥1.5 kg at birth, received VEKLURY 2.5 mg/kg on Day 1 followed by VEKLURY 1.25 mg/kg once daily on subsequent days. Assessments occurred at the following intervals: Screening; Day 1 (Baseline); Days 2–10, or until discharge, whichever came earlier; Follow-Up on Day 30 (±5). Treatment with VEKLURY was stopped in subjects who were discharged from the hospital prior to the completion of 10 days of treatment. Infants, children, and adolescents: At baseline, median age was 7 years (Q1, Q3: 2 years, 12 years); 57% were female, 70% were White, 30% were Black, and 44% were Hispanic or Latino; median weight was 25 kg (range: 4 to 192 kg). Subjects in this trial were unvaccinated. A total of 12 subjects (23%) were on invasive mechanical ventilation, 18 (34%) were on non-invasive ventilation or high-flow oxygen; 10 (19%) were on low-flow oxygen; and 13 (25%) were on room air, at baseline. The overall median (Q1, Q3) duration of symptoms and hospitalization prior to first dose of VEKLURY was 5 (3, 7) days and 1 (1, 3) day, respectively. The descriptive outcome analyses showed treatment with VEKLURY for up to 10 days resulted in an overall median (Q1, Q3) change from baseline in clinical status (assessed on a 7-point ordinal scale ranging from death [score of 1] to ventilatory support and decreasing levels of oxygen to hospital discharge [score of 7]) of +2.0 (1.0, 4.0) points on Day 10. Recovery (defined as an improvement from a baseline clinical status score of 2 through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7) was reported for 62% of subjects on Day 10; median (Q1, Q3) time to recovery was 7 (5, 16) days. Overall, 60% of subjects were discharged by Day 10, and 83% of subjects were discharged by Day 30. Three subjects (6%) from Cohorts 1–4 and Cohort 8 died during the study. Neonates and infants: At baseline, subjects ranged in age from 12 to 30 days; 3/5 were female, 4/5 were White, 1/5 was Black; weight ranged from 2.2 to 3.5 kg. Three subjects were on invasive mechanical ventilation and 2 were on high-flow oxygen. The duration of symptoms and hospitalization prior to first dose of VEKLURY ranged from 2 to 9 days and 1 to 9 days, respectively. The descriptive outcome analyses showed treatment with VEKLURY for up to 10 days resulted in recovery (defined as an improvement from a baseline clinical status score of 2 through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7) for 3 subjects, including for one subject by Day 10. Time to recovery ranged from 9 to 19 days. Overall, a total of 3 subjects were discharged by Day 30, of which one subject was discharged by Day 10. No subjects from Cohorts 5–7 died during the study."],"pharmacodynamics":["12.2 Pharmacodynamics Exposure-Response Remdesivir and metabolites exposure-response relationships and the time course of pharmacodynamics response are unknown. Cardiac Electrophysiology At 3 times the maximum recommended dose, clinically significant QTc interval prolongation was not observed."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetic (PK) properties of remdesivir and metabolites are provided in Table 12. The multiple dose PK parameters of remdesivir and metabolites in adults with COVID-19 are provided in Table 13. Table 12 Pharmacokinetic Properties of Remdesivir and Metabolites (GS-441524 and GS-704277) Remdesivir GS-441524 GS-704277 ND=not detected Absorption T max (h) Remdesivir administered as a 30-minute IV infusion (Study GS-US-399-5505); range of median observed on Day 1 and Day 5 or 10. 0.67–0.68 1.51–2.00 0.75–0.75 Distribution % bound to human plasma proteins 88–93.6 Range of protein binding for remdesivir from 2 independent experiments show no evidence of concentration-dependent protein binding for remdesivir. 2 1 Blood-to-plasma ratio 0.68–1.0 1.19 0.56 Elimination t 1/2 (h) Median (Study GS-US-399-4231). 1 27 1.3 Metabolism Metabolic pathway(s) CES1 (80%) Cathepsin A (10%) CYP3A (10%) Not significantly metabolized HINT1 Excretion Major route of elimination Metabolism Glomerular filtration and active tubular secretion Metabolism % of dose excreted in urine Mean (Study GS-US-399-4231). 10 49 2.9 % of dose excreted in feces ND 0.5 ND Table 13 Multiple Dose PK Parameters Population PK estimates for 30-minute IV infusion of remdesivir for 3 days (Study GS-US-540-9012, n=147). of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of VEKLURY 100 mg to Adults with COVID-19 Parameter Mean Geometric mean estimates. (95% CI) Remdesivir GS-441524 GS-704277 CI=Confidence Interval; ND=Not detectable (at 24 hours post-dose) C max (nanogram per mL) 2700 (2440, 2990) 143 (135, 152) 198 (180, 218) AUC tau (nanogram∙h per mL) 1710 (1480, 1980) 2410 (2250, 2580) 392 (348, 442) C trough (nanogram per mL) ND 61.5 (56.5, 66.8) ND Specific Populations Pharmacokinetic differences based on sex, race, age, and renal function on the exposures of remdesivir were evaluated using population pharmacokinetic analysis. Sex and race did not affect the pharmacokinetics of remdesivir and its metabolites (GS-441524 and GS-704277). Pregnant Individuals The pharmacokinetics of remdesivir and its circulating metabolites (GS-441524 and GS-704277) were evaluated in pregnant individuals with COVID-19. Exposures (AUC tau , C max , and C tau ) of remdesivir and its circulating metabolites during pregnancy were similar to those in non-pregnant individuals (see Table 14 ). Table 14 Multiple Dose PK Parameters Study CO-US-590-5961 (IMPAACT). of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY to Pregnant and Non-Pregnant Individuals with COVID-19 Parameter Mean Geometric mean estimates. (90% CI) Pregnant Individuals (N=21) Non-Pregnant Individuals (N=22) CI=Confidence Interval Remdesivir C max (nanogram per mL) 1360 (978, 1890) 1240 (891, 1720) AUC tau (nanogram∙h per mL) 1250 (916, 1700) N=18 1300 (1070, 1590) N=17 GS-441524 C max (nanogram per mL) 113 (102, 126) 121 (108, 136) AUC tau (nanogram∙h per mL) 1840 (1630, 2070) N=20 2050 (1780, 2350) N=21 C tau (nanogram per mL) 51.6 (44.7, 59.6) 57.1 (48.7, 66.9) GS-704277 C max (nanogram per mL) 217 (187, 252) 213 (188, 240) AUC tau (nanogram∙h per mL) 454 (406, 508) 437 (384, 497) Patients with Renal Impairment The pharmacokinetics of remdesivir and its metabolites (GS-441524 and GS-704277) and excipient SBECD were evaluated in healthy subjects, those with mild (eGFR 60–89 mL/minute/1.73m 2 ), moderate (eGFR 30–59 mL/minute/1.73m 2 ), severe (eGFR 15–29 mL/minute/1.73m 2 ) renal impairment, or kidney failure (eGFR <15 mL/minute/1.73m 2 ) on dialysis or not on dialysis following a single dose of up to 100 mg of VEKLURY (see Table 15 ); and in COVID-19 patients with severely reduced kidney function (AKI [defined as a 50% increase in serum creatinine within a 48-hour period that was sustained for ≥6 hours despite supportive care]; CKD [eGFR <30 mL/minute/1.73m 2 ]; or ESRD [eGFR <15 mL/minute/1.73m 2 ] requiring hemodialysis) receiving VEKLURY 200 mg loading dose on Day 1 followed by 100 mg from Day 2 to Day 5 (see Table 16 ). Pharmacokinetic exposures of remdesivir were not affected by renal function or timing of VEKLURY administration around dialysis. Exposures of GS-441524, GS-704277, and SBECD were up to 7.9-fold, 2.8-fold, and 21-fold higher, respectively, in those with renal impairment compared to those with normal renal function (see Table 15 and Table 16 ). These changes are not considered to be clinically significant [see Adverse Reactions (6.1) and Use in Specific Populations (8.6) ] . Remdesivir was not efficiently removed through hemodialysis. Average hemodialysis clearance of GS-441524 and GS-704277 was 149 mL/minute and 92.6 mL/minute, respectively. Table 15 Comparison of PK Parameters Exposures were estimated using noncompartmental analysis from a dedicated Phase 1 renal impairment Study GS-US-540-9015; single doses up to 100 mg were administered; each subject with renal impairment had a matched control participant enrolled with normal renal function (eGFR ≥90 mL/minute/1.73m 2 ), same sex, and similar BMI (± 20%) and age (± 10 years). of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of Single Dose VEKLURY to Adults with Renal Impairment eGFR was calculated using Modification of Diet in Renal Disease equation and values represent mL/minute/1.73m 2 . as Compared to Adults with Normal Renal Function Mean Ratio (90% CI) No effect=1.0 (0.5–2.0) 60–89 mL per minute N=10 30–59 mL per minute N=10 15–29 mL per minute N=10 <15 mL per minute Pre-hemodialysis N=6 Post-hemodialysis N=6 No dialysis N=3 CI=Confidence Interval Remdesivir C max 0.96 (0.71, 1.31) 1.20 (1.01, 1.42) 0.97 (0.83, 1.13) 0.89 (0.67, 1.18) 1.13 (0.79, 1.60) 0.94 (0.65, 1.35) AUC inf 1.00 (0.75, 1.32) 1.22 (0.98, 1.52) 0.94 (0.83, 1.07) 0.80 (0.59, 1.08) 1.08 (0.72, 1.63) 0.89 (0.55, 1.43) GS-441524 C max 1.07 (0.90, 1.26) 1.44 (1.13, 1.85) 1.68 (1.28, 2.20) 2.27 (1.72, 2.99) 3.07 (2.21, 4.26) 3.00 (2.63, 3.42) AUC inf 1.19 (0.97, 1.47) 2.02 (1.57, 2.62) 3.26 (2.39, 4.46) 4.97 (3.65, 6.77) 6.22 (4.44, 8.71) 7.87 (6.49, 9.53) GS-704277 C max 2.25 (1.20, 4.20) 1.83 (1.34, 2.49) 1.27 (0.96, 1.68) 1.43 (1.00, 2.05) 1.23 (0.84, 1.80) 1.76 (1.19, 2.61) AUC inf 1.39 (1.13, 1.71) 2.01 (1.48, 2.73) 1.78 (1.27, 2.49) 2.18 (1.61, 2.95) 2.06 (1.42, 2.97) 2.81 (1.79, 4.43) Table 16 Comparison of PK Parameters of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of VEKLURY (200 mg on Day 1 Followed by 100 mg Daily on Days 2–5) in Adults with COVID-19 with Population PK estimates for 30-minute IV infusion of remdesivir for 5 days (Study GS-US-540-5912, n=90). or without Population PK estimates for 30-minute IV infusion of remdesivir for 3 days (Study GS-US-540-9012, n=148). Severely Reduced Kidney Function AKI (defined as a 50% increase in serum creatinine within a 48-hour period that was sustained for ≥6 hours despite supportive care); CKD (eGFR <30 mL/minute/1.73m 2 ); or ESRD (eGFR <15 mL/minute/1.73m 2 ) requiring hemodialysis. Mean Ratio (90% CI) No effect=1.0 (0.5–2.0) Remdesivir GS-441524 GS-704277 CI=Confidence Interval; ND=Not detectable (at 24 hours post-dose) C max 1.39 (1.25, 1.54) 4.98 (4.61, 5.38) 1.84 (1.63, 2.08) AUC tau 1.79 (1.59, 2.01) 6.59 (6.05, 7.18) 3.94 (3.50, 4.43) C tau ND 5.82 (5.25, 6.45) ND Patients with Hepatic Impairment The pharmacokinetics of remdesivir and GS-441524 were evaluated in healthy subjects and those with moderate or severe hepatic impairment (Child-Pugh Class B or C) following a single dose of 100 mg of VEKLURY (see Table 17 ). Relative to subjects with normal hepatic function, mean exposures (AUC inf , C max ) of remdesivir and GS-441524 were similar in subjects with moderate hepatic impairment and higher in subjects with severe hepatic impairment. The exposure differences in subjects with severe hepatic impairment are not considered to be clinically significant [see Use in Specific Populations (8.7) ] . Table 17 Comparison of PK Parameters of Remdesivir and GS-441524 Following IV Administration of Single Dose VEKLURY to Adults with Hepatic Impairment as Compared to Adults with Normal Hepatic Function Mean Ratio (90% CI) No effect=1.0 (0.5–2.0) Moderate Hepatic Impairment N=10 Severe Hepatic Impairment N=6 CI=Confidence Interval Remdesivir AUC inf 1.21 (0.87, 1.67) 1.56 (1.20, 2.03) C max 1.10 (0.75, 1.60) 1.03 (0.70, 1.51) Unbound AUC inf 1.15 (0.86, 1.54) 2.44 (1.93, 3.08) Unbound C max 1.04 (0.73, 1.48) 1.57 (1.08, 2.29) GS-441524 AUC inf 0.90 (0.69, 1.17) 1.31 (0.93, 1.84) C max 1.09 (0.86, 1.38) 1.48 (1.17, 1.86) C 24 0.93 (0.69, 1.24) 1.16 (0.76, 1.77) Pediatric Patients Population pharmacokinetic models for remdesivir and its circulating metabolites (GS-441524 and GS-704277), developed using pooled data from studies in healthy subjects and in adult and pediatric patients with COVID-19, were used to estimate pharmacokinetic exposures in pediatric patients aged from birth to <18 years and weighing ≥1.5 kg (Study 5823). Geometric mean estimated exposures (AUC tau , C max , and C tau ) for patients ≥28 days to <18 years old and weighing ≥3 kg (Cohorts 1–4 and 8, n=50) at the doses administered were 33% to 130% higher for remdesivir, 3% lower to 60% higher for GS-441524, and 32% to 124% higher for GS-704277 as compared to those in adult patients with COVID-19; however, the increases were not considered clinically significant. Individual estimated exposures (AUC tau , C max , and C tau ) for patients 14 to <28 days old, GA >37 weeks, and weighing ≥2.5 kg (Cohort 5, n=3); patients <14 days old, GA >37 weeks, and weighing ≥2.5 kg at birth (Cohort 6, n=1); and patients <56 days old, GA ≤37 weeks, and weighing ≥1.5 kg at birth (Cohort 7, n=1) at the doses administered were higher for remdesivir, GS-441524, and GS-704277 as compared to median exposures in adult patients with COVID-19; however, the increases were not considered clinically significant. As limited PK data were available in Cohorts 5–7, additional analyses were conducted using a simulated population. Using age and weight distributions from pediatric growth charts, simulated population datasets were created for Cohorts 5–6. Modeling and simulation incorporating maturation functions that account for renal function and drug metabolizing enzyme ontogeny with age were used to predict exposures for subjects <28 days old, GA >37 weeks, and weighing ≥1.5 kg and subjects ≥28 days old and weighing ≥1.5 to <3 kg. Predicted geometric mean exposures (AUC tau , C max , and C tau ) at the recommended doses were 10% to 96% higher for remdesivir, 15% lower to 3% higher for GS-441524, and 14% lower to 132% higher for GS-704277 as compared to those in adult patients with COVID-19; however, changes in exposure were not considered clinically significant. Results of simulated population led to the recommended dosing regimen as they more closely align with adult exposures compared to the doses studied. Plasma exposures of excipient SBECD were generally similar for all pediatric patients at the doses administered in Study GS-US-540-5823 and were similar compared to adults with normal renal function, although data are very limited [see Use in Specific Populations (8.4) ]. The multiple dose PK parameters of remdesivir and metabolites in pediatric patients with COVID-19 in Cohorts 1–4 and 8 are provided in Table 18. Table 18 Multiple Dose PK Parameters Population PK estimates for 30-minutes IV infusion of remdesivir for up to 10 days (Study GS-US-540-5823). of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY 100 mg (Cohorts 1 and 8) or 2.5 mg/kg (Cohorts 2–4) to Pediatric Patients with COVID-19 Cohort 1 Cohort 8 Cohort 2 Cohort 3 Cohort 4 Parameter Mean Geometric mean estimates. (95% CI) 12 to <18 Years and Weighing ≥40 kg (N=12) <12 Years and Weighing ≥40 kg (N=5) 28 Days to <18 Years and Weighing 20 to <40 kg (N=12) 28 Days to <18 Years and Weighing 12 to <20 kg (N=11) 28 Days to <18 Years and Weighing 3 to <12 kg (N=10) CI=Confidence Interval Remdesivir C max (nanogram per mL) 3890 (3110, 4870) 3920 (2260, 6820) 5730 (4660, 7050) 5570 (4250, 7300) 4870 (3750, 6340) AUC tau (nanogram∙h per mL) 2470 (1920, 3160) 2270 (1200, 4310) 3510 (2560, 4820) 3930 (2140, 7210) 2910 (1880, 4510) GS-441524 C max (nanogram per mL) 196 (122, 315) 163 (57.6, 461) 183 (129, 260) 171 (130, 223) 205 (174, 241) AUC tau (nanogram∙h per mL) 3430 (1980, 5920) 2640 (767, 9100) 2370 (1500, 3740) 2410 (1740, 3340) 2850 (2290, 3540) C tau (nanogram per mL) 98.5 (59.1, 164) 76.2 (23.9, 243) 59.9 (34.2, 105) 68.9 (47.4, 100) 79.7 (59.5, 107) GS-704277 C max (nanogram per mL) 308 (211, 450) 266 (137, 514) 419 (306, 575) 444 (335, 587) 385 (294, 504) AUC tau (nanogram∙h per mL) 819 (474, 1420) 518 (192, 1400) 753 (542, 1050) 733 (504, 1060) 687 (484, 973) Drug Interaction Studies In vitro, remdesivir is a substrate for enzymes CYP3A, carboxylesterase 1 (CES1), and cathepsin A (CatA) and OATP1B1 and P-gp transporters; GS-704277 is a substrate for OATP1B1 and OATP1B3. In vitro, remdesivir is an inhibitor of CYP3A, UGT1A1, OATP1B1, OATP1B3, and MATE1; however, no clinically significant effects on substrates of UGT1A1 or MATE1 are expected. No inhibitory interactions were identified for GS-704277 or GS-441524 in vitro. Remdesivir is not a substrate for CYP1A1, 1A2, 2B6, 2C9, 2C19, or OATP1B3. GS-704277 and GS-441524 are not substrates for CYP1A1, 1A2, 2B6, 2C8, 2C9, 2D6, or 3A5. GS-441524 is also not a substrate for CYP2C19 or 3A4. GS-704277 and GS-441524 are not substrates for OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2k. GS-441524 is also not a substrate for OATP1B1 or OATP1B3. Drug-drug interaction studies were conducted with VEKLURY. Table 19 summarizes the pharmacokinetic effects of other drugs on remdesivir and metabolites GS-704277 and GS-441524. Table 20 summarizes the effects of remdesivir on the pharmacokinetics of other drugs. Table 19 Effect of Other Drugs on Remdesivir and Metabolites GS-704277 and GS-441524 Coadministered Drug Dose of Coadministered Drug (mg) Remdesivir Dose (mg) N Mean Ratio (90% CI) of Remdesivir, GS-704277, and GS-441524 PK With/Without Coadministered Drug No Effect = 1.00 (0.70–1.43) C max AUC inf C 24 CI=confidence interval Cyclosporin A Interaction study conducted in healthy volunteers. 400 single dose 100 single dose 9 remdesivir 1.49 (1.38–1.60) 1.89 (1.77–2.02) - GS-704277 2.51 (2.26–2.78) 2.97 (2.75–3.20) - GS-441524 1.17 (1.12–1.22) 1.03 (0.99–1.08) 1.02 (0.95–1.10) Carbamazepine 300 twice daily 100 single dose 8 remdesivir 0.87 (0.78–0.97) 0.92 (0.83–1.02) - GS-704277 0.96 (0.84–1.10) 0.98 (0.92–1.05) - GS-441524 0.97 (0.88–1.07) 0.83 (0.78–0.89) 0.71 (0.64–0.78) Table 20 Effect of Remdesivir on the Pharmacokinetics of Other Drugs Coadministered Drug Dose of Coadministered Drug (mg) Remdesivir Dose (mg) N Mean Ratio (90% CI) of Coadministered Drug PK With/Without Remdesivir No Effect = 1.00 (0.80–1.25) C max AUC inf CI=confidence Interval Midazolam Interaction study conducted in healthy volunteers. 2.5 single dose 200 single dose 19 1.29 (1.19–1.41) 1.20 (1.14–1.26) Midazolam 2.5 single dose 200 single dose followed by 100 once daily (10 doses) Midazolam administered with last dose of remdesivir. 14 1.45 (1.23– 1.70) 1.30 (1.16– 1.45) Pitavastatin 2 single dose 200 single dose 20 1.05 (0.92–1.20) 1.17 (1.09–1.24)"],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in other sections of the labeling: Hypersensitivity Including Infusion-related and Anaphylactic Reactions [see Warnings and Precautions (5.1) ] Increased Risk of Transaminase Elevations [see Warnings and Precautions (5.2) ] The most common adverse reactions (incidence greater than or equal to 5%, all grades) observed with treatment with VEKLURY are nausea, ALT increased, and AST increased. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials in Adult Subjects The safety of VEKLURY is based on data from four Phase 3 studies in 1,476 hospitalized adult subjects with COVID-19, one Phase 3 study in 279 non-hospitalized adult and pediatric subjects (12 years of age and older weighing at least 40 kg) with mild-to-moderate COVID-19, four Phase 1 studies in 131 healthy adults, and from patients with COVID-19 who received VEKLURY under the Emergency Use Authorization or in a compassionate use program. Clinical Trials Experience in Adults with COVID-19 NIAID ACTT-1 was a randomized, double-blind, placebo-controlled clinical trial in hospitalized subjects with mild, moderate, and severe COVID-19 treated with VEKLURY (n=532) or placebo (n=516) for up to 10 days. Subjects treated with VEKLURY received 200 mg on Day 1 and 100 mg once daily on subsequent days [see Clinical Studies (14.1) ] . The collection of adverse event data in this trial was limited to severe (Grade 3) or potentially life-threatening (Grade 4) adverse events, serious adverse events, adverse events leading to study drug discontinuation, and moderate (Grade 2) severity or higher hypersensitivity reactions. Rates of adverse reactions (≥ Grade 3), serious adverse reactions, and adverse reactions leading to treatment discontinuation are presented in Table 4. Table 4 Summary of Adverse Reaction Rates in Hospitalized Subjects with Mild, Moderate, or Severe COVID-19 in NIAID ACTT-1 Types of Adverse Reactions VEKLURY N=532 n (%) Placebo N=516 n (%) Adverse reactions, Grades ≥3 41 (8%) 46 (9%) Serious adverse reactions 2 (0.4%) Seizure (n=1), infusion-related reaction (n=1). 3 (0.6%) Adverse reactions leading to treatment discontinuation 11 (2%) Seizure (n=1), infusion-related reaction (n=1), transaminases increased (n=3), ALT increased and AST increased (n=1), GFR decreased (n=2), acute kidney injury (n=3). 15 (3%) Study GS-US-540-5773 was a randomized, open-label clinical trial in hospitalized subjects with severe COVID-19 treated with VEKLURY 200 mg on Day 1 and 100 mg once daily for 5 (n=200) or 10 days (n=197). Adverse reactions were reported in 33 (17%) subjects in the 5-day group and 40 (20%) subjects in the 10-day group [see Clinical Studies (14.2) ] . The most common adverse reactions occurring in at least 5% of subjects in either the VEKLURY 5-day or 10-day group, respectively, were nausea (5% vs 3%), AST increased (3% vs 6%), and ALT increased (2% vs 7%). Rates of any adverse reactions, serious adverse reactions, and adverse reactions leading to treatment discontinuation are presented in Table 5. Table 5 Summary of Adverse Reaction Rates in Hospitalized Subjects with Severe COVID-19 in Study 5773 Types of Adverse Reactions VEKLURY 5 Days N=200 n (%) VEKLURY 10 Days N=197 n (%) Any adverse reaction, all Grades 33 (17%) 40 (20%) Serious adverse reactions 3 (2%) Transaminases increased (n=5), hepatic enzyme increased (n=1), hypertransaminasaemia (n=1). 4 (2%) Adverse reactions leading to treatment discontinuation 5 (3%) Transaminases increased (n=4), hepatic enzyme increased (n=2), LFT increased (n=2), hypertransaminasaemia (n=1), ALT increased (n=1), ALT increased and AST increased (n=2), injection site erythema (n=1), rash (n=1). 9 (5%) Study GS-US-540-5774 was a randomized, open-label clinical trial in hospitalized subjects with moderate COVID-19 treated with VEKLURY 200 mg on Day 1 and 100 mg daily for 5 (n=191) or 10 days (n=193), or standard of care (SOC) only (n=200) [see Clinical Studies (14.3) ] . Adverse reactions were reported in 36 (19%) subjects in the 5-day group and 25 (13%) subjects in the 10-day group. The most common adverse reaction occurring in at least 5% of subjects in the VEKLURY groups was nausea (7% in the 5-day group, 4% in the 10-day group). Rates of any adverse reactions, serious adverse reactions, and adverse reactions leading to treatment discontinuation are presented in Table 6. Table 6 Summary of Adverse Reaction Attribution of events to study drug was not performed for the SOC group. Rates in Hospitalized Subjects with Moderate COVID-19 in Study 5774 Types of Adverse Reactions VEKLURY 5 Days N=191 n (%) VEKLURY 10 Days N=193 n (%) Any adverse reaction, all Grades 36 (19%) 25 (13%) Serious adverse reactions 1 (<1%) Heart rate decreased. 0 Adverse reactions leading to treatment discontinuation 4 (2%) ALT increased (n=2), ALT increased and AST increased (n=1), hypertransaminasaemia (n=1), blood alkaline phosphatase increased (n=1), rash (n=2), heart rate decreased (n=1). 4 (2%) Study GS-US-540-9012 was a randomized, double-blind, placebo-controlled clinical trial in subjects who were non-hospitalized, were symptomatic for COVID-19 for ≤7 days, had confirmed SARS-CoV-2 infection, and had at least one risk factor for progression to hospitalization treated with VEKLURY (n=279; 276 adults and 3 pediatric subjects 12 years of age and older weighing at least 40 kg) or placebo (n=283; 278 adults and 5 pediatric subjects 12 years of age and older weighing at least 40 kg) for 3 days. Of the 279 subjects treated with VEKLURY, 227 subjects received at least one dose of VEKLURY at an outpatient facility, 44 subjects received at least one dose of VEKLURY in a home healthcare setting, and 8 subjects received at least one dose of VEKLURY at a skilled nursing facility. Subjects treated with VEKLURY received 200 mg on Day 1 and 100 mg once daily on subsequent days [see Clinical Studies (14.4) ] . Adverse reactions (all grades) were reported in 34 (12%) subjects in the VEKLURY group and 25 (9%) subjects in the placebo group. The most common adverse reaction occurring in at least 5% of subjects in the VEKLURY group was nausea (6%). There were no serious adverse reactions or adverse reactions leading to treatment discontinuation in either treatment group. Safety in subjects who received VEKLURY in a home healthcare setting was comparable to that observed in the overall GS-US-540-9012 study population, but these findings are based on limited data. Less Common Adverse Reactions in Adults from Clinical Trials Clinically significant adverse reactions that were reported in <2% of subjects exposed to VEKLURY in clinical trials are listed below: Hypersensitivity reactions [see Warnings and Precautions (5.1) ]. Generalized seizure Rash Laboratory Abnormalities Study GS-US-399-5505 was a Phase 1, randomized, blinded, placebo-controlled clinical trial in healthy volunteers administered VEKLURY 200 mg on Day 1 and 100 mg for either 4 days or 9 days. Mild (Grade 1, n=8) to moderate (Grade 2, n=1) elevations in ALT were observed in 9 of 20 subjects receiving 10 days of VEKLURY; the elevations in ALT resolved upon discontinuation of VEKLURY. No subjects (0 of 9) who received 5 days of VEKLURY had graded increases in ALT. The frequencies of laboratory abnormalities (Grades 3–4) occurring in at least 3% of subjects with COVID-19 receiving VEKLURY in Trials NIAID ACTT-1, 5773, and 5774 are presented in Table 7, Table 8, and Table 9, respectively. Table 7 Laboratory Abnormalities (Grades 3–4) Reported in ≥3% of Hospitalized Subjects with Mild, Moderate, or Severe COVID-19 in NIAID ACTT-1 Laboratory Parameter Abnormality Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017. VEKLURY 10 Days N=532 Placebo N=516 ALT increased 3% 6% AST increased 6% 8% Bilirubin increased 2% 5% Creatinine clearance decreased Based on the Cockcroft-Gault formula. 18% 20% Creatinine increased 15% 16% eGFR decreased 18% 24% Glucose increased 12% 13% Hemoglobin decreased 15% 22% Lymphocytes decreased 11% 18% Prothrombin time increased 9% 4% Table 8 Laboratory Abnormalities (Grades 3–4) Reported in ≥3% of Hospitalized Subjects with Severe COVID-19 in Trial 5773 Laboratory Parameter Abnormality Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017. VEKLURY 5 Days N=200 VEKLURY 10 Days N=197 ALT increased 6% 8% AST increased 7% 6% Creatinine clearance decreased Based on the Cockcroft-Gault formula. 10% 19% Creatinine increased 5% 15% Glucose increased 11% 8% Hemoglobin decreased 6% 8% Table 9 Laboratory Abnormalities (Grades 3–4) Reported in ≥3% of Hospitalized Subjects with Moderate COVID-19 in Trial 5774 Laboratory Parameter Abnormality Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017. VEKLURY 5 Days N=191 VEKLURY 10 Days N=193 SOC N=200 SOC=Standard of care. ALT increased 2% 3% 8% Creatinine clearance decreased Based on the Cockcroft-Gault formula. 2% 5% 8% Glucose increased 4% 3% 2% Hemoglobin decreased 3% 1% 6% The frequencies of laboratory abnormalities (Grades 3–4) occurring in at least 2% of subjects with COVID-19 receiving VEKLURY in Trial GS-US-540-9012 are presented in Table 10. Table 10 Laboratory Abnormalities (Grades 3–4) Reported in ≥2% of Non-Hospitalized Subjects in Trial 9012 Laboratory Parameter Abnormality Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017. VEKLURY 3 Days N=279 Placebo N=283 Creatinine clearance decreased Based on the Cockcroft-Gault formula. 6% 2% Creatinine increased 3% 1% Glucose increased 6% 6% Lymphocytes decreased 2% 1% Prothrombin time increased 1% 2% Clinical Trials Experience in Adults with COVID-19 and Renal Impairment Study GS-US-540-5912 was a randomized, double-blind, placebo-controlled clinical trial in which 163 hospitalized subjects with confirmed COVID-19 and acute kidney injury (AKI; N=60), chronic kidney disease (CKD; eGFR <30 mL/minute/1.73m 2 ; N=44), or end-stage renal disease (ESRD; eGFR <15 mL/minute/1.73m 2 ; N=59) on hemodialysis received VEKLURY for up to 5 days [see Use in Specific Populations (8.6) ]. The adverse reactions observed were consistent with those observed in clinical trials of VEKLURY in adults. Adverse reactions (all grades) were reported in 13 (8%) subjects in the VEKLURY group and 3 (4%) subjects in the placebo group. The most common adverse reactions were nausea (1%), abdominal pain (1%), and diarrhea (1%). No subjects experienced serious adverse reactions. One subject permanently discontinued treatment due to an adverse reaction: lipase increased. The frequencies of laboratory abnormalities (Grades 3–4) occurring in at least 3% of subjects with COVID-19 receiving VEKLURY in Trial GS-US-540-5912 are presented in Table 11. Table 11 Laboratory Abnormalities (Grades 3–4) Reported in ≥3% of Hospitalized Subjects in Trial 5912 Laboratory Parameter Abnormality Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017. VEKLURY 5 Days N=163 Placebo N=80 Lymphocytes decreased 27% 27% Hemoglobin decreased 25% 25% Glucose increased 15% 19% Uric acid increased 11% 4% Creatinine increased 12% 14% Albumin decreased 12% 10% Lipase increased 12% 7% Prothrombin time increased 11% 4% Prothrombin INR increased 7% 4% AST increased 6% 4% Thromboplastin time increased 5% 4% ALT increased 5% 6% Sodium increased 3% 3% Calcium increased 3% 0 Clinical Trials in Pediatric Subjects Study GS-US-540-5823 was a Phase 2/3, single-arm, open-label clinical trial in hospitalized subjects from birth to <18 years of age and weighing at least 1.5 kg with mild, moderate, and severe COVID-19 treated with weight-based VEKLURY (n=58) for up to 10 days [see Clinical Studies (14.6) ] : Cohorts 1, 8: Subjects ≥12 years and weighing ≥40 kg (n=12) and subjects <12 years and weighing ≥40 kg (n=5): Received 200 mg on Day 1 and 100 mg once daily on subsequent days. Cohorts 2–4: Subjects ≥28 days and weighing ≥20 to <40 kg (n=12); subjects ≥28 days and weighing ≥12 to <20 kg (n=12); and subjects ≥28 days and weighing ≥3 to <12 kg (n=12): Received 5 mg/kg on Day 1 and 2.5 mg/kg once daily on subsequent days. Cohort 5: Subjects 14 to <28 days old, gestational age (GA) >37 weeks, and weighing ≥2.5 kg (n=3): Received 5 mg/kg on Day 1 and 2.5 mg/kg once daily on subsequent days. Cohorts 6–7: Subjects <14 days old, GA >37 weeks, and weighing ≥2.5 kg at birth (n=1); and subjects <56 days old, GA ≤ 37 weeks, and weighing ≥1.5 kg at birth (n=1): Received 2.5 mg/kg on Day 1 and 1.25 mg/kg once daily on subsequent days. The adverse reactions observed were consistent with those observed in clinical trials of VEKLURY in adults. Infants, children, and adolescents; Cohorts 1–4, 8: Adverse reactions (all grades) were reported in 8 (15%) subjects. The most common adverse reaction occurring in at least 5% of subjects was ALT increased (6%). No subjects experienced serious adverse reactions. Two (4%) subjects permanently discontinued treatment due to adverse reactions (ALT increased [n=1], ALT increased and AST increased and hyperbilirubinemia [n=1]). Laboratory abnormalities (Grades 3–4) occurring in at least 3% of subjects with COVID-19 receiving VEKLURY in Trial 5823 and who had at least one post-baseline value for the specified test were hemoglobin decreased (18%, 9/51), eGFR decreased (18%, 7/40), creatinine increased (10%, 5/52), direct bilirubin increased (9%, 2/23), prothrombin time increased (7%, 3/46), APTT increased (7%, 3/45), lymphocytes decreased (6% 2/33), proteinuria (6%, 2/36), WBC decreased (4%, 2/51), ALT increased (4%, 2/51), glucose increased (4%, 2/52), glycosuria (4%, 2/46), potassium decreased (4%, 2/52). Neonates and infants; Cohorts 5–7: Laboratory abnormalities (Grades 3–4) were reported in 3/5 subjects: APTT increased (2/5); direct bilirubin increased (1/5); creatinine increased (1/5); prothrombin time increased (1/5); prothrombin/INR increased (1/5); and potassium increased (1/5). Emergency Use Authorization Experience in Subjects with COVID-19 The following adverse reactions have been identified during use of VEKLURY under Emergency Use Authorization: General disorders and administration site conditions: Administration site extravasation Skin and subcutaneous tissue disorders: Rash Immune system disorders: Anaphylaxis, angioedema, infusion-related reactions, hypersensitivity Investigations: Transaminase elevations"],"contraindications":["4 CONTRAINDICATIONS VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any components of the product [see Warnings and Precautions (5.1) ]. VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any components of the product. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended [see Warnings and Precautions (5.3) and Microbiology (12.4) ]. Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) [see Clinical Pharmacology (12.3) ]. 7.2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 [see Clinical Pharmacology (12.3) ]."],"mechanism_of_action":["12.1 Mechanism of Action Remdesivir is an antiviral drug with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [see Microbiology (12.4) ]."],"recent_major_changes":["Dosage and Administration Dosage and Administration Overview ( 2.1 ) 10/2025 Dosage Preparation and Administration ( 2.5 ) 10/2025 Storage of Prepared Dosages ( 2.6 ) 10/2025"],"storage_and_handling":["Storage and Handling These products contain no preservative; therefore, partially used vials should be discarded [see Dosage and Administration (2.6) ] . Store VEKLURY for injection, 100 mg vials below 30°C (below 86°F) until required for use. After reconstitution, use vials immediately to prepare diluted solution. Dilute the reconstituted solution in 0.9% sodium chloride injection, USP within the same day as administration. The diluted VEKLURY solution in the infusion bags can be stored up to 24 hours at room temperature (20°C to 25°C [68°F to 77°F]) prior to administration or 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F])."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Remdesivir is an antiviral drug with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [see Microbiology (12.4) ]. 12.2 Pharmacodynamics Exposure-Response Remdesivir and metabolites exposure-response relationships and the time course of pharmacodynamics response are unknown. Cardiac Electrophysiology At 3 times the maximum recommended dose, clinically significant QTc interval prolongation was not observed. 12.3 Pharmacokinetics The pharmacokinetic (PK) properties of remdesivir and metabolites are provided in Table 12. The multiple dose PK parameters of remdesivir and metabolites in adults with COVID-19 are provided in Table 13. Table 12 Pharmacokinetic Properties of Remdesivir and Metabolites (GS-441524 and GS-704277) Remdesivir GS-441524 GS-704277 ND=not detected Absorption T max (h) Remdesivir administered as a 30-minute IV infusion (Study GS-US-399-5505); range of median observed on Day 1 and Day 5 or 10. 0.67–0.68 1.51–2.00 0.75–0.75 Distribution % bound to human plasma proteins 88–93.6 Range of protein binding for remdesivir from 2 independent experiments show no evidence of concentration-dependent protein binding for remdesivir. 2 1 Blood-to-plasma ratio 0.68–1.0 1.19 0.56 Elimination t 1/2 (h) Median (Study GS-US-399-4231). 1 27 1.3 Metabolism Metabolic pathway(s) CES1 (80%) Cathepsin A (10%) CYP3A (10%) Not significantly metabolized HINT1 Excretion Major route of elimination Metabolism Glomerular filtration and active tubular secretion Metabolism % of dose excreted in urine Mean (Study GS-US-399-4231). 10 49 2.9 % of dose excreted in feces ND 0.5 ND Table 13 Multiple Dose PK Parameters Population PK estimates for 30-minute IV infusion of remdesivir for 3 days (Study GS-US-540-9012, n=147). of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of VEKLURY 100 mg to Adults with COVID-19 Parameter Mean Geometric mean estimates. (95% CI) Remdesivir GS-441524 GS-704277 CI=Confidence Interval; ND=Not detectable (at 24 hours post-dose) C max (nanogram per mL) 2700 (2440, 2990) 143 (135, 152) 198 (180, 218) AUC tau (nanogram∙h per mL) 1710 (1480, 1980) 2410 (2250, 2580) 392 (348, 442) C trough (nanogram per mL) ND 61.5 (56.5, 66.8) ND Specific Populations Pharmacokinetic differences based on sex, race, age, and renal function on the exposures of remdesivir were evaluated using population pharmacokinetic analysis. Sex and race did not affect the pharmacokinetics of remdesivir and its metabolites (GS-441524 and GS-704277). Pregnant Individuals The pharmacokinetics of remdesivir and its circulating metabolites (GS-441524 and GS-704277) were evaluated in pregnant individuals with COVID-19. Exposures (AUC tau , C max , and C tau ) of remdesivir and its circulating metabolites during pregnancy were similar to those in non-pregnant individuals (see Table 14 ). Table 14 Multiple Dose PK Parameters Study CO-US-590-5961 (IMPAACT). of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY to Pregnant and Non-Pregnant Individuals with COVID-19 Parameter Mean Geometric mean estimates. (90% CI) Pregnant Individuals (N=21) Non-Pregnant Individuals (N=22) CI=Confidence Interval Remdesivir C max (nanogram per mL) 1360 (978, 1890) 1240 (891, 1720) AUC tau (nanogram∙h per mL) 1250 (916, 1700) N=18 1300 (1070, 1590) N=17 GS-441524 C max (nanogram per mL) 113 (102, 126) 121 (108, 136) AUC tau (nanogram∙h per mL) 1840 (1630, 2070) N=20 2050 (1780, 2350) N=21 C tau (nanogram per mL) 51.6 (44.7, 59.6) 57.1 (48.7, 66.9) GS-704277 C max (nanogram per mL) 217 (187, 252) 213 (188, 240) AUC tau (nanogram∙h per mL) 454 (406, 508) 437 (384, 497) Patients with Renal Impairment The pharmacokinetics of remdesivir and its metabolites (GS-441524 and GS-704277) and excipient SBECD were evaluated in healthy subjects, those with mild (eGFR 60–89 mL/minute/1.73m 2 ), moderate (eGFR 30–59 mL/minute/1.73m 2 ), severe (eGFR 15–29 mL/minute/1.73m 2 ) renal impairment, or kidney failure (eGFR <15 mL/minute/1.73m 2 ) on dialysis or not on dialysis following a single dose of up to 100 mg of VEKLURY (see Table 15 ); and in COVID-19 patients with severely reduced kidney function (AKI [defined as a 50% increase in serum creatinine within a 48-hour period that was sustained for ≥6 hours despite supportive care]; CKD [eGFR <30 mL/minute/1.73m 2 ]; or ESRD [eGFR <15 mL/minute/1.73m 2 ] requiring hemodialysis) receiving VEKLURY 200 mg loading dose on Day 1 followed by 100 mg from Day 2 to Day 5 (see Table 16 ). Pharmacokinetic exposures of remdesivir were not affected by renal function or timing of VEKLURY administration around dialysis. Exposures of GS-441524, GS-704277, and SBECD were up to 7.9-fold, 2.8-fold, and 21-fold higher, respectively, in those with renal impairment compared to those with normal renal function (see Table 15 and Table 16 ). These changes are not considered to be clinically significant [see Adverse Reactions (6.1) and Use in Specific Populations (8.6) ] . Remdesivir was not efficiently removed through hemodialysis. Average hemodialysis clearance of GS-441524 and GS-704277 was 149 mL/minute and 92.6 mL/minute, respectively. Table 15 Comparison of PK Parameters Exposures were estimated using noncompartmental analysis from a dedicated Phase 1 renal impairment Study GS-US-540-9015; single doses up to 100 mg were administered; each subject with renal impairment had a matched control participant enrolled with normal renal function (eGFR ≥90 mL/minute/1.73m 2 ), same sex, and similar BMI (± 20%) and age (± 10 years). of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of Single Dose VEKLURY to Adults with Renal Impairment eGFR was calculated using Modification of Diet in Renal Disease equation and values represent mL/minute/1.73m 2 . as Compared to Adults with Normal Renal Function Mean Ratio (90% CI) No effect=1.0 (0.5–2.0) 60–89 mL per minute N=10 30–59 mL per minute N=10 15–29 mL per minute N=10 <15 mL per minute Pre-hemodialysis N=6 Post-hemodialysis N=6 No dialysis N=3 CI=Confidence Interval Remdesivir C max 0.96 (0.71, 1.31) 1.20 (1.01, 1.42) 0.97 (0.83, 1.13) 0.89 (0.67, 1.18) 1.13 (0.79, 1.60) 0.94 (0.65, 1.35) AUC inf 1.00 (0.75, 1.32) 1.22 (0.98, 1.52) 0.94 (0.83, 1.07) 0.80 (0.59, 1.08) 1.08 (0.72, 1.63) 0.89 (0.55, 1.43) GS-441524 C max 1.07 (0.90, 1.26) 1.44 (1.13, 1.85) 1.68 (1.28, 2.20) 2.27 (1.72, 2.99) 3.07 (2.21, 4.26) 3.00 (2.63, 3.42) AUC inf 1.19 (0.97, 1.47) 2.02 (1.57, 2.62) 3.26 (2.39, 4.46) 4.97 (3.65, 6.77) 6.22 (4.44, 8.71) 7.87 (6.49, 9.53) GS-704277 C max 2.25 (1.20, 4.20) 1.83 (1.34, 2.49) 1.27 (0.96, 1.68) 1.43 (1.00, 2.05) 1.23 (0.84, 1.80) 1.76 (1.19, 2.61) AUC inf 1.39 (1.13, 1.71) 2.01 (1.48, 2.73) 1.78 (1.27, 2.49) 2.18 (1.61, 2.95) 2.06 (1.42, 2.97) 2.81 (1.79, 4.43) Table 16 Comparison of PK Parameters of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of VEKLURY (200 mg on Day 1 Followed by 100 mg Daily on Days 2–5) in Adults with COVID-19 with Population PK estimates for 30-minute IV infusion of remdesivir for 5 days (Study GS-US-540-5912, n=90). or without Population PK estimates for 30-minute IV infusion of remdesivir for 3 days (Study GS-US-540-9012, n=148). Severely Reduced Kidney Function AKI (defined as a 50% increase in serum creatinine within a 48-hour period that was sustained for ≥6 hours despite supportive care); CKD (eGFR <30 mL/minute/1.73m 2 ); or ESRD (eGFR <15 mL/minute/1.73m 2 ) requiring hemodialysis. Mean Ratio (90% CI) No effect=1.0 (0.5–2.0) Remdesivir GS-441524 GS-704277 CI=Confidence Interval; ND=Not detectable (at 24 hours post-dose) C max 1.39 (1.25, 1.54) 4.98 (4.61, 5.38) 1.84 (1.63, 2.08) AUC tau 1.79 (1.59, 2.01) 6.59 (6.05, 7.18) 3.94 (3.50, 4.43) C tau ND 5.82 (5.25, 6.45) ND Patients with Hepatic Impairment The pharmacokinetics of remdesivir and GS-441524 were evaluated in healthy subjects and those with moderate or severe hepatic impairment (Child-Pugh Class B or C) following a single dose of 100 mg of VEKLURY (see Table 17 ). Relative to subjects with normal hepatic function, mean exposures (AUC inf , C max ) of remdesivir and GS-441524 were similar in subjects with moderate hepatic impairment and higher in subjects with severe hepatic impairment. The exposure differences in subjects with severe hepatic impairment are not considered to be clinically significant [see Use in Specific Populations (8.7) ] . Table 17 Comparison of PK Parameters of Remdesivir and GS-441524 Following IV Administration of Single Dose VEKLURY to Adults with Hepatic Impairment as Compared to Adults with Normal Hepatic Function Mean Ratio (90% CI) No effect=1.0 (0.5–2.0) Moderate Hepatic Impairment N=10 Severe Hepatic Impairment N=6 CI=Confidence Interval Remdesivir AUC inf 1.21 (0.87, 1.67) 1.56 (1.20, 2.03) C max 1.10 (0.75, 1.60) 1.03 (0.70, 1.51) Unbound AUC inf 1.15 (0.86, 1.54) 2.44 (1.93, 3.08) Unbound C max 1.04 (0.73, 1.48) 1.57 (1.08, 2.29) GS-441524 AUC inf 0.90 (0.69, 1.17) 1.31 (0.93, 1.84) C max 1.09 (0.86, 1.38) 1.48 (1.17, 1.86) C 24 0.93 (0.69, 1.24) 1.16 (0.76, 1.77) Pediatric Patients Population pharmacokinetic models for remdesivir and its circulating metabolites (GS-441524 and GS-704277), developed using pooled data from studies in healthy subjects and in adult and pediatric patients with COVID-19, were used to estimate pharmacokinetic exposures in pediatric patients aged from birth to <18 years and weighing ≥1.5 kg (Study 5823). Geometric mean estimated exposures (AUC tau , C max , and C tau ) for patients ≥28 days to <18 years old and weighing ≥3 kg (Cohorts 1–4 and 8, n=50) at the doses administered were 33% to 130% higher for remdesivir, 3% lower to 60% higher for GS-441524, and 32% to 124% higher for GS-704277 as compared to those in adult patients with COVID-19; however, the increases were not considered clinically significant. Individual estimated exposures (AUC tau , C max , and C tau ) for patients 14 to <28 days old, GA >37 weeks, and weighing ≥2.5 kg (Cohort 5, n=3); patients <14 days old, GA >37 weeks, and weighing ≥2.5 kg at birth (Cohort 6, n=1); and patients <56 days old, GA ≤37 weeks, and weighing ≥1.5 kg at birth (Cohort 7, n=1) at the doses administered were higher for remdesivir, GS-441524, and GS-704277 as compared to median exposures in adult patients with COVID-19; however, the increases were not considered clinically significant. As limited PK data were available in Cohorts 5–7, additional analyses were conducted using a simulated population. Using age and weight distributions from pediatric growth charts, simulated population datasets were created for Cohorts 5–6. Modeling and simulation incorporating maturation functions that account for renal function and drug metabolizing enzyme ontogeny with age were used to predict exposures for subjects <28 days old, GA >37 weeks, and weighing ≥1.5 kg and subjects ≥28 days old and weighing ≥1.5 to <3 kg. Predicted geometric mean exposures (AUC tau , C max , and C tau ) at the recommended doses were 10% to 96% higher for remdesivir, 15% lower to 3% higher for GS-441524, and 14% lower to 132% higher for GS-704277 as compared to those in adult patients with COVID-19; however, changes in exposure were not considered clinically significant. Results of simulated population led to the recommended dosing regimen as they more closely align with adult exposures compared to the doses studied. Plasma exposures of excipient SBECD were generally similar for all pediatric patients at the doses administered in Study GS-US-540-5823 and were similar compared to adults with normal renal function, although data are very limited [see Use in Specific Populations (8.4) ]. The multiple dose PK parameters of remdesivir and metabolites in pediatric patients with COVID-19 in Cohorts 1–4 and 8 are provided in Table 18. Table 18 Multiple Dose PK Parameters Population PK estimates for 30-minutes IV infusion of remdesivir for up to 10 days (Study GS-US-540-5823). of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY 100 mg (Cohorts 1 and 8) or 2.5 mg/kg (Cohorts 2–4) to Pediatric Patients with COVID-19 Cohort 1 Cohort 8 Cohort 2 Cohort 3 Cohort 4 Parameter Mean Geometric mean estimates. (95% CI) 12 to <18 Years and Weighing ≥40 kg (N=12) <12 Years and Weighing ≥40 kg (N=5) 28 Days to <18 Years and Weighing 20 to <40 kg (N=12) 28 Days to <18 Years and Weighing 12 to <20 kg (N=11) 28 Days to <18 Years and Weighing 3 to <12 kg (N=10) CI=Confidence Interval Remdesivir C max (nanogram per mL) 3890 (3110, 4870) 3920 (2260, 6820) 5730 (4660, 7050) 5570 (4250, 7300) 4870 (3750, 6340) AUC tau (nanogram∙h per mL) 2470 (1920, 3160) 2270 (1200, 4310) 3510 (2560, 4820) 3930 (2140, 7210) 2910 (1880, 4510) GS-441524 C max (nanogram per mL) 196 (122, 315) 163 (57.6, 461) 183 (129, 260) 171 (130, 223) 205 (174, 241) AUC tau (nanogram∙h per mL) 3430 (1980, 5920) 2640 (767, 9100) 2370 (1500, 3740) 2410 (1740, 3340) 2850 (2290, 3540) C tau (nanogram per mL) 98.5 (59.1, 164) 76.2 (23.9, 243) 59.9 (34.2, 105) 68.9 (47.4, 100) 79.7 (59.5, 107) GS-704277 C max (nanogram per mL) 308 (211, 450) 266 (137, 514) 419 (306, 575) 444 (335, 587) 385 (294, 504) AUC tau (nanogram∙h per mL) 819 (474, 1420) 518 (192, 1400) 753 (542, 1050) 733 (504, 1060) 687 (484, 973) Drug Interaction Studies In vitro, remdesivir is a substrate for enzymes CYP3A, carboxylesterase 1 (CES1), and cathepsin A (CatA) and OATP1B1 and P-gp transporters; GS-704277 is a substrate for OATP1B1 and OATP1B3. In vitro, remdesivir is an inhibitor of CYP3A, UGT1A1, OATP1B1, OATP1B3, and MATE1; however, no clinically significant effects on substrates of UGT1A1 or MATE1 are expected. No inhibitory interactions were identified for GS-704277 or GS-441524 in vitro. Remdesivir is not a substrate for CYP1A1, 1A2, 2B6, 2C9, 2C19, or OATP1B3. GS-704277 and GS-441524 are not substrates for CYP1A1, 1A2, 2B6, 2C8, 2C9, 2D6, or 3A5. GS-441524 is also not a substrate for CYP2C19 or 3A4. GS-704277 and GS-441524 are not substrates for OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2k. GS-441524 is also not a substrate for OATP1B1 or OATP1B3. Drug-drug interaction studies were conducted with VEKLURY. Table 19 summarizes the pharmacokinetic effects of other drugs on remdesivir and metabolites GS-704277 and GS-441524. Table 20 summarizes the effects of remdesivir on the pharmacokinetics of other drugs. Table 19 Effect of Other Drugs on Remdesivir and Metabolites GS-704277 and GS-441524 Coadministered Drug Dose of Coadministered Drug (mg) Remdesivir Dose (mg) N Mean Ratio (90% CI) of Remdesivir, GS-704277, and GS-441524 PK With/Without Coadministered Drug No Effect = 1.00 (0.70–1.43) C max AUC inf C 24 CI=confidence interval Cyclosporin A Interaction study conducted in healthy volunteers. 400 single dose 100 single dose 9 remdesivir 1.49 (1.38–1.60) 1.89 (1.77–2.02) - GS-704277 2.51 (2.26–2.78) 2.97 (2.75–3.20) - GS-441524 1.17 (1.12–1.22) 1.03 (0.99–1.08) 1.02 (0.95–1.10) Carbamazepine 300 twice daily 100 single dose 8 remdesivir 0.87 (0.78–0.97) 0.92 (0.83–1.02) - GS-704277 0.96 (0.84–1.10) 0.98 (0.92–1.05) - GS-441524 0.97 (0.88–1.07) 0.83 (0.78–0.89) 0.71 (0.64–0.78) Table 20 Effect of Remdesivir on the Pharmacokinetics of Other Drugs Coadministered Drug Dose of Coadministered Drug (mg) Remdesivir Dose (mg) N Mean Ratio (90% CI) of Coadministered Drug PK With/Without Remdesivir No Effect = 1.00 (0.80–1.25) C max AUC inf CI=confidence Interval Midazolam Interaction study conducted in healthy volunteers. 2.5 single dose 200 single dose 19 1.29 (1.19–1.41) 1.20 (1.14–1.26) Midazolam 2.5 single dose 200 single dose followed by 100 once daily (10 doses) Midazolam administered with last dose of remdesivir. 14 1.45 (1.23– 1.70) 1.30 (1.16– 1.45) Pitavastatin 2 single dose 200 single dose 20 1.05 (0.92–1.20) 1.17 (1.09–1.24) 12.4 Microbiology Mechanism of Action Remdesivir is an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), which is essential for viral replication. Remdesivir is an adenosine nucleotide prodrug that distributes into cells where it is metabolized to a nucleoside monophosphate intermediate by carboxyesterase 1 and/or cathepsin A, depending upon the cell type. The nucleoside monophosphate is subsequently phosphorylated by cellular kinases to form the pharmacologically active nucleoside triphosphate metabolite (GS-443902). Remdesivir triphosphate (RDV-TP) acts as an analog of adenosine triphosphate (ATP) and competes with high selectivity (3.65-fold) over the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV-2 RdRp, which results in delayed chain termination (position i+3) during replication of the viral RNA. In a biochemical assay assessing RDV-TP incorporation by the MERS-CoV RdRp complex, RDV-TP inhibited RNA synthesis with an IC 50 value of 0.032 µM. RDV-TP can also inhibit viral RNA synthesis following its incorporation into the template viral RNA as a result of read-through by the viral polymerase that may occur at higher nucleotide concentrations. When remdesivir nucleotide is present in the viral RNA template, the efficiency of incorporation of the complementary natural nucleotide is compromised, thereby inhibiting viral RNA synthesis. Remdesivir triphosphate is a weak inhibitor of mammalian DNA and RNA polymerases, including human mitochondrial RNA polymerase. Antiviral Activity In Cell Culture Remdesivir exhibited cell culture antiviral activity against a clinical isolate of SARS‑CoV‑2 in primary human airway epithelial (HAE) cells with a 50% effective concentration (EC 50 ) of 9.9 nM after 48 hours of treatment. Remdesivir inhibited the replication of SARS-CoV-2 in the continuous human lung epithelial cell lines Calu-3 and A549-hACE2 with EC 50 values of 280 nM after 72 hours of treatment and 115 nM after 48 hours of treatment, respectively. Remdesivir EC 50 values for SARS-CoV-2 in A549-hACE2 cells were not different when combined with chloroquine phosphate or hydroxychloroquine sulfate at concentrations up to 2.5 µM. In a separate study, the antiviral activity of remdesivir was antagonized by chloroquine phosphate in a dose-dependent manner when the two drugs were co-incubated at clinically relevant concentrations in HEp-2 cells infected with respiratory syncytial virus (RSV). Higher remdesivir EC 50 values were observed with increasing concentrations of chloroquine phosphate. Increasing concentrations of chloroquine phosphate or hydroxychloroquine sulfate reduced formation of remdesivir triphosphate in A549-hACE2, HEp-2, and normal human bronchial epithelial cells. Based on cell culture susceptibility testing by virus yield reduction assay and/or N protein ELISA assay, remdesivir retained similar antiviral activity against clinical isolates of SARS-CoV-2 variants compared to an earlier lineage SARS-CoV-2 (lineage A) isolate, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Epsilon (B.1.429), Zeta (P.2), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Omicron variants (including B.1.1.529/BA.1, BA.2, BA.2.12.1, BA.2.75, BA.2.86, BA.4, BA.4.6, BA.5, BF.5, BF.7, BQ.1, BQ.1.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF). For these variants, the EC 50 fold change values ranged between 0.2 and 2.3 compared to an earlier lineage SARS-CoV-2 (lineage A) isolate. Using the SARS-CoV-2 replicon system, remdesivir retained similar antiviral activity against Omicron subvariants JN.1.7, JN.1.18, KP.2, KP.3, LB.1, and XBB.1.9.2 compared to the wildtype reference replicon (lineage B). In Clinical Trials SARS-CoV-2 RNA shedding results from GS-US-540-5776 (ACTT-1) indicate that remdesivir does not significantly reduce the amount of detectable SARS-CoV-2 RNA in oropharyngeal or nasopharyngeal swabs or plasma samples in hospitalized patients compared to placebo, and SARS-CoV-2 RNA shedding results from GS-US-540-9012 indicate that remdesivir does not significantly reduce the amount of detectable SARS-CoV-2 RNA in nasopharyngeal swabs in non-hospitalized patients compared to placebo. Resistance In Cell Culture SARS-CoV-2 isolates with reduced susceptibility to remdesivir have been selected in cell culture. In a selection with GS-441524, the parent nucleoside of remdesivir, virus pools emerged expressing amino acid substitutions at V166A, N198S, S759A, V792I, C799F, and C799R in the viral RdRp (nsp12). When these substitutions were individually introduced into a wild-type recombinant virus by site-directed mutagenesis, 1.7- to 3.5-fold reductions in susceptibility to remdesivir were observed. In a cell culture resistance selection experiment with remdesivir, nsp12 substitution E802D emerged, resulting in a 1.4- to 2.5-fold reduction in susceptibility to remdesivir. In another selection with remdesivir using a SARS-CoV-2 isolate containing the P323L substitution in the viral polymerase, a single amino acid substitution at V166L emerged. Recombinant SARS-CoV-2 with substitutions at P323L alone or P323L+V166L in combination exhibited 1.3- and 1.5-fold reductions in remdesivir susceptibility, respectively. Cell culture resistance profiling of remdesivir using the rodent CoV murine hepatitis virus identified two substitutions (F476L and V553L) in the viral RdRp (nsp12) at residues conserved across CoVs. Introduction of the corresponding substitutions (F480L and V557L) into SARS-CoV resulted in 6-fold reduction in susceptibility to remdesivir in cell culture and attenuated SARS-CoV pathogenesis in a mouse model. When individually introduced into a SARS-CoV-2 recombinant virus, the corresponding substitutions at F480L and V557L each conferred 2-fold reduced susceptibility to remdesivir. In Clinical Studies In a literature publication, the SARS-CoV-2 nsp12 E802D substitution previously identified in a resistance selection experiment emerged in one individual treated with remdesivir. The E802D substitution resulted in a 1.4- to 2.5-fold increase in the remdesivir EC 50 value. In Study CO-US-540-5776 (ACTT-1), among 61 subjects with baseline and post-baseline sequencing data available, the rate of emerging substitutions in the viral RdRp (nsp12) was similar in subjects treated with VEKLURY compared to placebo. Two subjects treated with VEKLURY had an emergent substitution previously identified in resistance selection experiments (nsp12 V792I in one and C799F in the other). These substitutions are associated with 2.2- and 2.5-fold decreases in remdesivir susceptibility, respectively, based on assessments of clinical isolates. In one subject treated with VEKLURY, nsp12 V792F emerged at low frequency and was associated with a 1.8-fold decrease in remdesivir susceptibility. In Study GS-US-540-5773, among 19 subjects treated with VEKLURY with baseline and post-baseline sequencing data available, the V792F substitution in viral RdRp (nsp12) emerged at low frequency in one subject. In Study GS-US-540-9012, among 244 subjects with baseline and post-baseline sequencing data available, the rate of emerging substitutions in the viral RdRp (nsp12) was similar in subjects treated with VEKLURY compared to placebo. In one subject treated with VEKLURY, one substitution in the RdRp (nsp12 A376V) emerged and was associated with a 12.6-fold decrease in remdesivir susceptibility in a subgenomic replicon assay. This subject was not hospitalized and showed alleviation of all baseline symptoms, except loss of taste and smell, prior to or on Day 14. In Study GS-US-540-5912, among 60 subjects with baseline and post-baseline sequencing data available, substitutions in the viral RdRp (nsp12) emerged in 8 subjects treated with VEKLURY. In 4 subjects treated with VEKLURY, three substitutions in the RdRp (nsp12 E136V, M794I, or C799F) emerged and were associated with 2.9-, 2.9-, and 3.4-fold reduced susceptibility to remdesivir in a subgenomic replicon assay. In Study GS-US-540-5823, among pediatric subjects with baseline and post-baseline sequencing data available, treatment-emergent substitutions in the viral RdRp (nsp12) were observed in 3 of 27 subjects treated with VEKLURY and were evaluated for susceptibility to remdesivir. In one subject, two substitutions (nsp12 substitutions V166L and V792I) emerged and were associated with 1.85- and 3.6-fold decreases in remdesivir susceptibility relative to reference, respectively. This subject was hospitalized at baseline, recovered from COVID-19, and was released from the hospital on Day 13. None of the substitutions observed in any of the other genes (nsp9–10, nsp13–14) encoding for proteins of the viral replication-transcription complex have been associated with reduced susceptibility to remdesivir. The relationship between the level of reduced susceptibility to remdesivir observed in subgenomic replicon assays and the inhibition of SARS-CoV-2 replication by remdesivir in humans has not been fully established."],"indications_and_usage":["1 INDICATIONS AND USAGE VEKLURY is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are [see Clinical Studies (14) ] : Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. VEKLURY is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are: Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypersensitivity including infusion-related and anaphylactic reactions: Hypersensitivity reactions have been observed during and following administration of VEKLURY. Slower infusion rates, with a maximum infusion time of up to 120 minutes, can be considered to potentially prevent signs and symptoms of hypersensitivity. Monitor patients during infusion and observe patients for at least one hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate. If signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue administration of VEKLURY and initiate appropriate treatment. ( 5.1 ) Increased risk of transaminase elevations: Transaminase elevations have been observed in healthy volunteers and have also been reported in patients with COVID-19 who received VEKLURY. Perform hepatic laboratory testing in all patients before starting VEKLURY and while receiving VEKLURY as clinically appropriate. Consider discontinuing VEKLURY if ALT levels increase to greater than 10 times the upper limit of normal. Discontinue VEKLURY if ALT elevation is accompanied by signs or symptoms of liver inflammation. ( 5.2 ) Risk of reduced antiviral activity when coadministered with chloroquine phosphate or hydroxychloroquine sulfate: Coadministration of VEKLURY and chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments demonstrating a potential antagonistic effect of chloroquine on the intracellular metabolic activation and antiviral activity of VEKLURY. ( 5.3 ) 5.1 Hypersensitivity Including Infusion-related and Anaphylactic Reactions Hypersensitivity reactions, including infusion-related and anaphylactic reactions, have been observed during and following administration of VEKLURY; most occurred within one hour. Signs and symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering. Slower infusion rates, with a maximum infusion time of up to 120 minutes, can be considered to potentially prevent these signs and symptoms. Monitor patients during infusion and observe patients for at least one hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate. If signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue administration of VEKLURY and initiate appropriate treatment. The use of VEKLURY is contraindicated in patients with known hypersensitivity to VEKLURY or any components of the product [see Contraindications (4) ] . 5.2 Increased Risk of Transaminase Elevations Transaminase elevations have been observed in healthy volunteers who received 200 mg of VEKLURY followed by 100 mg doses for up to 10 days; the transaminase elevations were mild (Grade 1) to moderate (Grade 2) in severity and resolved upon discontinuation of VEKLURY. Transaminase elevations have also been reported in patients with COVID-19 who received VEKLURY [see Adverse Reactions (6.1) ] . Because transaminase elevations have been reported as a clinical feature of COVID-19, and the incidence was similar in patients receiving placebo versus VEKLURY in clinical trials of VEKLURY, discerning the contribution of VEKLURY to transaminase elevations in patients with COVID-19 can be challenging. Perform hepatic laboratory testing in all patients before starting VEKLURY and while receiving VEKLURY as clinically appropriate [see Dosage and Administration (2.1) and Use in Specific Populations (8.7) ] . Consider discontinuing VEKLURY if ALT levels increase to greater than 10 times the upper limit of normal. Discontinue VEKLURY if ALT elevation is accompanied by signs or symptoms of liver inflammation. 5.3 Risk of Reduced Antiviral Activity When Coadministered with Chloroquine Phosphate or Hydroxychloroquine Sulfate Coadministration of VEKLURY and chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments demonstrating a potential antagonistic effect of chloroquine on the intracellular metabolic activation and antiviral activity of VEKLURY [see Drug Interactions (7) and Microbiology (12.4) ]."],"clinical_studies_table":["<table width=\"90%\"><caption>Table 21 Trials Conducted with VEKLURY in Subjects with COVID-19</caption><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"30%\" align=\"center\" valign=\"top\"/><col width=\"30%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Rrule\">Trial</th><th styleCode=\"Rrule\">Population</th><th styleCode=\"Rrule\">Trial Arms (N)</th><th>Timepoint</th></tr></thead><tfoot><tr><td colspan=\"4\" align=\"left\">COVID-19: coronavirus disease 2019</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">NIAID ACTT-1<footnote ID=\"foot10\">Randomized, double-blind, placebo-controlled trial.</footnote>  (NCT04280705)</td><td styleCode=\"Rrule\">Hospitalized with mild/moderate and severe COVID-19</td><td styleCode=\"Rrule\">VEKLURY 10 Days (532)  Placebo (516)</td><td>29 Days after Randomization</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">GS-US-540-5773<footnote ID=\"foot11\">Randomized, open-label trial.</footnote>  (NCT04292899)</td><td styleCode=\"Rrule\">Hospitalized with severe COVID-19</td><td styleCode=\"Rrule\">VEKLURY 5 Days (200)  VEKLURY 10 Days (197)</td><td>Day 14</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">GS-US-540-5774<footnoteRef IDREF=\"foot11\"/>  (NCT04292730)</td><td styleCode=\"Rrule\">Hospitalized with moderate COVID-19</td><td styleCode=\"Rrule\">VEKLURY 5 Days (191)  VEKLURY 10 Days (193)  Standard of care (200)</td><td>Day 11</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">GS-US-540-9012<footnoteRef IDREF=\"foot10\"/>  (NCT04501952)</td><td styleCode=\"Rrule\">Non-hospitalized with mild-to-moderate COVID-19 and at high risk for progression to severe disease</td><td styleCode=\"Rrule\">VEKLURY 3 Days (279)  Placebo (283)</td><td>Day 28</td></tr><tr><td styleCode=\"Rrule\">GS-US-540-5823 (Cohorts 1&#x2013;8)<footnote>Open-label trial, descriptive outcome analyses.</footnote>  (NCT04431453)</td><td styleCode=\"Rrule\">Hospitalized pediatric subjects from birth to &lt;18 years of age and weighing at least 1.5 kg with COVID-19</td><td styleCode=\"Rrule\">VEKLURY up to 10 Days (58)</td><td>Day 10</td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis and Mutagenesis Given the short-term administration of VEKLURY for the treatment of COVID-19, long-term animal studies to evaluate the carcinogenic potential of remdesivir were not conducted. Remdesivir was not genotoxic in a battery of assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes, and in vivo rat micronucleus assays. Impairment of Fertility Nonclinical toxicity studies in rats demonstrated no adverse effect on male fertility at exposures of the predominant circulating metabolite (GS-441524) approximately 2 times the exposure in humans at the RHD. Reproductive toxicity, including decreases in corpora lutea, numbers of implantation sites, and viable embryos, was seen when remdesivir was administered by daily intravenous administration at a systemically toxic dose (10 mg/kg) in female rats 14 days prior to mating and during conception; exposures of the predominant circulating metabolite (GS-441524) were 1.3 times the exposure in humans at the RHD. 13.2 Animal Toxicology and/or Pharmacology Intravenous administration (slow bolus) of remdesivir to male rhesus monkeys at dosage levels of 5, 10, and 20 mg/kg/day for 7 days resulted, at all dose levels, in increased mean urea nitrogen and increased mean creatinine, renal tubular atrophy, and basophilia and casts. Intravenous administration (slow bolus) of remdesivir to rats at dosage levels of ≥3 mg/kg/day for up to 4 weeks resulted in findings indicative of kidney injury and/or dysfunction. Kidney-related effects in rats and monkeys were observed at exposures of the predominant circulating metabolite (GS-441524) that are lower than the exposure in humans at the RHD."],"pharmacokinetics_table":["<table width=\"90%\" ID=\"Table12\"><caption>Table 12 Pharmacokinetic Properties of Remdesivir and Metabolites (GS-441524 and GS-704277)</caption><col width=\"28%\" align=\"left\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">Remdesivir</th><th styleCode=\"Rrule\">GS-441524</th><th styleCode=\"Rrule\">GS-704277</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">ND=not detected</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Absorption</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">T<sub>max</sub> (h)<footnote>Remdesivir administered as a 30-minute IV infusion (Study GS-US-399-5505); range of median observed on Day 1 and Day 5 or 10.</footnote></td><td styleCode=\"Rrule\">0.67&#x2013;0.68</td><td styleCode=\"Rrule\">1.51&#x2013;2.00</td><td styleCode=\"Rrule\">0.75&#x2013;0.75</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Distribution</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">% bound to human plasma proteins</td><td styleCode=\"Rrule\">88&#x2013;93.6<footnote>Range of protein binding for remdesivir from 2 independent experiments show no evidence of concentration-dependent protein binding for remdesivir.</footnote></td><td styleCode=\"Rrule\">2</td><td styleCode=\"Rrule\">1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Blood-to-plasma ratio</td><td styleCode=\"Rrule\">0.68&#x2013;1.0</td><td styleCode=\"Rrule\">1.19</td><td styleCode=\"Rrule\">0.56</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Elimination</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">t<sub>1/2</sub> (h)<footnote>Median (Study GS-US-399-4231).</footnote></td><td styleCode=\"Rrule\">1</td><td styleCode=\"Rrule\">27</td><td styleCode=\"Rrule\">1.3</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Metabolism </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Metabolic pathway(s)</td><td styleCode=\"Rrule\">CES1 (80%)  Cathepsin A (10%)  CYP3A (10%)</td><td styleCode=\"Rrule\">Not significantly metabolized</td><td styleCode=\"Rrule\">HINT1</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Excretion</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Major route of elimination</td><td styleCode=\"Rrule\">Metabolism</td><td styleCode=\"Rrule\">Glomerular filtration and active tubular secretion</td><td styleCode=\"Rrule\">Metabolism</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">% of dose excreted in urine<footnote ID=\"foot5\">Mean (Study GS-US-399-4231).</footnote></td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">49</td><td styleCode=\"Rrule\">2.9</td></tr><tr><td styleCode=\"Lrule Rrule\">% of dose excreted in feces<footnoteRef IDREF=\"foot5\"/></td><td styleCode=\"Rrule\">ND</td><td styleCode=\"Rrule\">0.5</td><td styleCode=\"Rrule\">ND</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table13\"><caption>Table 13 Multiple Dose PK Parameters<footnote>Population PK estimates for 30-minute IV infusion of remdesivir for 3 days (Study GS-US-540-9012, n=147).</footnote> of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of VEKLURY 100 mg to Adults with COVID-19</caption><col width=\"28%\" align=\"left\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Parameter Mean<footnote>Geometric mean estimates.</footnote> (95% CI)</th><th styleCode=\"Rrule\">Remdesivir</th><th styleCode=\"Rrule\">GS-441524</th><th styleCode=\"Rrule\">GS-704277</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">CI=Confidence Interval; ND=Not detectable (at 24 hours post-dose)</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">2700 (2440, 2990)</td><td styleCode=\"Rrule\">143 (135, 152)</td><td styleCode=\"Rrule\">198 (180, 218)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">1710 (1480, 1980)</td><td styleCode=\"Rrule\">2410 (2250, 2580)</td><td styleCode=\"Rrule\">392 (348, 442)</td></tr><tr><td styleCode=\"Lrule Rrule\">C<sub>trough</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">ND</td><td styleCode=\"Rrule\">61.5 (56.5, 66.8)</td><td styleCode=\"Rrule\">ND</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table14\"><caption>Table 14 Multiple Dose PK Parameters<footnote>Study CO-US-590-5961 (IMPAACT).</footnote> of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY to Pregnant and Non-Pregnant Individuals with COVID-19 </caption><col width=\"34%\" align=\"left\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Parameter  Mean<footnote>Geometric mean estimates.</footnote> (90% CI)</th><th styleCode=\"Rrule\">Pregnant Individuals (N=21)</th><th styleCode=\"Rrule\">Non-Pregnant Individuals (N=22)</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"3\">CI=Confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Remdesivir</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">1360 (978, 1890)</td><td styleCode=\"Rrule\">1240 (891, 1720)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">1250 (916, 1700)<footnote>N=18</footnote></td><td styleCode=\"Rrule\">1300 (1070, 1590)<footnote>N=17</footnote></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-441524</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">113 (102, 126)</td><td styleCode=\"Rrule\">121 (108, 136)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">1840 (1630, 2070)<footnote ID=\"t14fe\">N=20</footnote></td><td styleCode=\"Rrule\">2050 (1780, 2350)<footnote ID=\"t14ff\">N=21</footnote></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>tau</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">51.6 (44.7, 59.6)<footnoteRef IDREF=\"t14fe\"/></td><td styleCode=\"Rrule\">57.1 (48.7, 66.9)<footnoteRef IDREF=\"t14ff\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-704277</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">217 (187, 252)</td><td styleCode=\"Rrule\">213 (188, 240)</td></tr><tr><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">454 (406, 508)<footnoteRef IDREF=\"t14fe\"/></td><td styleCode=\"Rrule\">437 (384, 497)</td></tr></tbody></table>","<table width=\"95%\" ID=\"Table15\"><caption>Table 15 Comparison of PK Parameters<footnote>Exposures were estimated using noncompartmental analysis from a dedicated Phase 1 renal impairment Study GS-US-540-9015; single doses up to 100 mg were administered; each subject with renal impairment had a matched control participant enrolled with normal renal function (eGFR &#x2265;90 mL/minute/1.73m<sup>2</sup>), same sex, and similar BMI (&#xB1; 20%) and age (&#xB1; 10 years).</footnote> of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of Single Dose VEKLURY to Adults with Renal Impairment<footnote ID=\"t15fb\">eGFR was calculated using Modification of Diet in Renal Disease equation and values represent mL/minute/1.73m<sup>2</sup>.</footnote> as Compared to Adults with Normal Renal Function</caption><col width=\"14%\" align=\"left\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"bottom\" align=\"center\">Mean Ratio (90% CI)<footnote>No effect=1.0 (0.5&#x2013;2.0)</footnote></th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">60&#x2013;89 mL per minute<footnoteRef IDREF=\"t15fb\"/> N=10</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">30&#x2013;59 mL per minute<footnoteRef IDREF=\"t15fb\"/> N=10</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">15&#x2013;29 mL per minute<footnoteRef IDREF=\"t15fb\"/> N=10</th><th styleCode=\"Rrule\" colspan=\"3\" valign=\"bottom\">&lt;15 mL per minute<footnoteRef IDREF=\"t15fb\"/></th></tr><tr><th styleCode=\"Lrule Rrule\" valign=\"bottom\" align=\"center\">Pre-hemodialysis N=6</th><th styleCode=\"Rrule\" valign=\"bottom\">Post-hemodialysis N=6</th><th styleCode=\"Rrule\" valign=\"bottom\">No dialysis N=3</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"7\">CI=Confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Remdesivir</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">0.96 (0.71, 1.31)</td><td styleCode=\"Rrule\">1.20 (1.01, 1.42)</td><td styleCode=\"Rrule\">0.97 (0.83, 1.13)</td><td styleCode=\"Rrule\">0.89 (0.67, 1.18)</td><td styleCode=\"Rrule\">1.13 (0.79, 1.60)</td><td styleCode=\"Rrule\">0.94 (0.65, 1.35)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.00 (0.75, 1.32)</td><td styleCode=\"Rrule\">1.22 (0.98, 1.52)</td><td styleCode=\"Rrule\">0.94 (0.83, 1.07)</td><td styleCode=\"Rrule\">0.80 (0.59, 1.08)</td><td styleCode=\"Rrule\">1.08 (0.72, 1.63)</td><td styleCode=\"Rrule\">0.89 (0.55, 1.43)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-441524</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">1.07 (0.90, 1.26)</td><td styleCode=\"Rrule\">1.44 (1.13, 1.85)</td><td styleCode=\"Rrule\">1.68 (1.28, 2.20)</td><td styleCode=\"Rrule\">2.27 (1.72, 2.99)</td><td styleCode=\"Rrule\">3.07 (2.21, 4.26)</td><td styleCode=\"Rrule\">3.00 (2.63, 3.42)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.19 (0.97, 1.47)</td><td styleCode=\"Rrule\">2.02 (1.57, 2.62)</td><td styleCode=\"Rrule\">3.26 (2.39, 4.46)</td><td styleCode=\"Rrule\">4.97 (3.65, 6.77)</td><td styleCode=\"Rrule\">6.22 (4.44, 8.71)</td><td styleCode=\"Rrule\">7.87 (6.49, 9.53)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-704277</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">2.25 (1.20, 4.20)</td><td styleCode=\"Rrule\">1.83 (1.34, 2.49)</td><td styleCode=\"Rrule\">1.27 (0.96, 1.68)</td><td styleCode=\"Rrule\">1.43 (1.00, 2.05)</td><td styleCode=\"Rrule\">1.23 (0.84, 1.80)</td><td styleCode=\"Rrule\">1.76 (1.19, 2.61)</td></tr><tr><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.39 (1.13, 1.71)</td><td styleCode=\"Rrule\">2.01 (1.48, 2.73)</td><td styleCode=\"Rrule\">1.78 (1.27, 2.49)</td><td styleCode=\"Rrule\">2.18 (1.61, 2.95)</td><td styleCode=\"Rrule\">2.06 (1.42, 2.97)</td><td styleCode=\"Rrule\">2.81 (1.79, 4.43)</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table16\"><caption>Table 16 Comparison of PK Parameters of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of VEKLURY (200 mg on Day 1 Followed by 100 mg Daily on Days 2&#x2013;5) in Adults with COVID-19 with<footnote>Population PK estimates for 30-minute IV infusion of remdesivir for 5 days (Study GS-US-540-5912, n=90).</footnote> or without<footnote>Population PK estimates for 30-minute IV infusion of remdesivir for 3 days (Study GS-US-540-9012, n=148).</footnote> Severely Reduced Kidney Function<footnote>AKI (defined as a 50% increase in serum creatinine within a 48-hour period that was sustained for &#x2265;6 hours despite supportive care); CKD (eGFR &lt;30 mL/minute/1.73m<sup>2</sup>); or ESRD (eGFR &lt;15 mL/minute/1.73m<sup>2</sup>) requiring hemodialysis.</footnote></caption><col width=\"27%\" align=\"left\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"27%\" align=\"center\" valign=\"middle\"/><col width=\"27%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" valign=\"top\">Mean Ratio (90% CI)<footnote>No effect=1.0 (0.5&#x2013;2.0)</footnote></th><th styleCode=\"Rrule\">Remdesivir</th><th styleCode=\"Rrule\">GS-441524</th><th styleCode=\"Rrule\">GS-704277</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"4\">CI=Confidence Interval; ND=Not detectable (at 24 hours post-dose)</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">C<sub>max</sub></td><td styleCode=\"Rrule\">1.39 (1.25, 1.54)</td><td styleCode=\"Rrule\">4.98 (4.61, 5.38)</td><td styleCode=\"Rrule\">1.84 (1.63, 2.08)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">AUC<sub>tau</sub></td><td styleCode=\"Rrule\">1.79 (1.59, 2.01)</td><td styleCode=\"Rrule\">6.59 (6.05, 7.18)</td><td styleCode=\"Rrule\">3.94 (3.50, 4.43)</td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">C<sub>tau</sub></td><td styleCode=\"Rrule\">ND</td><td styleCode=\"Rrule\">5.82 (5.25, 6.45)</td><td styleCode=\"Rrule\">ND</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table17\"><caption>Table 17 Comparison of PK Parameters of Remdesivir and GS-441524 Following IV Administration of Single Dose VEKLURY to Adults with Hepatic Impairment as Compared to Adults with Normal Hepatic Function</caption><col width=\"30%\" align=\"left\" valign=\"middle\"/><col width=\"35%\" align=\"center\" valign=\"middle\"/><col width=\"35%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Mean Ratio (90% CI)<footnote>No effect=1.0 (0.5&#x2013;2.0)</footnote></th><th styleCode=\"Rrule\">Moderate Hepatic Impairment  N=10</th><th styleCode=\"Rrule\">Severe Hepatic Impairment  N=6</th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\">CI=Confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Remdesivir</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.21 (0.87, 1.67)</td><td styleCode=\"Rrule\">1.56 (1.20, 2.03)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">1.10 (0.75, 1.60)</td><td styleCode=\"Rrule\">1.03 (0.70, 1.51)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Unbound AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.15 (0.86, 1.54)</td><td styleCode=\"Rrule\">2.44 (1.93, 3.08)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Unbound C<sub>max</sub></td><td styleCode=\"Rrule\">1.04 (0.73, 1.48)</td><td styleCode=\"Rrule\">1.57 (1.08, 2.29)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-441524</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">0.90 (0.69, 1.17)</td><td styleCode=\"Rrule\">1.31 (0.93, 1.84)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">1.09 (0.86, 1.38)</td><td styleCode=\"Rrule\">1.48 (1.17, 1.86)</td></tr><tr><td styleCode=\"Lrule Rrule\">C<sub>24</sub></td><td styleCode=\"Rrule\">0.93 (0.69, 1.24)</td><td styleCode=\"Rrule\">1.16 (0.76, 1.77)</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table18\"><caption>Table 18 Multiple Dose PK Parameters<footnote>Population PK estimates for 30-minutes IV infusion of remdesivir for up to 10 days (Study GS-US-540-5823).</footnote> of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY 100 mg (Cohorts 1 and 8) or 2.5 mg/kg (Cohorts 2&#x2013;4) to Pediatric Patients with COVID-19</caption><col width=\"15%\" align=\"left\" valign=\"top\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Botrule Rrule\">Cohort 1</th><th styleCode=\"Botrule Rrule\">Cohort 8</th><th styleCode=\"Botrule Rrule\">Cohort 2</th><th styleCode=\"Botrule Rrule\">Cohort 3</th><th styleCode=\"Botrule Rrule\">Cohort 4</th></tr><tr><th styleCode=\"Lrule Rrule\" valign=\"bottom\">Parameter  Mean<footnote>Geometric mean estimates.</footnote> (95% CI)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">12 to &lt;18 Years and Weighing &#x2265;40 kg (N=12)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">&lt;12 Years and Weighing &#x2265;40 kg (N=5)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">28 Days to &lt;18 Years and Weighing 20 to &lt;40 kg (N=12)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">28 Days to &lt;18 Years and Weighing 12 to &lt;20 kg (N=11)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">28 Days to &lt;18 Years and Weighing 3 to &lt;12 kg (N=10)</th></tr></thead><tfoot><tr><td colspan=\"6\" align=\"left\">CI=Confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Remdesivir</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">3890 (3110, 4870)</td><td styleCode=\"Rrule\">3920 (2260, 6820)</td><td styleCode=\"Rrule\">5730 (4660, 7050)</td><td styleCode=\"Rrule\">5570 (4250, 7300)</td><td styleCode=\"Rrule\">4870 (3750, 6340)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">2470 (1920, 3160)</td><td styleCode=\"Rrule\">2270 (1200, 4310)</td><td styleCode=\"Rrule\">3510 (2560, 4820)</td><td styleCode=\"Rrule\">3930 (2140, 7210)</td><td styleCode=\"Rrule\">2910 (1880, 4510)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-441524</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">196 (122, 315)</td><td styleCode=\"Rrule\">163 (57.6, 461)</td><td styleCode=\"Rrule\">183 (129, 260)</td><td styleCode=\"Rrule\">171 (130, 223)</td><td styleCode=\"Rrule\">205 (174, 241)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">3430 (1980, 5920)</td><td styleCode=\"Rrule\">2640 (767, 9100)</td><td styleCode=\"Rrule\">2370 (1500, 3740)</td><td styleCode=\"Rrule\">2410 (1740, 3340)</td><td styleCode=\"Rrule\">2850 (2290, 3540)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>tau</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">98.5 (59.1, 164)</td><td styleCode=\"Rrule\">76.2 (23.9, 243)</td><td styleCode=\"Rrule\">59.9 (34.2, 105)</td><td styleCode=\"Rrule\">68.9 (47.4, 100)</td><td styleCode=\"Rrule\">79.7 (59.5, 107)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-704277</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">308 (211, 450)</td><td styleCode=\"Rrule\">266 (137, 514)</td><td styleCode=\"Rrule\">419 (306, 575)</td><td styleCode=\"Rrule\">444 (335, 587)</td><td styleCode=\"Rrule\">385 (294, 504)</td></tr><tr><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">819 (474, 1420)</td><td styleCode=\"Rrule\">518 (192, 1400)</td><td styleCode=\"Rrule\">753 (542, 1050)</td><td styleCode=\"Rrule\">733 (504, 1060)</td><td styleCode=\"Rrule\">687 (484, 973)</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table19\"><caption>Table 19 Effect of Other Drugs on Remdesivir and Metabolites GS-704277 and GS-441524</caption><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><col width=\"15%\" align=\"center\" valign=\"middle\"/><col width=\"5%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"9%\" align=\"center\" valign=\"middle\"/><col width=\"9%\" align=\"center\" valign=\"middle\"/><col width=\"9%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" valign=\"bottom\" rowspan=\"2\" align=\"center\">Coadministered Drug</th><th styleCode=\"Rrule\" valign=\"bottom\" rowspan=\"2\">Dose of Coadministered Drug (mg)</th><th styleCode=\"Rrule\" valign=\"bottom\" rowspan=\"2\">Remdesivir Dose  (mg)</th><th styleCode=\"Rrule\" valign=\"bottom\" rowspan=\"2\">N  </th><th styleCode=\"Rrule\" valign=\"bottom\" colspan=\"4\">Mean Ratio (90% CI) of Remdesivir, GS-704277, and GS-441524 PK With/Without Coadministered Drug  No Effect = 1.00 (0.70&#x2013;1.43)</th></tr><tr><th styleCode=\"Rrule\"/><th styleCode=\"Rrule\">C<sub>max</sub></th><th styleCode=\"Rrule\">AUC<sub>inf</sub></th><th styleCode=\"Rrule\">C<sub>24</sub></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"8\">CI=confidence interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\">Cyclosporin A<footnote ID=\"foot12\">Interaction study conducted in healthy volunteers.</footnote></td><td styleCode=\"Rrule\" rowspan=\"3\">400 single dose</td><td styleCode=\"Rrule\" rowspan=\"3\">100 single dose</td><td styleCode=\"Rrule\" rowspan=\"3\">9</td><td styleCode=\"Rrule\">remdesivir</td><td styleCode=\"Rrule\">1.49  (1.38&#x2013;1.60)</td><td styleCode=\"Rrule\">1.89  (1.77&#x2013;2.02)</td><td styleCode=\"Rrule\">-</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Rrule\">GS-704277</td><td styleCode=\"Rrule\">2.51  (2.26&#x2013;2.78)</td><td styleCode=\"Rrule\">2.97  (2.75&#x2013;3.20)</td><td styleCode=\"Rrule\">-</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Rrule\">GS-441524</td><td styleCode=\"Rrule\">1.17  (1.12&#x2013;1.22)</td><td styleCode=\"Rrule\">1.03  (0.99&#x2013;1.08)</td><td styleCode=\"Rrule\">1.02  (0.95&#x2013;1.10)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\">Carbamazepine<footnoteRef IDREF=\"foot12\"/></td><td styleCode=\"Rrule\" rowspan=\"3\">300 twice daily</td><td styleCode=\"Rrule\" rowspan=\"3\">100 single dose</td><td styleCode=\"Rrule\" rowspan=\"3\">8</td><td styleCode=\"Rrule\">remdesivir</td><td styleCode=\"Rrule\">0.87  (0.78&#x2013;0.97)</td><td styleCode=\"Rrule\">0.92  (0.83&#x2013;1.02)</td><td styleCode=\"Rrule\">-</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\" align=\"center\">GS-704277</td><td styleCode=\"Rrule\">0.96  (0.84&#x2013;1.10)</td><td styleCode=\"Rrule\">0.98  (0.92&#x2013;1.05)</td><td styleCode=\"Rrule\">-</td></tr><tr><td styleCode=\"Rrule\" align=\"center\">GS-441524</td><td styleCode=\"Rrule\">0.97  (0.88&#x2013;1.07)</td><td styleCode=\"Rrule\">0.83  (0.78&#x2013;0.89)</td><td styleCode=\"Rrule\">0.71  (0.64&#x2013;0.78)</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table20\"><caption>Table 20 Effect of Remdesivir on the Pharmacokinetics of Other Drugs</caption><col width=\"19%\" align=\"left\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"5%\" align=\"center\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"bottom\" align=\"center\">Coadministered Drug</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">Dose of Coadministered Drug (mg)</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">Remdesivir Dose (mg)</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">N</th><th styleCode=\"Rrule\" colspan=\"2\" valign=\"bottom\">Mean Ratio (90% CI) of Coadministered Drug PK With/Without Remdesivir No Effect = 1.00 (0.80&#x2013;1.25)</th></tr><tr><th styleCode=\"Lrule Rrule\" valign=\"bottom\" align=\"center\">C<sub>max</sub></th><th styleCode=\"Rrule\" valign=\"bottom\">AUC<sub>inf</sub></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"6\">CI=confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Midazolam<footnote ID=\"t22ft1\">Interaction study conducted in healthy volunteers.</footnote></td><td styleCode=\"Rrule\">2.5 single dose</td><td styleCode=\"Rrule\">200 single dose</td><td styleCode=\"Rrule\">19</td><td styleCode=\"Rrule\">1.29 (1.19&#x2013;1.41)</td><td styleCode=\"Rrule\">1.20 (1.14&#x2013;1.26)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Midazolam<footnoteRef IDREF=\"t22ft1\"/></td><td styleCode=\"Rrule\">2.5 single dose</td><td styleCode=\"Rrule\">200 single dose followed by 100 once daily (10 doses)<footnote>Midazolam administered with last dose of remdesivir.</footnote></td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">1.45 (1.23&#x2013; 1.70)</td><td styleCode=\"Rrule\">1.30 (1.16&#x2013; 1.45)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Pitavastatin<footnoteRef IDREF=\"t22ft1\"/></td><td styleCode=\"Rrule\">2 single dose</td><td styleCode=\"Rrule\">200 single dose</td><td styleCode=\"Rrule\">20</td><td styleCode=\"Rrule\">1.05 (0.92&#x2013;1.20)</td><td styleCode=\"Rrule\">1.17 (1.09&#x2013;1.24)</td></tr></tbody></table>"],"adverse_reactions_table":["<table width=\"90%\" ID=\"Table4\"><caption>Table 4 Summary of Adverse Reaction Rates in Hospitalized Subjects with Mild, Moderate, or Severe COVID-19 in NIAID ACTT-1</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Types of Adverse Reactions</th><th styleCode=\"Rrule\">VEKLURY  N=532  n (%)</th><th styleCode=\"Rrule\">Placebo  N=516  n (%)</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Adverse reactions, Grades &#x2265;3</td><td styleCode=\"Rrule\">41 (8%)</td><td styleCode=\"Rrule\">46 (9%)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Serious adverse reactions</td><td styleCode=\"Rrule\">2 (0.4%)<footnote>Seizure (n=1), infusion-related reaction (n=1).</footnote></td><td styleCode=\"Rrule\">3 (0.6%)</td></tr><tr><td styleCode=\"Lrule Rrule\">Adverse reactions leading to treatment discontinuation</td><td styleCode=\"Rrule\">11 (2%)<footnote>Seizure (n=1), infusion-related reaction (n=1), transaminases increased (n=3), ALT increased and AST increased (n=1), GFR decreased (n=2), acute kidney injury (n=3).</footnote></td><td styleCode=\"Rrule\">15 (3%)</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table5\"><caption>Table 5 Summary of Adverse Reaction Rates in Hospitalized Subjects with Severe COVID-19 in Study 5773</caption><col width=\"60%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Types of Adverse Reactions</th><th styleCode=\"Rrule\">VEKLURY  5 Days  N=200  n (%)</th><th styleCode=\"Rrule\">VEKLURY  10 Days  N=197  n (%)</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Any adverse reaction, all Grades</td><td styleCode=\"Rrule\">33 (17%)</td><td styleCode=\"Rrule\">40 (20%)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Serious adverse reactions</td><td styleCode=\"Rrule\">3 (2%)<footnote ID=\"foot1\">Transaminases increased (n=5), hepatic enzyme increased (n=1), hypertransaminasaemia (n=1).</footnote></td><td styleCode=\"Rrule\">4 (2%)<footnoteRef IDREF=\"foot1\"/></td></tr><tr><td styleCode=\"Lrule Rrule\">Adverse reactions leading to treatment discontinuation</td><td styleCode=\"Rrule\">5 (3%)<footnote ID=\"foot2\">Transaminases increased (n=4), hepatic enzyme increased (n=2), LFT increased (n=2), hypertransaminasaemia (n=1), ALT increased (n=1), ALT increased and AST increased (n=2), injection site erythema (n=1), rash (n=1).</footnote></td><td styleCode=\"Rrule\">9 (5%)<footnoteRef IDREF=\"foot2\"/></td></tr></tbody></table>","<table width=\"90%\" ID=\"Table6\"><caption>Table 6 Summary of Adverse Reaction<footnote>Attribution of events to study drug was not performed for the SOC group.</footnote> Rates in Hospitalized Subjects with Moderate COVID-19 in Study 5774</caption><col width=\"60%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Types of Adverse Reactions</th><th styleCode=\"Rrule\">VEKLURY  5 Days  N=191  n (%)</th><th styleCode=\"Rrule\">VEKLURY  10 Days  N=193  n (%)</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Any adverse reaction, all Grades</td><td styleCode=\"Rrule\">36 (19%)</td><td styleCode=\"Rrule\">25 (13%)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Serious adverse reactions</td><td styleCode=\"Rrule\">1 (&lt;1%)<footnote>Heart rate decreased.</footnote></td><td styleCode=\"Rrule\">0</td></tr><tr><td styleCode=\"Lrule Rrule\">Adverse reactions leading to treatment discontinuation</td><td styleCode=\"Rrule\">4 (2%)<footnote ID=\"foot3\">ALT increased (n=2), ALT increased and AST increased (n=1), hypertransaminasaemia (n=1), blood alkaline phosphatase increased (n=1), rash (n=2), heart rate decreased (n=1).</footnote></td><td styleCode=\"Rrule\">4 (2%)<footnoteRef IDREF=\"foot3\"/></td></tr></tbody></table>","<table width=\"90%\" ID=\"Table7\"><caption>Table 7 Laboratory Abnormalities (Grades 3&#x2013;4) Reported in &#x2265;3% of Hospitalized Subjects with Mild, Moderate, or Severe COVID-19 in NIAID ACTT-1</caption><col width=\"40%\" align=\"left\" valign=\"bottom\"/><col width=\"30%\" align=\"center\" valign=\"bottom\"/><col width=\"30%\" align=\"center\" valign=\"bottom\"/><thead><tr><th styleCode=\"Lrule Rrule\">Laboratory Parameter Abnormality<footnote>Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017.</footnote></th><th styleCode=\"Rrule\">VEKLURY 10 Days  N=532</th><th styleCode=\"Rrule\">Placebo  N=516</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">ALT increased</td><td styleCode=\"Rrule\">3%</td><td styleCode=\"Rrule\">6%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AST increased</td><td styleCode=\"Rrule\">6%</td><td styleCode=\"Rrule\">8%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Bilirubin increased</td><td styleCode=\"Rrule\">2%</td><td styleCode=\"Rrule\">5%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Creatinine clearance decreased<footnote>Based on the Cockcroft-Gault formula.</footnote></td><td styleCode=\"Rrule\">18%</td><td styleCode=\"Rrule\">20%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Creatinine increased</td><td styleCode=\"Rrule\">15%</td><td styleCode=\"Rrule\">16%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">eGFR decreased</td><td styleCode=\"Rrule\">18%</td><td styleCode=\"Rrule\">24%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Glucose increased</td><td styleCode=\"Rrule\">12%</td><td styleCode=\"Rrule\">13%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hemoglobin decreased</td><td styleCode=\"Rrule\">15%</td><td styleCode=\"Rrule\">22%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Lymphocytes decreased</td><td styleCode=\"Rrule\">11%</td><td styleCode=\"Rrule\">18%</td></tr><tr><td styleCode=\"Lrule Rrule\">Prothrombin time increased</td><td styleCode=\"Rrule\">9%</td><td styleCode=\"Rrule\">4%</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table8\"><caption>Table 8 Laboratory Abnormalities (Grades 3&#x2013;4) Reported in &#x2265;3% of Hospitalized Subjects with Severe COVID-19 in Trial 5773</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Laboratory Parameter Abnormality<footnote>Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017.</footnote></th><th styleCode=\"Rrule\">VEKLURY  5 Days  N=200</th><th styleCode=\"Rrule\">VEKLURY  10 Days  N=197</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">ALT increased</td><td styleCode=\"Rrule\">6%</td><td styleCode=\"Rrule\">8%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AST increased</td><td styleCode=\"Rrule\">7%</td><td styleCode=\"Rrule\">6%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Creatinine clearance decreased<footnote>Based on the Cockcroft-Gault formula.</footnote></td><td styleCode=\"Rrule\">10%</td><td styleCode=\"Rrule\">19%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Creatinine increased</td><td styleCode=\"Rrule\">5%</td><td styleCode=\"Rrule\">15%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Glucose increased</td><td styleCode=\"Rrule\">11%</td><td styleCode=\"Rrule\">8%</td></tr><tr><td styleCode=\"Lrule Rrule\">Hemoglobin decreased</td><td styleCode=\"Rrule\">6%</td><td styleCode=\"Rrule\">8%</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table9\"><caption>Table 9 Laboratory Abnormalities (Grades 3&#x2013;4) Reported in &#x2265;3% of Hospitalized Subjects with Moderate COVID-19 in Trial 5774</caption><col width=\"37%\" align=\"left\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"18%\" align=\"center\" valign=\"middle\"/><col width=\"21%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Laboratory Parameter Abnormality<footnote>Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017.</footnote></th><th styleCode=\"Rrule\">VEKLURY 5 Days N=191</th><th styleCode=\"Rrule\" valign=\"bottom\">VEKLURY 10 Days N=193</th><th styleCode=\"Rrule\" valign=\"bottom\">SOC N=200</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">SOC=Standard of care.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">ALT increased</td><td styleCode=\"Rrule\">2%</td><td styleCode=\"Rrule\">3%</td><td styleCode=\"Rrule\">8%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Creatinine clearance decreased<footnote>Based on the Cockcroft-Gault formula.</footnote></td><td styleCode=\"Rrule\">2%</td><td styleCode=\"Rrule\">5%</td><td styleCode=\"Rrule\">8%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Glucose increased</td><td styleCode=\"Rrule\">4%</td><td styleCode=\"Rrule\">3%</td><td styleCode=\"Rrule\">2%</td></tr><tr><td styleCode=\"Lrule Rrule\">Hemoglobin decreased</td><td styleCode=\"Rrule\">3%</td><td styleCode=\"Rrule\">1%</td><td styleCode=\"Rrule\">6%</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table10\"><caption>Table 10 Laboratory Abnormalities (Grades 3&#x2013;4) Reported in &#x2265;2% of Non-Hospitalized Subjects in Trial 9012</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" valign=\"bottom\">Laboratory Parameter Abnormality<footnote>Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017.</footnote></th><th styleCode=\"Rrule\" valign=\"bottom\">VEKLURY 3 Days  N=279</th><th styleCode=\"Rrule\" valign=\"bottom\">Placebo  N=283</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Creatinine clearance decreased<footnote>Based on the Cockcroft-Gault formula.</footnote></td><td styleCode=\"Rrule\">6%</td><td styleCode=\"Rrule\">2%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Creatinine increased</td><td styleCode=\"Rrule\">3%</td><td styleCode=\"Rrule\">1%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Glucose increased</td><td styleCode=\"Rrule\">6%</td><td styleCode=\"Rrule\">6%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Lymphocytes decreased</td><td styleCode=\"Rrule\">2%</td><td styleCode=\"Rrule\">1%</td></tr><tr><td styleCode=\"Lrule Rrule\">Prothrombin time increased</td><td styleCode=\"Rrule\">1%</td><td styleCode=\"Rrule\">2%</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table11\"><caption>Table 11 Laboratory Abnormalities (Grades 3&#x2013;4) Reported in &#x2265;3% of Hospitalized Subjects in Trial 5912</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" valign=\"bottom\">Laboratory Parameter Abnormality<footnote>Frequencies are based on treatment-emergent laboratory abnormalities. Graded per Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017.</footnote></th><th styleCode=\"Rrule\" valign=\"bottom\">VEKLURY 5 Days  N=163</th><th styleCode=\"Rrule\" valign=\"bottom\">Placebo  N=80</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Lymphocytes decreased</td><td styleCode=\"Rrule\">27%</td><td styleCode=\"Rrule\">27%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hemoglobin decreased</td><td styleCode=\"Rrule\">25%</td><td styleCode=\"Rrule\">25%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Glucose increased</td><td styleCode=\"Rrule\">15%</td><td styleCode=\"Rrule\">19%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Uric acid increased</td><td styleCode=\"Rrule\">11%</td><td styleCode=\"Rrule\">4%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Creatinine increased</td><td styleCode=\"Rrule\">12%</td><td styleCode=\"Rrule\">14%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Albumin decreased</td><td styleCode=\"Rrule\">12%</td><td styleCode=\"Rrule\">10%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Lipase increased</td><td styleCode=\"Rrule\">12%</td><td styleCode=\"Rrule\">7%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Prothrombin time increased</td><td styleCode=\"Rrule\">11%</td><td styleCode=\"Rrule\">4%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Prothrombin INR increased</td><td styleCode=\"Rrule\">7%</td><td styleCode=\"Rrule\">4%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AST increased </td><td styleCode=\"Rrule\">6%</td><td styleCode=\"Rrule\">4%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Thromboplastin time increased</td><td styleCode=\"Rrule\">5%</td><td styleCode=\"Rrule\">4%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">ALT increased</td><td styleCode=\"Rrule\">5%</td><td styleCode=\"Rrule\">6%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Sodium increased</td><td styleCode=\"Rrule\">3%</td><td styleCode=\"Rrule\">3%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Calcium increased </td><td styleCode=\"Rrule\">3%</td><td styleCode=\"Rrule\">0</td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Hypersensitivity Reactions Inform patients that hypersensitivity reactions have been seen in patients receiving VEKLURY during and after infusion. Advise patients to inform their healthcare provider if they experience any of the following: changes in heart rate; fever; shortness of breath, wheezing; swelling of the lips, face, or throat; rash; nausea; sweating; or shivering [see Warnings and Precautions (5.1) ]. Increased Risk of Transaminase Elevations Inform patients that VEKLURY may increase the risk of hepatic laboratory abnormalities. Advise patients to alert their healthcare provider immediately if they experience any symptoms of liver inflammation [see Warnings and Precaution (5.2) ]. Drug Interactions Inform patients that VEKLURY may interact with other drugs. Advise patients to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products, including chloroquine phosphate or hydroxychloroquine sulfate [see Warnings and Precautions (5.3) , Drug Interactions (7) , and Microbiology (12.4) ]. Pregnancy Inform patients to notify their healthcare provider in the event of a pregnancy [see Use in Specific Populations (8.1) ]."],"spl_unclassified_section":["VEKLURY is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners. © 2025 Gilead Sciences, Inc. All rights reserved"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Testing: In all patients, before starting VEKLURY and during treatment as clinically appropriate, perform hepatic laboratory testing. Assess prothrombin time before starting VEKLURY and monitor as clinically appropriate. ( 2.2 ) Recommended dosage: Adults and pediatric patients weighing at least 40 kg: a single loading dose of VEKLURY 200 mg on Day 1 followed by once-daily maintenance doses of VEKLURY 100 mg from Day 2 via intravenous infusion. ( 2.3 ) Pediatric patients (birth to less than 18 years of age) weighing 1.5 kg to less than 40 kg: Recommended dosage is based on weight. Refer to Table 1 of the full prescribing information for specific dosing guidelines based on body weight. ( 2.3 ) Hospitalized patients: The treatment course of VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 has been made. ( 2.3 ) For hospitalized patients requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 10 days. ( 2.3 ) For hospitalized patients not requiring invasive mechanical ventilation and/or ECMO, the recommended treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. ( 2.3 ) Non-hospitalized patients: The treatment course of VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 has been made and within 7 days of symptom onset. ( 2.3 ) For non-hospitalized patients diagnosed with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death, the recommended total treatment duration is 3 days ( 2.3 ). Renal impairment: No dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment, including those on dialysis. ( 2.4 ) Administer VEKLURY via intravenous (IV) infusion over 30 to 120 minutes. ( 2.5 ) Dose preparation and administration: Refer to the full prescribing information for further details. ( 2.5 ) Storage of prepared dosages: VEKLURY contains no preservative. ( 2.6 ) 2.1 Dosage and Administration Overview VEKLURY may only be administered in settings in which healthcare providers have immediate access to medications to treat a severe infusion or hypersensitivity reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary [see Dosage and Administration (2.5) , Warnings and Precautions (5.1) ] . Administer VEKLURY for the treatment of COVID-19 in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) by intravenous infusion only. Do not administer by any other route. VEKLURY for injection must be reconstituted with Sterile Water for Injection prior to diluting with 0.9% sodium chloride injection. 2.2 Testing Before Starting and During Treatment with VEKLURY Perform hepatic laboratory testing in all patients before starting VEKLURY and while receiving VEKLURY as clinically appropriate [see Warnings and Precautions (5.2) and Use in Specific Populations (8.7) ]. Determine prothrombin time in all patients before starting VEKLURY and monitor while receiving VEKLURY as clinically appropriate [see Adverse Reactions (6.1) ]. 2.3 Recommended Dosage in Adults and Pediatric Patients (Birth to Less than 18 Years of Age Weighing at Least 1.5 kg) The recommended dosage for adults and pediatric patients weighing at least 40 kg is a single loading dose of VEKLURY 200 mg on Day 1 via intravenous infusion followed by once-daily maintenance doses of VEKLURY 100 mg from Day 2 via intravenous infusion. The recommended dosage for pediatric patients weighing 1.5 kg to less than 40 kg is presented in Table 1. Table 1 Recommended Dosage in Pediatric Patients Including Term Gestational age greater than 37 weeks. Neonates and Infants Weighing 1.5 kg to Less than 40 kg Pediatric Patient Population Loading Dose Via Intravenous Infusion Maintenance Dose Via Intravenous Infusion Less than 28 days old and at least 1.5 kg VEKLURY 2.5 mg/kg on Day 1 VEKLURY 1.25 mg/kg once daily from Day 2 At least 28 days old and 1.5 kg to less than 3 kg At least 28 days old and 3 kg to less than 40 kg VEKLURY 5 mg/kg on Day 1 VEKLURY 2.5 mg/kg once daily from Day 2 The treatment course of VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 has been made. The recommended total treatment duration for hospitalized patients requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) is 10 days. The recommended treatment duration for hospitalized patients not requiring invasive mechanical ventilation and/or ECMO is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Non-hospitalized patients : The treatment course of VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 has been made and within 7 days of symptom onset. The recommended total treatment duration for non-hospitalized patients diagnosed with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death, is 3 days. VEKLURY must be diluted prior to intravenous infusion. Refer to Dosage and Administration (2.5) for detailed preparation and administration instructions. 2.4 Renal Impairment No dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment, including patients on dialysis. VEKLURY may be administered without regard to the timing of dialysis [see Dosage and Administration (2.3) and Use in Specific Populations (8.4 , 8.6) ]. 2.5 Dosage Preparation and Administration Reconstitution Instructions Remove the required number of single-dose vial(s) from storage. For each vial: Inspect the vial to ensure the container closure is free from defects. Aseptically reconstitute VEKLURY lyophilized powder by adding 19 mL of Sterile Water for Injection using a suitably sized syringe and needle per vial, and insert the needle in the center of the vial stopper. Only use Sterile Water for Injection to reconstitute VEKLURY lyophilized powder. Discard the vial if a vacuum does not pull the Sterile Water for Injection into the vial. Immediately shake the vial for 30 seconds. Allow the contents of the vial to settle for 2 to 3 minutes. A clear, colorless to yellow solution, free of visible particles, should result. If the contents of the vial are not completely dissolved, shake the vial again for 30 seconds and allow the contents to settle for 2 to 3 minutes. Repeat this procedure as necessary until the contents of the vial are completely dissolved. Discard the vial if the contents are not completely dissolved. Following reconstitution, each vial contains 100 mg/20 mL (5 mg/mL) of remdesivir solution. Use reconstituted product immediately to prepare the diluted drug product. Detailed dilution and administration instruction based on patient’s weight is provided below. Dilution Instructions for Adults and Pediatric Patients Weighing at Least 40 kg Care should be taken during admixture to prevent inadvertent microbial contamination. As there is no preservative or bacteriostatic agent present in this product, aseptic technique must be used in preparation of the final parenteral solution. It is always recommended to administer intravenous medication immediately after preparation when possible. Reconstituted VEKLURY for injection, containing 100 mg/20 mL remdesivir solution, must be further diluted in either a 100 mL or 250 mL 0.9% sodium chloride injection infusion bag. Refer to Table 2 for instructions. Table 2 Recommended Dilution Instructions—Reconstituted VEKLURY for Injection in Adults and Pediatric Patients Weighing at Least 40 kg VEKLURY dose 0.9% sodium chloride injection infusion bag volume to be used Volume to be withdrawn and discarded from 0.9% sodium chloride injection infusion bag Required volume of reconstituted VEKLURY for injection Loading dose 200 mg (2 vials) 250 mL 40 mL 40 mL (2 × 20 mL) 100 mL 40 mL 40 mL (2 × 20 mL) Maintenance dose 100 mg (1 vial) 250 mL 20 mL 20 mL 100 mL 20 mL 20 mL Withdraw and discard the required volume of 0.9% sodium chloride injection from the bag following instructions in Table 2, using an appropriately sized syringe and needle. Inspect the reconstituted VEKLURY for injection vial to ensure the solution is free of particulate matter. Withdraw the required volume of reconstituted VEKLURY for injection from the VEKLURY vial following instructions in Table 2, using an appropriately sized syringe. Discard any unused portion remaining in the reconstituted vial. Transfer the required volume of reconstituted VEKLURY for injection to the selected infusion bag. Gently invert the bag 20 times to mix the solution in the bag. Do not shake. The prepared infusion solution can be stored for 24 hours at room temperature (20°C to 25°C [68°F to 77°F]) or 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) prior to administration. Administration Instructions for Adults and Pediatric Patients Weighing at Least 40 kg Do not administer the prepared diluted solution simultaneously with any other medication. The compatibility of VEKLURY injection with intravenous solutions and medications other than 0.9% sodium chloride injection, USP is not known. Administer VEKLURY via intravenous infusion over 30 to 120 minutes. Administration should be under conditions where management of severe hypersensitivity reactions, such as anaphylaxis, is possible. Monitor patients during infusion and observe patients for at least one hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate [see Warnings and Precautions (5.1) ] . Administer the diluted solution with the infusion rate described in Table 3. Table 3 Recommended Rate of Infusion—Diluted VEKLURY for Injection in Adults and Pediatric Patients Weighing at Least 40 kg Infusion bag volume Infusion time Rate of infusion 250 mL 30 min 8.33 mL/min 60 min 4.17 mL/min 120 min 2.08 mL/min 100 mL 30 min 3.33 mL/min 60 min 1.67 mL/min 120 min 0.83 mL/min Dilution Instructions for Pediatric Patients (Birth to Less than 18 Years of Age) Weighing 1.5 kg to Less than 40 kg Care should be taken during admixture to prevent inadvertent microbial contamination. As there is no preservative or bacteriostatic agent present in this product, aseptic technique must be used in preparation of the final parenteral solution. It is always recommended to administer intravenous medication immediately after preparation when possible. Inspect the reconstituted VEKLURY for injection vial to ensure the reconstituted solution is free of particulate matter. For pediatric patients (birth to less than 18 years of age) weighing 1.5 kg to less than 40 kg, the 100 mg/20 mL (5 mg/mL) remdesivir reconstituted solution should be further diluted to a fixed concentration of 1.25 mg/mL using 0.9% sodium chloride injection. The final required infusion volume concentration of 1.25 mg/mL remdesivir diluted solution for infusion is based on the pediatric weight-based dosing regimens. Small 0.9% sodium chloride injection infusion bags (e.g., 25, 50, or 100 mL) or an appropriately sized syringe should be used for pediatric dosing. The recommended dose is administered via intravenous infusion in a total volume dependent on the dose to yield the target remdesivir concentration of 1.25 mg/mL. A syringe and syringe pump may be used for infusion volumes less than 50 mL. Infusion with IV Bag Determine the total infusion volume needed to achieve a final infusion volume concentration of 1.25 mg/mL of remdesivir diluted solution based on the patient's calculated dose. Select an appropriately sized infusion bag (either prefilled with 0.9% sodium chloride injection or empty) to prepare VEKLURY diluted solution. If using a prefilled 0.9% sodium chloride injection infusion bag, withdraw and discard the amount of diluent equal to the volume of reconstituted VEKLURY solution needed per patient's dose plus a quantity sufficient to achieve a 1.25 mg/mL final volume concentration of remdesivir diluted solution. Withdraw the required volume of reconstituted VEKLURY solution into an appropriately sized syringe. Transfer the required volume of reconstituted VEKLURY solution to the 0.9% sodium chloride injection infusion bag. Gently invert the bag 20 times to mix the solution in the bag. Do not shake. If using an empty infusion bag, transfer the required volume of reconstituted VEKLURY solution to the bag, followed by a volume of 0.9% sodium chloride injection sufficient to achieve a 1.25 mg/mL final volume concentration of remdesivir diluted solution. The prepared infusion solution is stable for 24 hours at room temperature (20°C to 25°C [68°F to 77°F]) or 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]). Infusion with Syringe Determine the total infusion volume needed to achieve a final infusion volume concentration of 1.25 mg/mL of remdesivir diluted solution based on patient's calculated dose. Select an appropriately sized syringe equal to or larger than the calculated total infusion volume of 1.25 mg/mL remdesivir solution needed. Withdraw the required volume of reconstituted VEKLURY solution from the vial into the syringe based on patient's calculated dose, followed by the required volume of 0.9% sodium chloride injection needed to achieve a 1.25 mg/mL final volume concentration of remdesivir diluted solution. Gently invert the syringe 20 times to mix the solution in the syringe. Do not shake. The prepared diluted solution should be used immediately. Administration Instructions for Pediatric Patients (Birth to Less than 18 Years of Age) Weighing 1.5 kg to Less than 40 kg The prepared diluted solution should not be administered simultaneously with any other medication. The compatibility of VEKLURY with IV solutions and medications other than 0.9% sodium chloride injection, USP is not known. Administer VEKLURY via intravenous infusion over 30 to 120 minutes. The rate of infusion (mL/min) should be calculated based on the total infusion volume and total infusion time. Administration should be under conditions where management of severe hypersensitivity reactions, such as anaphylaxis, is possible. Monitor patients during infusion and observe patients for at least one hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate [see Warnings and Precautions (5.1) ] . 2.6 Storage of Prepared Dosages After reconstitution, use vials immediately to prepare diluted solution. The diluted VEKLURY solution in the infusion bags can be stored up to 24 hours at room temperature (20°C to 25°C [68°F to 77°F]) prior to administration or 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]). IMPORTANT: This product contains no preservative. Any unused portion of a single-dose VEKLURY vial should be discarded after a diluted solution is prepared."],"spl_product_data_elements":["Veklury remdesivir REMDESIVIR REMDESIVIR BETADEX SULFOBUTYL ETHER SODIUM WATER HYDROCHLORIC ACID SODIUM HYDROXIDE Veklury remdesivir REMDESIVIR REMDESIVIR BETADEX SULFOBUTYL ETHER SODIUM WATER HYDROCHLORIC ACID SODIUM HYDROXIDE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS VEKLURY for injection, 100 mg, available as a sterile, preservative-free white to off-white to yellow lyophilized powder in single-dose vial for reconstitution. For injection: 100 mg of remdesivir as a lyophilized powder, in a single-dose vial. ( 3 )"],"recent_major_changes_table":["<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"75%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"right\" valign=\"top\"/><tbody><tr><td>Dosage and Administration</td><td/></tr><tr><td> Dosage and Administration Overview (<linkHtml href=\"#S2.1\">2.1</linkHtml>)</td><td>10/2025</td></tr><tr><td> Dosage Preparation and Administration (<linkHtml href=\"#S2.5\">2.5</linkHtml>)</td><td>10/2025</td></tr><tr><td> Storage of Prepared Dosages (<linkHtml href=\"#S2.6\">2.6</linkHtml>)</td><td>10/2025</td></tr></tbody></table>"],"spl_patient_package_insert":["This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 10/2025 PATIENT INFORMATION VEKLURY ® (VEK-lur-ee) (remdesivir) for injection What is VEKLURY? VEKLURY is a prescription medicine used for the treatment of coronavirus disease 2019 (COVID-19) in adults and children weighing at least 3 pounds (1.5 kg) who are: Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. It is not known if VEKLURY is safe and effective in children weighing less than 3 pounds (1.5 kg). Do not take VEKLURY if you are allergic to remdesivir or any of the ingredients in VEKLURY. See the end of this leaflet for a complete list of ingredients in VEKLURY. Before receiving VEKLURY, tell your healthcare provider about all of your medical conditions, including if you: have liver problems are pregnant or plan to become pregnant. It is not known if VEKLURY may harm your unborn baby if taken during the first trimester of pregnancy. Tell your healthcare provider right away if you are or if you become pregnant. are breastfeeding or plan to breastfeed. VEKLURY can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. VEKLURY may interact with other medicines. Especially tell your healthcare provider if you are taking the medicines chloroquine phosphate or hydroxychloroquine sulfate. How will I receive VEKLURY? Hospitalized : VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for up to 10 days. Your healthcare provider will decide how many doses you need. Not hospitalized: VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for 3 days. Your healthcare provider will do certain blood tests before starting and during treatment with VEKLURY. What are the possible side effects of VEKLURY? VEKLURY may cause serious side effects, including: Allergic reactions. Allergic reactions can happen during or after infusion with VEKLURY. Your healthcare provider will monitor you for signs and symptoms of allergic reactions during your infusion and for at least 1 hour after your infusion. Tell your healthcare provider right away if you get any of the following signs and symptoms of an allergic reaction: changes in your heart rate fever shortness of breath, wheezing swelling of the lips, face, or throat rash nausea sweating shivering Increase in liver enzymes. Increases in liver enzymes are common in people who have received VEKLURY and may be a sign of liver injury. Your healthcare provider will do blood tests to check your liver enzymes before and during treatment with VEKLURY as needed. Your healthcare provider may stop treatment with VEKLURY if you develop liver problems. The most common side effect of VEKLURY is nausea. These are not all of the possible side effects of VEKLURY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of VEKLURY. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about VEKLURY that is written for healthcare professionals. What are the ingredients in VEKLURY? Active ingredient: remdesivir Inactive ingredients: betadex sulfobutyl ether sodium and may include hydrochloric acid and/or sodium hydroxide for pH adjustment. Manufactured and distributed by: Gilead Sciences, Inc., Foster City, CA 94404 VEKLURY is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners. © 2025 Gilead Sciences, Inc. All rights reserved. 214787-GS-022 For more information, call 1-800-445-3235 or go to www.VEKLURY.com."],"clinical_pharmacology_table":["<table width=\"90%\" ID=\"Table12\"><caption>Table 12 Pharmacokinetic Properties of Remdesivir and Metabolites (GS-441524 and GS-704277)</caption><col width=\"28%\" align=\"left\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">Remdesivir</th><th styleCode=\"Rrule\">GS-441524</th><th styleCode=\"Rrule\">GS-704277</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">ND=not detected</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Absorption</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">T<sub>max</sub> (h)<footnote>Remdesivir administered as a 30-minute IV infusion (Study GS-US-399-5505); range of median observed on Day 1 and Day 5 or 10.</footnote></td><td styleCode=\"Rrule\">0.67&#x2013;0.68</td><td styleCode=\"Rrule\">1.51&#x2013;2.00</td><td styleCode=\"Rrule\">0.75&#x2013;0.75</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Distribution</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">% bound to human plasma proteins</td><td styleCode=\"Rrule\">88&#x2013;93.6<footnote>Range of protein binding for remdesivir from 2 independent experiments show no evidence of concentration-dependent protein binding for remdesivir.</footnote></td><td styleCode=\"Rrule\">2</td><td styleCode=\"Rrule\">1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Blood-to-plasma ratio</td><td styleCode=\"Rrule\">0.68&#x2013;1.0</td><td styleCode=\"Rrule\">1.19</td><td styleCode=\"Rrule\">0.56</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Elimination</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">t<sub>1/2</sub> (h)<footnote>Median (Study GS-US-399-4231).</footnote></td><td styleCode=\"Rrule\">1</td><td styleCode=\"Rrule\">27</td><td styleCode=\"Rrule\">1.3</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Metabolism </content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Metabolic pathway(s)</td><td styleCode=\"Rrule\">CES1 (80%)  Cathepsin A (10%)  CYP3A (10%)</td><td styleCode=\"Rrule\">Not significantly metabolized</td><td styleCode=\"Rrule\">HINT1</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Excretion</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Major route of elimination</td><td styleCode=\"Rrule\">Metabolism</td><td styleCode=\"Rrule\">Glomerular filtration and active tubular secretion</td><td styleCode=\"Rrule\">Metabolism</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">% of dose excreted in urine<footnote ID=\"foot5\">Mean (Study GS-US-399-4231).</footnote></td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">49</td><td styleCode=\"Rrule\">2.9</td></tr><tr><td styleCode=\"Lrule Rrule\">% of dose excreted in feces<footnoteRef IDREF=\"foot5\"/></td><td styleCode=\"Rrule\">ND</td><td styleCode=\"Rrule\">0.5</td><td styleCode=\"Rrule\">ND</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table13\"><caption>Table 13 Multiple Dose PK Parameters<footnote>Population PK estimates for 30-minute IV infusion of remdesivir for 3 days (Study GS-US-540-9012, n=147).</footnote> of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of VEKLURY 100 mg to Adults with COVID-19</caption><col width=\"28%\" align=\"left\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Parameter Mean<footnote>Geometric mean estimates.</footnote> (95% CI)</th><th styleCode=\"Rrule\">Remdesivir</th><th styleCode=\"Rrule\">GS-441524</th><th styleCode=\"Rrule\">GS-704277</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">CI=Confidence Interval; ND=Not detectable (at 24 hours post-dose)</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">2700 (2440, 2990)</td><td styleCode=\"Rrule\">143 (135, 152)</td><td styleCode=\"Rrule\">198 (180, 218)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">1710 (1480, 1980)</td><td styleCode=\"Rrule\">2410 (2250, 2580)</td><td styleCode=\"Rrule\">392 (348, 442)</td></tr><tr><td styleCode=\"Lrule Rrule\">C<sub>trough</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">ND</td><td styleCode=\"Rrule\">61.5 (56.5, 66.8)</td><td styleCode=\"Rrule\">ND</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table14\"><caption>Table 14 Multiple Dose PK Parameters<footnote>Study CO-US-590-5961 (IMPAACT).</footnote> of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY to Pregnant and Non-Pregnant Individuals with COVID-19 </caption><col width=\"34%\" align=\"left\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Parameter  Mean<footnote>Geometric mean estimates.</footnote> (90% CI)</th><th styleCode=\"Rrule\">Pregnant Individuals (N=21)</th><th styleCode=\"Rrule\">Non-Pregnant Individuals (N=22)</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"3\">CI=Confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Remdesivir</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">1360 (978, 1890)</td><td styleCode=\"Rrule\">1240 (891, 1720)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">1250 (916, 1700)<footnote>N=18</footnote></td><td styleCode=\"Rrule\">1300 (1070, 1590)<footnote>N=17</footnote></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-441524</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">113 (102, 126)</td><td styleCode=\"Rrule\">121 (108, 136)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">1840 (1630, 2070)<footnote ID=\"t14fe\">N=20</footnote></td><td styleCode=\"Rrule\">2050 (1780, 2350)<footnote ID=\"t14ff\">N=21</footnote></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>tau</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">51.6 (44.7, 59.6)<footnoteRef IDREF=\"t14fe\"/></td><td styleCode=\"Rrule\">57.1 (48.7, 66.9)<footnoteRef IDREF=\"t14ff\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-704277</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">217 (187, 252)</td><td styleCode=\"Rrule\">213 (188, 240)</td></tr><tr><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">454 (406, 508)<footnoteRef IDREF=\"t14fe\"/></td><td styleCode=\"Rrule\">437 (384, 497)</td></tr></tbody></table>","<table width=\"95%\" ID=\"Table15\"><caption>Table 15 Comparison of PK Parameters<footnote>Exposures were estimated using noncompartmental analysis from a dedicated Phase 1 renal impairment Study GS-US-540-9015; single doses up to 100 mg were administered; each subject with renal impairment had a matched control participant enrolled with normal renal function (eGFR &#x2265;90 mL/minute/1.73m<sup>2</sup>), same sex, and similar BMI (&#xB1; 20%) and age (&#xB1; 10 years).</footnote> of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of Single Dose VEKLURY to Adults with Renal Impairment<footnote ID=\"t15fb\">eGFR was calculated using Modification of Diet in Renal Disease equation and values represent mL/minute/1.73m<sup>2</sup>.</footnote> as Compared to Adults with Normal Renal Function</caption><col width=\"14%\" align=\"left\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"bottom\" align=\"center\">Mean Ratio (90% CI)<footnote>No effect=1.0 (0.5&#x2013;2.0)</footnote></th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">60&#x2013;89 mL per minute<footnoteRef IDREF=\"t15fb\"/> N=10</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">30&#x2013;59 mL per minute<footnoteRef IDREF=\"t15fb\"/> N=10</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">15&#x2013;29 mL per minute<footnoteRef IDREF=\"t15fb\"/> N=10</th><th styleCode=\"Rrule\" colspan=\"3\" valign=\"bottom\">&lt;15 mL per minute<footnoteRef IDREF=\"t15fb\"/></th></tr><tr><th styleCode=\"Lrule Rrule\" valign=\"bottom\" align=\"center\">Pre-hemodialysis N=6</th><th styleCode=\"Rrule\" valign=\"bottom\">Post-hemodialysis N=6</th><th styleCode=\"Rrule\" valign=\"bottom\">No dialysis N=3</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"7\">CI=Confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Remdesivir</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">0.96 (0.71, 1.31)</td><td styleCode=\"Rrule\">1.20 (1.01, 1.42)</td><td styleCode=\"Rrule\">0.97 (0.83, 1.13)</td><td styleCode=\"Rrule\">0.89 (0.67, 1.18)</td><td styleCode=\"Rrule\">1.13 (0.79, 1.60)</td><td styleCode=\"Rrule\">0.94 (0.65, 1.35)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.00 (0.75, 1.32)</td><td styleCode=\"Rrule\">1.22 (0.98, 1.52)</td><td styleCode=\"Rrule\">0.94 (0.83, 1.07)</td><td styleCode=\"Rrule\">0.80 (0.59, 1.08)</td><td styleCode=\"Rrule\">1.08 (0.72, 1.63)</td><td styleCode=\"Rrule\">0.89 (0.55, 1.43)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-441524</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">1.07 (0.90, 1.26)</td><td styleCode=\"Rrule\">1.44 (1.13, 1.85)</td><td styleCode=\"Rrule\">1.68 (1.28, 2.20)</td><td styleCode=\"Rrule\">2.27 (1.72, 2.99)</td><td styleCode=\"Rrule\">3.07 (2.21, 4.26)</td><td styleCode=\"Rrule\">3.00 (2.63, 3.42)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.19 (0.97, 1.47)</td><td styleCode=\"Rrule\">2.02 (1.57, 2.62)</td><td styleCode=\"Rrule\">3.26 (2.39, 4.46)</td><td styleCode=\"Rrule\">4.97 (3.65, 6.77)</td><td styleCode=\"Rrule\">6.22 (4.44, 8.71)</td><td styleCode=\"Rrule\">7.87 (6.49, 9.53)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-704277</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">2.25 (1.20, 4.20)</td><td styleCode=\"Rrule\">1.83 (1.34, 2.49)</td><td styleCode=\"Rrule\">1.27 (0.96, 1.68)</td><td styleCode=\"Rrule\">1.43 (1.00, 2.05)</td><td styleCode=\"Rrule\">1.23 (0.84, 1.80)</td><td styleCode=\"Rrule\">1.76 (1.19, 2.61)</td></tr><tr><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.39 (1.13, 1.71)</td><td styleCode=\"Rrule\">2.01 (1.48, 2.73)</td><td styleCode=\"Rrule\">1.78 (1.27, 2.49)</td><td styleCode=\"Rrule\">2.18 (1.61, 2.95)</td><td styleCode=\"Rrule\">2.06 (1.42, 2.97)</td><td styleCode=\"Rrule\">2.81 (1.79, 4.43)</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table16\"><caption>Table 16 Comparison of PK Parameters of Remdesivir and Metabolites (GS-441524 and GS-704277) Following IV Administration of VEKLURY (200 mg on Day 1 Followed by 100 mg Daily on Days 2&#x2013;5) in Adults with COVID-19 with<footnote>Population PK estimates for 30-minute IV infusion of remdesivir for 5 days (Study GS-US-540-5912, n=90).</footnote> or without<footnote>Population PK estimates for 30-minute IV infusion of remdesivir for 3 days (Study GS-US-540-9012, n=148).</footnote> Severely Reduced Kidney Function<footnote>AKI (defined as a 50% increase in serum creatinine within a 48-hour period that was sustained for &#x2265;6 hours despite supportive care); CKD (eGFR &lt;30 mL/minute/1.73m<sup>2</sup>); or ESRD (eGFR &lt;15 mL/minute/1.73m<sup>2</sup>) requiring hemodialysis.</footnote></caption><col width=\"27%\" align=\"left\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"27%\" align=\"center\" valign=\"middle\"/><col width=\"27%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" valign=\"top\">Mean Ratio (90% CI)<footnote>No effect=1.0 (0.5&#x2013;2.0)</footnote></th><th styleCode=\"Rrule\">Remdesivir</th><th styleCode=\"Rrule\">GS-441524</th><th styleCode=\"Rrule\">GS-704277</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"4\">CI=Confidence Interval; ND=Not detectable (at 24 hours post-dose)</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">C<sub>max</sub></td><td styleCode=\"Rrule\">1.39 (1.25, 1.54)</td><td styleCode=\"Rrule\">4.98 (4.61, 5.38)</td><td styleCode=\"Rrule\">1.84 (1.63, 2.08)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">AUC<sub>tau</sub></td><td styleCode=\"Rrule\">1.79 (1.59, 2.01)</td><td styleCode=\"Rrule\">6.59 (6.05, 7.18)</td><td styleCode=\"Rrule\">3.94 (3.50, 4.43)</td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">C<sub>tau</sub></td><td styleCode=\"Rrule\">ND</td><td styleCode=\"Rrule\">5.82 (5.25, 6.45)</td><td styleCode=\"Rrule\">ND</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table17\"><caption>Table 17 Comparison of PK Parameters of Remdesivir and GS-441524 Following IV Administration of Single Dose VEKLURY to Adults with Hepatic Impairment as Compared to Adults with Normal Hepatic Function</caption><col width=\"30%\" align=\"left\" valign=\"middle\"/><col width=\"35%\" align=\"center\" valign=\"middle\"/><col width=\"35%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Mean Ratio (90% CI)<footnote>No effect=1.0 (0.5&#x2013;2.0)</footnote></th><th styleCode=\"Rrule\">Moderate Hepatic Impairment  N=10</th><th styleCode=\"Rrule\">Severe Hepatic Impairment  N=6</th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\">CI=Confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Remdesivir</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.21 (0.87, 1.67)</td><td styleCode=\"Rrule\">1.56 (1.20, 2.03)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">1.10 (0.75, 1.60)</td><td styleCode=\"Rrule\">1.03 (0.70, 1.51)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Unbound AUC<sub>inf</sub></td><td styleCode=\"Rrule\">1.15 (0.86, 1.54)</td><td styleCode=\"Rrule\">2.44 (1.93, 3.08)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Unbound C<sub>max</sub></td><td styleCode=\"Rrule\">1.04 (0.73, 1.48)</td><td styleCode=\"Rrule\">1.57 (1.08, 2.29)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-441524</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>inf</sub></td><td styleCode=\"Rrule\">0.90 (0.69, 1.17)</td><td styleCode=\"Rrule\">1.31 (0.93, 1.84)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub></td><td styleCode=\"Rrule\">1.09 (0.86, 1.38)</td><td styleCode=\"Rrule\">1.48 (1.17, 1.86)</td></tr><tr><td styleCode=\"Lrule Rrule\">C<sub>24</sub></td><td styleCode=\"Rrule\">0.93 (0.69, 1.24)</td><td styleCode=\"Rrule\">1.16 (0.76, 1.77)</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table18\"><caption>Table 18 Multiple Dose PK Parameters<footnote>Population PK estimates for 30-minutes IV infusion of remdesivir for up to 10 days (Study GS-US-540-5823).</footnote> of Remdesivir and Metabolites (GS-441524 and GS-704277) Following Intravenous Administration of VEKLURY 100 mg (Cohorts 1 and 8) or 2.5 mg/kg (Cohorts 2&#x2013;4) to Pediatric Patients with COVID-19</caption><col width=\"15%\" align=\"left\" valign=\"top\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><col width=\"17%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Botrule Rrule\">Cohort 1</th><th styleCode=\"Botrule Rrule\">Cohort 8</th><th styleCode=\"Botrule Rrule\">Cohort 2</th><th styleCode=\"Botrule Rrule\">Cohort 3</th><th styleCode=\"Botrule Rrule\">Cohort 4</th></tr><tr><th styleCode=\"Lrule Rrule\" valign=\"bottom\">Parameter  Mean<footnote>Geometric mean estimates.</footnote> (95% CI)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">12 to &lt;18 Years and Weighing &#x2265;40 kg (N=12)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">&lt;12 Years and Weighing &#x2265;40 kg (N=5)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">28 Days to &lt;18 Years and Weighing 20 to &lt;40 kg (N=12)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">28 Days to &lt;18 Years and Weighing 12 to &lt;20 kg (N=11)</th><th styleCode=\"Rrule Toprule\" valign=\"bottom\">28 Days to &lt;18 Years and Weighing 3 to &lt;12 kg (N=10)</th></tr></thead><tfoot><tr><td colspan=\"6\" align=\"left\">CI=Confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Remdesivir</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">3890 (3110, 4870)</td><td styleCode=\"Rrule\">3920 (2260, 6820)</td><td styleCode=\"Rrule\">5730 (4660, 7050)</td><td styleCode=\"Rrule\">5570 (4250, 7300)</td><td styleCode=\"Rrule\">4870 (3750, 6340)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">2470 (1920, 3160)</td><td styleCode=\"Rrule\">2270 (1200, 4310)</td><td styleCode=\"Rrule\">3510 (2560, 4820)</td><td styleCode=\"Rrule\">3930 (2140, 7210)</td><td styleCode=\"Rrule\">2910 (1880, 4510)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-441524</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">196 (122, 315)</td><td styleCode=\"Rrule\">163 (57.6, 461)</td><td styleCode=\"Rrule\">183 (129, 260)</td><td styleCode=\"Rrule\">171 (130, 223)</td><td styleCode=\"Rrule\">205 (174, 241)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">3430 (1980, 5920)</td><td styleCode=\"Rrule\">2640 (767, 9100)</td><td styleCode=\"Rrule\">2370 (1500, 3740)</td><td styleCode=\"Rrule\">2410 (1740, 3340)</td><td styleCode=\"Rrule\">2850 (2290, 3540)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>tau</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">98.5 (59.1, 164)</td><td styleCode=\"Rrule\">76.2 (23.9, 243)</td><td styleCode=\"Rrule\">59.9 (34.2, 105)</td><td styleCode=\"Rrule\">68.9 (47.4, 100)</td><td styleCode=\"Rrule\">79.7 (59.5, 107)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">GS-704277</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">C<sub>max</sub> (nanogram per mL)</td><td styleCode=\"Rrule\">308 (211, 450)</td><td styleCode=\"Rrule\">266 (137, 514)</td><td styleCode=\"Rrule\">419 (306, 575)</td><td styleCode=\"Rrule\">444 (335, 587)</td><td styleCode=\"Rrule\">385 (294, 504)</td></tr><tr><td styleCode=\"Lrule Rrule\">AUC<sub>tau</sub> (nanogram&#x2219;h per mL)</td><td styleCode=\"Rrule\">819 (474, 1420)</td><td styleCode=\"Rrule\">518 (192, 1400)</td><td styleCode=\"Rrule\">753 (542, 1050)</td><td styleCode=\"Rrule\">733 (504, 1060)</td><td styleCode=\"Rrule\">687 (484, 973)</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table19\"><caption>Table 19 Effect of Other Drugs on Remdesivir and Metabolites GS-704277 and GS-441524</caption><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><col width=\"15%\" align=\"center\" valign=\"middle\"/><col width=\"5%\" align=\"center\" valign=\"middle\"/><col width=\"13%\" align=\"center\" valign=\"middle\"/><col width=\"9%\" align=\"center\" valign=\"middle\"/><col width=\"9%\" align=\"center\" valign=\"middle\"/><col width=\"9%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" valign=\"bottom\" rowspan=\"2\" align=\"center\">Coadministered Drug</th><th styleCode=\"Rrule\" valign=\"bottom\" rowspan=\"2\">Dose of Coadministered Drug (mg)</th><th styleCode=\"Rrule\" valign=\"bottom\" rowspan=\"2\">Remdesivir Dose  (mg)</th><th styleCode=\"Rrule\" valign=\"bottom\" rowspan=\"2\">N  </th><th styleCode=\"Rrule\" valign=\"bottom\" colspan=\"4\">Mean Ratio (90% CI) of Remdesivir, GS-704277, and GS-441524 PK With/Without Coadministered Drug  No Effect = 1.00 (0.70&#x2013;1.43)</th></tr><tr><th styleCode=\"Rrule\"/><th styleCode=\"Rrule\">C<sub>max</sub></th><th styleCode=\"Rrule\">AUC<sub>inf</sub></th><th styleCode=\"Rrule\">C<sub>24</sub></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"8\">CI=confidence interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\">Cyclosporin A<footnote ID=\"foot12\">Interaction study conducted in healthy volunteers.</footnote></td><td styleCode=\"Rrule\" rowspan=\"3\">400 single dose</td><td styleCode=\"Rrule\" rowspan=\"3\">100 single dose</td><td styleCode=\"Rrule\" rowspan=\"3\">9</td><td styleCode=\"Rrule\">remdesivir</td><td styleCode=\"Rrule\">1.49  (1.38&#x2013;1.60)</td><td styleCode=\"Rrule\">1.89  (1.77&#x2013;2.02)</td><td styleCode=\"Rrule\">-</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Rrule\">GS-704277</td><td styleCode=\"Rrule\">2.51  (2.26&#x2013;2.78)</td><td styleCode=\"Rrule\">2.97  (2.75&#x2013;3.20)</td><td styleCode=\"Rrule\">-</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Rrule\">GS-441524</td><td styleCode=\"Rrule\">1.17  (1.12&#x2013;1.22)</td><td styleCode=\"Rrule\">1.03  (0.99&#x2013;1.08)</td><td styleCode=\"Rrule\">1.02  (0.95&#x2013;1.10)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\">Carbamazepine<footnoteRef IDREF=\"foot12\"/></td><td styleCode=\"Rrule\" rowspan=\"3\">300 twice daily</td><td styleCode=\"Rrule\" rowspan=\"3\">100 single dose</td><td styleCode=\"Rrule\" rowspan=\"3\">8</td><td styleCode=\"Rrule\">remdesivir</td><td styleCode=\"Rrule\">0.87  (0.78&#x2013;0.97)</td><td styleCode=\"Rrule\">0.92  (0.83&#x2013;1.02)</td><td styleCode=\"Rrule\">-</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\" align=\"center\">GS-704277</td><td styleCode=\"Rrule\">0.96  (0.84&#x2013;1.10)</td><td styleCode=\"Rrule\">0.98  (0.92&#x2013;1.05)</td><td styleCode=\"Rrule\">-</td></tr><tr><td styleCode=\"Rrule\" align=\"center\">GS-441524</td><td styleCode=\"Rrule\">0.97  (0.88&#x2013;1.07)</td><td styleCode=\"Rrule\">0.83  (0.78&#x2013;0.89)</td><td styleCode=\"Rrule\">0.71  (0.64&#x2013;0.78)</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table20\"><caption>Table 20 Effect of Remdesivir on the Pharmacokinetics of Other Drugs</caption><col width=\"19%\" align=\"left\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"5%\" align=\"center\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><col width=\"19%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"bottom\" align=\"center\">Coadministered Drug</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">Dose of Coadministered Drug (mg)</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">Remdesivir Dose (mg)</th><th styleCode=\"Rrule\" rowspan=\"2\" valign=\"bottom\">N</th><th styleCode=\"Rrule\" colspan=\"2\" valign=\"bottom\">Mean Ratio (90% CI) of Coadministered Drug PK With/Without Remdesivir No Effect = 1.00 (0.80&#x2013;1.25)</th></tr><tr><th styleCode=\"Lrule Rrule\" valign=\"bottom\" align=\"center\">C<sub>max</sub></th><th styleCode=\"Rrule\" valign=\"bottom\">AUC<sub>inf</sub></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"6\">CI=confidence Interval</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Midazolam<footnote ID=\"t22ft1\">Interaction study conducted in healthy volunteers.</footnote></td><td styleCode=\"Rrule\">2.5 single dose</td><td styleCode=\"Rrule\">200 single dose</td><td styleCode=\"Rrule\">19</td><td styleCode=\"Rrule\">1.29 (1.19&#x2013;1.41)</td><td styleCode=\"Rrule\">1.20 (1.14&#x2013;1.26)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Midazolam<footnoteRef IDREF=\"t22ft1\"/></td><td styleCode=\"Rrule\">2.5 single dose</td><td styleCode=\"Rrule\">200 single dose followed by 100 once daily (10 doses)<footnote>Midazolam administered with last dose of remdesivir.</footnote></td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">1.45 (1.23&#x2013; 1.70)</td><td styleCode=\"Rrule\">1.30 (1.16&#x2013; 1.45)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Pitavastatin<footnoteRef IDREF=\"t22ft1\"/></td><td styleCode=\"Rrule\">2 single dose</td><td styleCode=\"Rrule\">200 single dose</td><td styleCode=\"Rrule\">20</td><td styleCode=\"Rrule\">1.05 (0.92&#x2013;1.20)</td><td styleCode=\"Rrule\">1.17 (1.09&#x2013;1.24)</td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Available data from a clinical trial (IMPAACT 2032), published reports, the COVID-PR pregnancy exposure registry, and compassionate use of remdesivir in pregnant individuals have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following exposure in the second and third trimester. However, there are insufficient pregnancy data available to evaluate the risk of remdesivir exposure during the first trimester. A study evaluating the pharmacokinetics of remdesivir during pregnancy demonstrated no clinically relevant differences between pregnant and non-pregnant individuals. No dose adjustments are recommended in patients who receive VEKLURY during pregnancy (see Data ) and [see Clinical Pharmacology (12.3) ] . In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryo-fetal development when administered to pregnant animals at systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS-441524) that were 4 times (rats and rabbits) the exposure in humans at the recommended human dose (RHD) (see Data ). There are maternal and fetal risks associated with untreated COVID-19 in pregnancy (see Clinical Considerations ). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo-fetal risk COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death. Data Human Data A non-randomized, open-label clinical study (IMPAACT 2032) evaluated pharmacokinetics and safety of up to 10 days of treatment with VEKLURY in 25 hospitalized pregnant and 28 hospitalized non-pregnant individuals of childbearing potential. Subjects received VEKLURY 200 mg once daily for 1 day followed by VEKLURY 100 mg once daily on subsequent days via intravenous infusion. Subjects were enrolled prior to their fourth VEKLURY infusion. Assessments occurred at the following intervals: Screening; Pre-infusion (defined as 48 hours prior to start of first infusion); each infusion day; 48 hours after the last infusion; 7 days after the last infusion; 4 weeks after the last infusion. Assessments also occurred 24 hours post-delivery in subjects who delivered. Treatment with VEKLURY was stopped in subjects who were discharged from the hospital prior to the completion of 10 days of treatment. Of the 25 pregnant subjects, median age was 33 years (Q1, Q3: 27 years, 37 years); 40% were White, 24% were Black, and 48% were Hispanic or Latino. A total of 9 subjects (36%) were on high-flow oxygen; 12 subjects (48%) were on low-flow oxygen; and 1 subject (4%) was on room air, at baseline. Three subjects (12%) did not have data available on baseline oxygen status. The overall median (Q1, Q3) duration of symptoms prior to hospitalization was 7 (6, 9) days. The overall median (Q1, Q3) duration of symptoms prior to first dose of VEKLURY was 8 (6, 9) days. Of the 25 pregnant subjects, median gestational age was 28 weeks at baseline (range 22 to 33 weeks) and about half of subjects were in each of the second and third trimester of pregnancy. No clinically relevant differences in the pharmacokinetics of remdesivir or its metabolites (GS-704277 and GS-441524) were observed between pregnant (n=21) and non-pregnant (n=22) individuals [see Clinical Pharmacology (12.3) ] . No difference in pharmacokinetics of remdesivir or its metabolites is expected between the first and second/third trimesters. The adverse reactions observed were consistent with those observed in clinical trials of VEKLURY in adults [see Adverse Reactions (6.1) ] . There were no adverse reactions in infants born during the study (n=16). Animal Data Remdesivir was administered via intravenous injection to pregnant rats and rabbits (up to 20 mg/kg/day) on Gestation Days 6 through 17, and 7 through 20, respectively, and also to rats from Gestation Day 6 to Lactation/Post-partum Day 20. No adverse effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed in rats and rabbits at nontoxic doses in pregnant animals. During organogenesis, exposures to the predominant circulating metabolite (GS-441524) were 4 times higher (rats and rabbits) than the exposure in humans at the RHD. In a pre/postnatal development study, exposures to the predominant circulating metabolite of remdesivir (GS-441524) were similar to the human exposures at the RHD. 8.2 Lactation Risk Summary A published case report describes the presence of remdesivir and active metabolite GS-441524 in human milk. Available data (n=11) from pharmacovigilance reports do not indicate adverse effects on breastfed infants from exposure to remdesivir and its metabolite through breastmilk. There are no available data on the effects of remdesivir on milk production. In animal studies, remdesivir and metabolites have been detected in the nursing pups of mothers given remdesivir, likely due to the presence of remdesivir in milk (see Data ). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VEKLURY and any potential adverse effects on the breastfed child from VEKLURY or from the underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19. Data Remdesivir and its metabolites were detected in the plasma of nursing rat pups, likely due to the presence of remdesivir and/or its metabolites in milk, following daily intravenous administration of remdesivir to pregnant rats from Gestation Day 6 to Lactation Day 20. Exposures in nursing pups were approximately 1% that of maternal exposure on Lactation Day 10. The concentration of remdesivir in animal milk does not necessarily predict the concentration of drug in human milk. 8.4 Pediatric Use The safety and effectiveness of VEKLURY for the treatment of COVID-19 have been established in pediatric patients from birth to less than 18 years of age and weighing at least 1.5 kg, who are: Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. Use in this age group is supported by the following: Trials in adults [see Clinical Studies (14.1 , 14.2 , 14.3 , 14.4 , 14.5) ] An open-label trial (Study 5823) in 58 hospitalized pediatric subjects [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14.6) ]. Use of VEKLURY in pediatric patients from birth to less than 18 years of age and weighing at least 1.5 kg is supported by Study 5823 where 58 hospitalized pediatric subjects were treated with weight-based VEKLURY for up to 10 days in the following cohorts: Cohorts 1–4, 8; infants, children, and adolescents: Subjects ≥12 years and weighing ≥40 kg (n=12); subjects <12 years and weighing ≥40 kg (n=5); subjects ≥28 days and weighing ≥20 to <40 kg (n=12); subjects ≥28 days and weighing ≥12 to <20 kg (n=12); and subjects ≥28 days and weighing ≥3 to <12 kg (n=12); Cohorts 5–7; neonates and infants: Subjects 14 to <28 days old, GA >37 weeks, and weighing ≥2.5 kg (n=3); subjects <14 days old, GA >37 weeks, and weighing ≥2.5 kg at birth (n=1); and subjects <56 days old, GA ≤37 weeks, and weighing ≥1.5 kg at birth (n=1). The safety and pharmacokinetic results in pediatric subjects were similar to those in adults [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , Clinical Studies (14.6) ]. Use of VEKLURY in pediatric patients weighing at least 40 kg is further supported by a clinical trial of VEKLURY in non-hospitalized subjects that included 3 pediatric subjects 12 years and older, and by clinical trials in hospitalized subjects that included 30 adult subjects weighing 40 to 50 kg. The safety in this weight group was comparable to adult subjects weighing greater than 50 kg. Thirty-nine pediatric patients 12 years and older and weighing at least 40 kg received VEKLURY in a compassionate use program in hospitalized subjects; the available clinical data from these patients are limited [see Adverse Reactions (6.1) and Clinical Studies (14) ]. Use of VEKLURY in pediatric patients with renal impairment is supported by safety data in adults [see Adverse Reactions (6.1) , Use in Specific Populations (8.6) ]. Limited data are available regarding the safety of VEKLURY in pediatric patients with mild or moderate renal impairment. No data are available regarding the safety of VEKLURY in pediatric patients with severe renal impairment . In adults with severe renal impairment, including those requiring dialysis, exposures of GS-441524 and GS-704277, the metabolites of remdesivir, and betadex sulfobutyl ether sodium (SBECD) are increased [see Clinical Pharmacology (12.3) ] . VEKLURY contains SBECD which, when administered intravenously, is eliminated through glomerular filtration and therefore when administered to pediatric patients with renal immaturity or renal impairment, may result in higher exposure to SBECD. The safety and effectiveness of VEKLURY have not been established in pediatric patients weighing less than 1.5 kg. 8.5 Geriatric Use Of the 1,062 hospitalized subjects with SARS-CoV-2 infection randomized in ACTT-1, 36% were 65 years or older. Of the 397 hospitalized subjects with SARS-CoV-2 infection randomized in Study GS-US-540-5773, 42% were 65 years or older. Of the 584 hospitalized subjects with SARS-CoV-2 infection randomized in Study GS-US-540-5774, 27% were 65 years or older. Of the 562 non-hospitalized subjects with SARS-CoV-2 infection randomized in Study GS-US-540-9012, 17% were 65 years or older. Reported clinical experience has not identified differences in responses between the elderly and younger patients [see Clinical Studies (14) ] . No dosage adjustment is required in patients over the age of 65 years. In general, appropriate caution should be exercised in the administration of VEKLURY and monitoring of elderly patients, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 8.6 Renal Impairment Use of VEKLURY in patients with COVID-19 and renal impairment, including those on dialysis, is supported by safety and pharmacokinetic data from the following: a randomized, double-blind, placebo-controlled trial (Study 5912) in adults [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ]. an open-label, parallel-group, single-dose trial in subjects with normal renal function and renal impairment (Study 9015) [see Clinical Pharmacology (12.3) ]. The pharmacokinetics and safety of VEKLURY in patients with COVID-19 and renal impairment, including those on dialysis, were evaluated in 163 subjects in a randomized, double-blind, placebo-controlled trial, Study GS-US-540-5912 [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ]. Study GS-US-540-5912 evaluated VEKLURY 200 mg once daily for 1 day followed by VEKLURY 100 mg once daily for 4 days (for a total of up to 5 days of intravenously administered therapy) in 243 hospitalized adult subjects with confirmed COVID-19 and renal impairment. The trial included 90 subjects (37%) with AKI (defined as a 50% increase in serum creatinine within a 48-hour period that was sustained for ≥6 hours despite supportive care), 64 subjects (26%) with CKD (eGFR <30 mL/minute/1.73m 2 ), and 89 subjects (37%) with ESRD (eGFR <15 mL/minute/1.73m 2 ) requiring hemodialysis. Subjects were randomized in a 2:1 manner, stratified by ESRD, high-flow oxygen requirement, and region (US vs ex-US) to receive VEKLURY (n=163) or placebo (n=80), plus standard of care. At baseline, mean age was 69 years (with 62% of subjects aged 65 or older); 57% of subjects were male, 67% were White, 26% were Black, and 3% were Asian. The most common baseline risk factors were hypertension (89%), diabetes mellitus (79%), and cardiovascular or cerebrovascular disease (51%); the distribution of risk factors was similar between the two treatment groups. A total of 45 subjects (19%) were on high-flow oxygen, 144 (59%) were on low-flow oxygen, and 54 (22%) were on room air at baseline; no subjects were on invasive mechanical ventilation (IMV). A total of 182 subjects (75%) were not on renal replacement therapy, and 31 subjects (13%) had received a COVID-19 vaccine. The safety results in subjects with COVID-19 and renal impairment, including those on dialysis, were consistent with those observed in clinical trials of VEKLURY in adults [see Adverse Reactions (6.1) ]. Study GS-US-540-5912 closed prematurely due to feasibility issues and was underpowered to assess for efficacy because of lower than expected enrollment. The pharmacokinetics and safety of VEKLURY in subjects with normal renal function and renal impairment, including those on dialysis, were evaluated in 75 subjects (43 subjects with renal impairment plus 32 matched control subjects with normal renal function) in an open-label, parallel-group, single-dose trial, Study GS-US-540-9015 [see Clinical Pharmacology (12.3) ]. In studies GS-US-540-5912 and GS-US-540-9015, exposures of GS-441524 and GS-704277, the metabolites of remdesivir, and SBECD are increased in subjects with mild to severe renal impairment, including those requiring dialysis, relative to subjects with normal renal function [see Clinical Pharmacology (12.3) ] . No dosage adjustment of VEKLURY is recommended for patients with any degree of renal impairment, including those on dialysis [see Dosage and Administration (2.2 , 2.4) , Use in Specific Populations (8.4) ]. 8.7 Hepatic Impairment No dosage adjustment of VEKLURY is recommended for patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C) [see Clinical Pharmacology (12.3) ] . Perform hepatic laboratory testing in all patients before starting VEKLURY and while receiving VEKLURY as clinically appropriate [see Dosage and Administration (2.2) and Warnings and Precautions (5.2) ]."],"dosage_and_administration_table":["<table width=\"90%\" ID=\"Table1\"><caption>Table 1 Recommended Dosage in Pediatric Patients Including Term<footnote>Gestational age greater than 37 weeks. </footnote> Neonates and Infants Weighing 1.5 kg to Less than 40 kg</caption><col width=\"40%\" align=\"center\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\"> Pediatric Patient Population </th><th styleCode=\"Rrule\">Loading Dose Via Intravenous Infusion</th><th styleCode=\"Rrule\">Maintenance Dose Via Intravenous Infusion</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Less than 28 days old and at least 1.5 kg</td><td styleCode=\"Rrule\" rowspan=\"2\">VEKLURY 2.5 mg/kg on Day 1</td><td styleCode=\"Rrule\" rowspan=\"2\">VEKLURY 1.25 mg/kg once daily from Day 2</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">At least 28 days old and 1.5 kg to less than 3 kg</td></tr><tr><td styleCode=\"Lrule Rrule\">At least 28 days old and 3 kg to less than 40 kg</td><td styleCode=\"Rrule\">VEKLURY 5 mg/kg on Day 1</td><td styleCode=\"Rrule\">VEKLURY 2.5 mg/kg once daily from Day 2</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table2\"><caption>Table 2 Recommended Dilution Instructions&#x2014;Reconstituted VEKLURY for Injection in Adults and Pediatric Patients Weighing at Least 40 kg</caption><col width=\"25%\" align=\"center\" valign=\"middle\"/><col width=\"15%\" align=\"center\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" valign=\"bottom\">VEKLURY dose</th><th styleCode=\"Rrule\" valign=\"bottom\">0.9% sodium chloride injection infusion bag volume to be used</th><th styleCode=\"Rrule\" valign=\"bottom\">Volume to be withdrawn and discarded from 0.9% sodium chloride injection infusion bag</th><th styleCode=\"Rrule\" valign=\"bottom\">Required volume of reconstituted VEKLURY for injection</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Loading dose  200 mg  (2 vials)</td><td styleCode=\"Rrule\">250 mL</td><td styleCode=\"Rrule\">40 mL</td><td styleCode=\"Rrule\">40 mL (2 &#xD7; 20 mL)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">100 mL</td><td styleCode=\"Rrule\">40 mL</td><td styleCode=\"Rrule\">40 mL (2 &#xD7; 20 mL)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Maintenance dose  100 mg  (1 vial)</td><td styleCode=\"Rrule\">250 mL</td><td styleCode=\"Rrule\">20 mL</td><td styleCode=\"Rrule\">20 mL</td></tr><tr><td styleCode=\"Rrule\">100 mL</td><td styleCode=\"Rrule\">20 mL</td><td styleCode=\"Rrule\">20 mL</td></tr></tbody></table>","<table width=\"90%\" ID=\"Table3\"><caption>Table 3 Recommended Rate of Infusion&#x2014;Diluted VEKLURY for Injection in Adults and Pediatric Patients Weighing at Least 40 kg</caption><col width=\"34%\" align=\"center\" valign=\"middle\"/><col width=\"33%\" align=\"center\" valign=\"middle\"/><col width=\"33%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Infusion bag volume</th><th styleCode=\"Rrule\">Infusion time</th><th styleCode=\"Rrule\">Rate of infusion</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\">250 mL</td><td styleCode=\"Rrule\">30 min</td><td styleCode=\"Rrule\">8.33 mL/min</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">60 min</td><td styleCode=\"Rrule\">4.17 mL/min</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">120 min</td><td styleCode=\"Rrule\">2.08 mL/min</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\">100 mL</td><td styleCode=\"Rrule\">30 min</td><td styleCode=\"Rrule\">3.33 mL/min</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">60 min</td><td styleCode=\"Rrule\">1.67 mL/min</td></tr><tr><td styleCode=\"Rrule\">120 min</td><td styleCode=\"Rrule\">0.83 mL/min</td></tr></tbody></table>"],"spl_patient_package_insert_table":["<table width=\"100%\"><col width=\"3%\" align=\"left\" valign=\"top\"/><col width=\"47%\" align=\"left\" valign=\"top\"/><col width=\"30%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"left\" valign=\"top\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">This Patient Information has been approved by the U.S. Food and Drug Administration.</td><td align=\"right\" styleCode=\"top\">Revised: 10/2025 </td></tr><tr><td/><td/><td/><td/></tr></tfoot><tbody><tr><td colspan=\"4\" align=\"center\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">PATIENT INFORMATION</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" colspan=\"4\">VEKLURY<sup>&#xAE;</sup> (VEK-lur-ee)  (remdesivir)  for injection</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What is VEKLURY?</content> VEKLURY is a prescription medicine used for the treatment of coronavirus disease 2019 (COVID-19) in adults and children weighing at least 3 pounds (1.5 kg) who are:<list styleCode=\"disc\" listType=\"unordered\"><item>Hospitalized, <content styleCode=\"bold\">or</content></item><item>Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.</item></list>It is not known if VEKLURY is safe and effective in children weighing less than 3 pounds (1.5 kg).</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Do not take VEKLURY if you are allergic to remdesivir or any of the ingredients in VEKLURY.</content> See the end of this leaflet for a complete list of ingredients in VEKLURY.</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Before receiving VEKLURY, tell your healthcare provider about all of your medical conditions, including if you:</content><list listType=\"unordered\"><item>have liver problems</item><item>are pregnant or plan to become pregnant. It is not known if VEKLURY may harm your unborn baby if taken during the first trimester of pregnancy. <content styleCode=\"bold\">Tell your healthcare provider right away if you are or if you become pregnant.</content></item><item>are breastfeeding or plan to breastfeed. VEKLURY can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby.</item></list><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VEKLURY may interact with other medicines.  <content styleCode=\"bold\">Especially tell your healthcare provider if you are taking the medicines chloroquine phosphate or hydroxychloroquine sulfate.</content></td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">How will I receive VEKLURY? </content><list listType=\"unordered\"><item><content styleCode=\"bold\">Hospitalized</content>: VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for up to 10 days. Your healthcare provider will decide how many doses you need.</item><item><content styleCode=\"bold\">Not hospitalized:</content> VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for 3 days.</item><item>Your healthcare provider will do certain blood tests before starting and during treatment with VEKLURY.</item></list></td></tr><tr><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What are the possible side effects of VEKLURY? VEKLURY may cause serious side effects, including: </content><list listType=\"unordered\"><item><content styleCode=\"bold\">Allergic reactions.</content> Allergic reactions can happen during or after infusion with VEKLURY. Your healthcare provider will monitor you for signs and symptoms of allergic reactions during your infusion and for at least 1 hour after your infusion. Tell your healthcare provider right away if you get any of the following signs and symptoms of an allergic reaction:</item></list></td></tr><tr><td styleCode=\"Lrule\"/><td><list listType=\"unordered\" styleCode=\"circle\"><item>changes in your heart rate </item><item>fever</item><item>shortness of breath, wheezing</item><item>swelling of the lips, face, or throat</item></list></td><td colspan=\"2\" styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"circle\"><item>rash</item><item>nausea</item><item>sweating</item><item>shivering</item></list></td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Increase in liver enzymes.</content> Increases in liver enzymes are common in people who have received VEKLURY and may be a sign of liver injury. Your healthcare provider will do blood tests to check your liver enzymes before and during treatment with VEKLURY as needed. Your healthcare provider may stop treatment with VEKLURY if you develop liver problems.</item></list><content styleCode=\"bold\">The most common side effect of VEKLURY</content> is nausea. These are not all of the possible side effects of VEKLURY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">General information about the safe and effective use of VEKLURY. </content> Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about VEKLURY that is written for healthcare professionals.</td></tr><tr><td colspan=\"4\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What are the ingredients in VEKLURY?</content> <content styleCode=\"bold\">Active ingredient:</content> remdesivir <content styleCode=\"bold\">Inactive ingredients: </content>betadex sulfobutyl ether sodium and may include hydrochloric acid and/or sodium hydroxide for pH adjustment. Manufactured and distributed by: Gilead Sciences, Inc., Foster City, CA 94404 VEKLURY is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners. &#xA9; 2025 Gilead Sciences, Inc. All rights reserved. 214787-GS-022 For more information, call 1-800-445-3235 or go to www.VEKLURY.com.</td></tr></tbody></table>"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Intravenous administration (slow bolus) of remdesivir to male rhesus monkeys at dosage levels of 5, 10, and 20 mg/kg/day for 7 days resulted, at all dose levels, in increased mean urea nitrogen and increased mean creatinine, renal tubular atrophy, and basophilia and casts. Intravenous administration (slow bolus) of remdesivir to rats at dosage levels of ≥3 mg/kg/day for up to 4 weeks resulted in findings indicative of kidney injury and/or dysfunction. Kidney-related effects in rats and monkeys were observed at exposures of the predominant circulating metabolite (GS-441524) that are lower than the exposure in humans at the RHD."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 100 mg Vial Label Veklury ® (remdesivir) for injection 100 mg/vial Single-Dose Vial: Discard Unused Portion Must be reconstituted and further diluted prior to use. For Intravenous Infusion. 90288101 Rx only PRINCIPAL DISPLAY PANEL - 100 mg Vial Label","PRINCIPAL DISPLAY PANEL - 100 mg Vial Carton NDC 61958-2901-2 Rx only Veklury ® (remdesivir) for injection 100 mg/vial Single-Dose Vial: Discard Unused Portion Must be reconstituted and further diluted prior to use. For Intravenous Infusion. GILEAD PRINCIPAL DISPLAY PANEL - 100 mg Vial Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis and Mutagenesis Given the short-term administration of VEKLURY for the treatment of COVID-19, long-term animal studies to evaluate the carcinogenic potential of remdesivir were not conducted. Remdesivir was not genotoxic in a battery of assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes, and in vivo rat micronucleus assays. Impairment of Fertility Nonclinical toxicity studies in rats demonstrated no adverse effect on male fertility at exposures of the predominant circulating metabolite (GS-441524) approximately 2 times the exposure in humans at the RHD. Reproductive toxicity, including decreases in corpora lutea, numbers of implantation sites, and viable embryos, was seen when remdesivir was administered by daily intravenous administration at a systemically toxic dose (10 mg/kg) in female rats 14 days prior to mating and during conception; exposures of the predominant circulating metabolite (GS-441524) were 1.3 times the exposure in humans at the RHD."]},"tags":[{"label":"SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J05AB16","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Disease caused by Severe acute respiratory syndrome coronavirus 2","category":"indication"},{"label":"Gilead Sciences Inc","category":"company"},{"label":"Approved 2020s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"2208 reports"},{"date":"","signal":"ALANINE AMINOTRANSFERASE INCREASED","source":"FDA FAERS","actionTaken":"933 reports"},{"date":"","signal":"COVID-19","source":"FDA FAERS","actionTaken":"896 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"762 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"751 reports"},{"date":"","signal":"BRADYCARDIA","source":"FDA FAERS","actionTaken":"651 reports"},{"date":"","signal":"ASPARTATE AMINOTRANSFERASE INCREASED","source":"FDA FAERS","actionTaken":"627 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"622 reports"},{"date":"","signal":"RESPIRATORY FAILURE","source":"FDA FAERS","actionTaken":"526 reports"},{"date":"","signal":"COVID-19 PNEUMONIA","source":"FDA FAERS","actionTaken":"480 reports"}],"drugInteractions":[{"drug":"Chloroquine phosphate or hydroxychloroquine sulfate","severity":"Moderate","mechanism":"Potential antagonism based on cell culture experiments","management":"Concomitant use is not recommended","clinicalEffect":"Reduced antiviral efficacy"},{"drug":"CYP3A4 inducers","severity":"Minor","mechanism":"Remdesivir is metabolized by CYP3A (10%)","management":"No dose adjustment needed","clinicalEffect":"No clinically significant drug interactions expected"},{"drug":"OATP1B1/1B3 inhibitors and P-glycoprotein inhibitors","severity":"Minor","mechanism":"Based on drug interaction studies","management":"No dose adjustment needed","clinicalEffect":"No clinically significant drug interactions expected"}],"commonSideEffects":[{"effect":"Glomerular filtration rate decreased","drugRate":"9.4%","placeboRate":"","totalAtRisk":1465,"totalAffected":138,"trialsReporting":3},{"effect":"Lymphocyte count decreased","drugRate":"6.4%","placeboRate":"","totalAtRisk":1968,"totalAffected":125,"trialsReporting":4},{"effect":"Anaemia","drugRate":"6.8%","placeboRate":"","totalAtRisk":1436,"totalAffected":98,"trialsReporting":4},{"effect":"Haemoglobin decreased","drugRate":"6.6%","placeboRate":"","totalAtRisk":1465,"totalAffected":97,"trialsReporting":3},{"effect":"Hyperglycaemia","drugRate":"5.6%","placeboRate":"","totalAtRisk":1436,"totalAffected":80,"trialsReporting":4},{"effect":"Dyspnea","drugRate":"9.0%","placeboRate":"","totalAtRisk":710,"totalAffected":64,"trialsReporting":1},{"effect":"Blood glucose increased","drugRate":"3.1%","placeboRate":"","totalAtRisk":1733,"totalAffected":53,"trialsReporting":3},{"effect":"Pyrexia","drugRate":"3.4%","placeboRate":"","totalAtRisk":1426,"totalAffected":49,"trialsReporting":3},{"effect":"Constipation","drugRate":"3.5%","placeboRate":"","totalAtRisk":1314,"totalAffected":46,"trialsReporting":4},{"effect":"Acute kidney injury","drugRate":"2.1%","placeboRate":"","totalAtRisk":2072,"totalAffected":44,"trialsReporting":5},{"effect":"Nausea","drugRate":"3.8%","placeboRate":"","totalAtRisk":1101,"totalAffected":42,"trialsReporting":3},{"effect":"Aspartate aminotransferase increased","drugRate":"5.7%","placeboRate":"","totalAtRisk":716,"totalAffected":41,"trialsReporting":2},{"effect":"Hypotension","drugRate":"3.6%","placeboRate":"","totalAtRisk":1123,"totalAffected":40,"trialsReporting":3},{"effect":"Blood creatinine increased","drugRate":"7.0%","placeboRate":"","totalAtRisk":516,"totalAffected":36,"trialsReporting":1},{"effect":"Lymphopenia","drugRate":"5.8%","placeboRate":"","totalAtRisk":516,"totalAffected":30,"trialsReporting":1},{"effect":"Hypokalaemia","drugRate":"4.3%","placeboRate":"","totalAtRisk":604,"totalAffected":26,"trialsReporting":3},{"effect":"Pneumonia","drugRate":"1.8%","placeboRate":"","totalAtRisk":1427,"totalAffected":25,"trialsReporting":3},{"effect":"Diarrhoea","drugRate":"5.6%","placeboRate":"","totalAtRisk":391,"totalAffected":22,"trialsReporting":2},{"effect":"Fatigue","drugRate":"3.1%","placeboRate":"","totalAtRisk":710,"totalAffected":22,"trialsReporting":1},{"effect":"Hypoxia","drugRate":"3.1%","placeboRate":"","totalAtRisk":710,"totalAffected":22,"trialsReporting":1},{"effect":"Cough","drugRate":"2.3%","placeboRate":"","totalAtRisk":710,"totalAffected":16,"trialsReporting":1},{"effect":"Transaminases increased","drugRate":"3.1%","placeboRate":"","totalAtRisk":413,"totalAffected":13,"trialsReporting":2},{"effect":"Headache","drugRate":"1.4%","placeboRate":"","totalAtRisk":901,"totalAffected":13,"trialsReporting":2},{"effect":"Insomnia","drugRate":"1.2%","placeboRate":"","totalAtRisk":910,"totalAffected":11,"trialsReporting":2},{"effect":"Urinary tract infection","drugRate":"5.2%","placeboRate":"","totalAtRisk":213,"totalAffected":11,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"5.0%","placeboRate":"","totalAtRisk":200,"totalAffected":10,"trialsReporting":1},{"effect":"Mental status change","drugRate":"1.3%","placeboRate":"","totalAtRisk":710,"totalAffected":9,"trialsReporting":1},{"effect":"Deep vein thrombosis","drugRate":"0.6%","placeboRate":"","totalAtRisk":1352,"totalAffected":8,"trialsReporting":3},{"effect":"Anemia","drugRate":"1.1%","placeboRate":"","totalAtRisk":710,"totalAffected":8,"trialsReporting":1},{"effect":"Hypertension","drugRate":"0.8%","placeboRate":"","totalAtRisk":910,"totalAffected":7,"trialsReporting":2},{"effect":"Acute respiratory failure","drugRate":"1.0%","placeboRate":"","totalAtRisk":710,"totalAffected":7,"trialsReporting":1},{"effect":"Anxiety","drugRate":"0.8%","placeboRate":"","totalAtRisk":710,"totalAffected":6,"trialsReporting":1},{"effect":"incomplete study drug infusion(s)","drugRate":"3.4%","placeboRate":"","totalAtRisk":175,"totalAffected":6,"trialsReporting":1},{"effect":"Pneumonia bacterial","drugRate":"0.7%","placeboRate":"","totalAtRisk":710,"totalAffected":5,"trialsReporting":1},{"effect":"Hyperglycemia","drugRate":"0.7%","placeboRate":"","totalAtRisk":710,"totalAffected":5,"trialsReporting":1},{"effect":"Acute respiratory distress syndrome","drugRate":"0.7%","placeboRate":"","totalAtRisk":710,"totalAffected":5,"trialsReporting":1},{"effect":"Respiratory failure","drugRate":"0.7%","placeboRate":"","totalAtRisk":710,"totalAffected":5,"trialsReporting":1},{"effect":"Bradycardia","drugRate":"0.6%","placeboRate":"","totalAtRisk":710,"totalAffected":4,"trialsReporting":1},{"effect":"Decreased appetite","drugRate":"0.6%","placeboRate":"","totalAtRisk":710,"totalAffected":4,"trialsReporting":1},{"effect":"Respiratory distress","drugRate":"0.6%","placeboRate":"","totalAtRisk":710,"totalAffected":4,"trialsReporting":1},{"effect":"Atrial fibrillation","drugRate":"0.4%","placeboRate":"","totalAtRisk":710,"totalAffected":3,"trialsReporting":1},{"effect":"Staphylococcal bacteremia","drugRate":"0.4%","placeboRate":"","totalAtRisk":710,"totalAffected":3,"trialsReporting":1},{"effect":"Hypervolemia","drugRate":"0.4%","placeboRate":"","totalAtRisk":710,"totalAffected":3,"trialsReporting":1},{"effect":"Pulmonary embolism","drugRate":"0.4%","placeboRate":"","totalAtRisk":710,"totalAffected":3,"trialsReporting":1},{"effect":"Leukocytosis","drugRate":"0.2%","placeboRate":"","totalAtRisk":910,"totalAffected":2,"trialsReporting":2},{"effect":"Agitation","drugRate":"0.2%","placeboRate":"","totalAtRisk":910,"totalAffected":2,"trialsReporting":2},{"effect":"Delirium","drugRate":"0.2%","placeboRate":"","totalAtRisk":910,"totalAffected":2,"trialsReporting":2},{"effect":"Cardiac arrest","drugRate":"0.3%","placeboRate":"","totalAtRisk":710,"totalAffected":2,"trialsReporting":1},{"effect":"Tachycardia","drugRate":"0.3%","placeboRate":"","totalAtRisk":710,"totalAffected":2,"trialsReporting":1},{"effect":"Gastrointestinal hemorrhage","drugRate":"0.3%","placeboRate":"","totalAtRisk":710,"totalAffected":2,"trialsReporting":1}],"contraindications":["History of clinically significant hypersensitivity reactions to remdesivir or any components of the product"],"specialPopulations":{"Lactation":"11.2 Lactation. Risk SummaryThere are no available data on the presence of remdesivir in human milk, the effects on the breastfed infant, or the effects on milk production. In animal studies, remdesivir and metabolites have been detected in the nursing pups of mothers given remdesivir, likely due to the presence of remdesivir in milk. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for VEKLURY and any potential adverse effects on t","Pregnancy":"11.1 Pregnancy. Pregnancy Exposure RegistryThere is pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to VEKLURY during pregnancy. Pregnant and recently pregnant individuals can go to https://covid-pr.pregistry.com to enroll or call 1-800-616-3791 to obtain information about the registry.. Risk SummaryAvailable data from published case reports and compassionate use of remdesivir in pregnant women are insufficient to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryo-fetal development when administered to pregnant animals at systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS-441524) that were times (rats and rabbits) the exposure in humans at the recommended human dose (RHD) (see Data ). There are maternal and fetal risks associated with untreated COVID-19 in pregnancy (see Clinical Considerations). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively.. Clinical Considerations. Disease-associated maternal and/or","Paediatric use":"11.3 Pediatric Use. The safety and effectiveness of VEKLURY have not been established in pediatric patients weighing 3.5 kg to less than 40 kg or pediatric patients less than 12 years of age weighing at least 3.5 kg, with positive results of direct SARS-CoV-2 viral testing, and who are:Hospitalized, orNot hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.VEKLURY for injection (supplied as 100 mg lyophilize"}},"trials":[],"aliases":[],"company":"Gilead Sciences","patents":[{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"May 28, 2041","useCode":"U-3835","territory":"US","drugProduct":false,"patentNumber":"11975012","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Sep 16, 2036","useCode":"U-3829","territory":"US","drugProduct":false,"patentNumber":"11007208","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Jul 10, 2038","useCode":"U-3832","territory":"US","drugProduct":false,"patentNumber":"11266681","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Sep 16, 2036","useCode":"U-3831","territory":"US","drugProduct":false,"patentNumber":"11382926","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Sep 16, 2036","useCode":"U-3831","territory":"US","drugProduct":false,"patentNumber":"10695361","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"May 28, 2041","useCode":"U-3833","territory":"US","drugProduct":false,"patentNumber":"11903953","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"May 28, 2041","useCode":"U-3834","territory":"US","drugProduct":false,"patentNumber":"11491169","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Oct 29, 2035","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9949994","drugSubstance":true},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Dec 8, 2031","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11492353","drugSubstance":true},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Apr 22, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8318682","drugSubstance":true},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Sep 6, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8008264","drugSubstance":true},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Apr 22, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"RE46762","drugSubstance":true},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Oct 29, 2035","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9724360","drugSubstance":true},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Sep 16, 2031","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10065958","drugSubstance":true},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Jul 10, 2038","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11975017","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Jul 10, 2038","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10675296","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Jun 8, 2032","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11492353*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Nov 28, 2041","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11491169*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Nov 28, 2041","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11903953*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Mar 16, 2037","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11007208*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Mar 16, 2037","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11382926*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Apr 29, 2036","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9949994*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Jan 10, 2039","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10675296*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Mar 6, 2030","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8008264*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Oct 22, 2029","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8318682*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Mar 16, 2032","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10065958*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Mar 16, 2037","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10695361*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Oct 22, 2029","useCode":"","territory":"US","drugProduct":false,"patentNumber":"RE46762*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Apr 29, 2036","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9724360*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Jan 10, 2039","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11266681*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Jan 10, 2039","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11975017*PED","drugSubstance":false},{"applNo":"N214787","source":"FDA Orange Book","status":"Active","expires":"Nov 28, 2041","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11975012*PED","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=remdesivir","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:40:27.877089+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:40:27.877012+00:00"},"mechanism":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:34:35.089665+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:40:34.199836+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:40:27.944147+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:40:24.807615+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:34:35.089687+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=remdesivir","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:40:34.758117+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:40:22.545407+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:40:22.545467+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:40:22.545473+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:40:36.412102+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5280654/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:40:35.545003+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA214787","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:40:22.545477+00:00"}},"allNames":"veklury","offLabel":[],"synonyms":["veklury","captisol-enabled remdesivir","captisol-enabled GS 5734","remdesivir","GS-5734"],"timeline":[{"date":"2020-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GILEAD SCIENCES INC to Gilead Sciences Inc"},{"date":"2020-03-07","type":"positive","source":"DrugCentral","milestone":"EMA approval (Gilead Sciences Ireland UC)"},{"date":"2020-05-07","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Gilead Sciences K.K.)"},{"date":"2020-10-22","type":"positive","source":"DrugCentral","milestone":"FDA approval (Gilead Sciences Inc)"},{"date":"2025-10-22","type":"negative","source":"FDA Orange Book","milestone":"New Chemical Entity exclusivity expires"},{"date":"2026-04-22","type":"negative","source":"FDA Orange Book","milestone":"Pediatric exclusivity expires"},{"date":"2026-07-13","type":"negative","source":"FDA Orange Book","milestone":"M-301 exclusivity expires"},{"date":"2027-01-13","type":"negative","source":"FDA Orange Book","milestone":"Pediatric exclusivity expires"},{"date":"2029-04-22","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8318682 expires"},{"date":"2029-09-06","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8008264 expires"},{"date":"2031-09-16","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 10065958 expires"},{"date":"2031-12-08","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 11492353 expires"},{"date":"2035-10-29","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 9949994 expires"}],"aiSummary":"Veklury, also known as Remdesivir, is a broad-spectrum antiviral medication administered via injection into a vein. It has been approved or authorized for emergency use to treat COVID-19 in numerous countries.","approvals":[{"date":"2020-03-07","orphan":false,"company":"Gilead Sciences Ireland UC","regulator":"EMA"},{"date":"2020-05-07","orphan":false,"company":"Gilead Sciences K.K.","regulator":"PMDA"},{"date":"2020-10-22","orphan":false,"company":"GILEAD SCIENCES INC","regulator":"FDA"}],"brandName":"Veklury","ecosystem":[{"indication":"Disease caused by Severe acute respiratory syndrome coronavirus 2","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"SARS-CoV-2 RNA polymerase","novelty":"Follow-on","modality":"Small molecule antiviral","drugClass":"Nucleotide analog RNA polymerase inhibitor","explanation":"Remdesivir is an antiviral drug with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It functions as a nucleotide analog that inhibits viral RNA polymerase, thereby interfering with viral replication. The drug is indicated for treatment of COVID-19 in both hospitalized patients and non-hospitalized patients with mild-to-moderate disease at high risk for progression to severe COVID-19.","oneSentence":"Remdesivir is an antiviral nucleotide analog RNA polymerase inhibitor with activity against SARS-CoV-2.","technicalDetail":"Remdesivir is a nucleotide analog that acts as a chain terminator by incorporating itself into the viral RNA via a phosphodiester bond, thereby preventing further RNA synthesis and replication of the SARS-CoV-2 virus."},"commercial":{"launchDate":"2020","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2020-10-22, GILEAD SCIENCES INC)","annualRevenue":2200,"revenueSource":"Gilead AR 2024 (Veklury)","revenueCurrency":"USD","revenueConfidence":"verified","revenueExtractedAt":"2026-03-31T19:26:35.983735","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5376","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=remdesivir","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=remdesivir","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:31:18.816224","_validation":{"fieldsValidated":7,"lastValidatedAt":"2026-04-20T08:34:39.998229+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"acyclovir","drugSlug":"acyclovir","fdaApproval":"1982-03-29","patentExpiry":"Mar 23, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"idoxuridine","drugSlug":"idoxuridine","fdaApproval":"1963-06-11","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"vidarabine","drugSlug":"vidarabine","fdaApproval":"1976-11-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ganciclovir","drugSlug":"ganciclovir","fdaApproval":"1989-06-23","patentExpiry":"Sep 2, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"famciclovir","drugSlug":"famciclovir","fdaApproval":"1994-06-29","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"valaciclovir","drugSlug":"valaciclovir","fdaApproval":"1995-06-23","relationship":"same-class"},{"drugName":"cidofovir","drugSlug":"cidofovir","fdaApproval":"1996-06-26","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"penciclovir","drugSlug":"penciclovir","fdaApproval":"1996-09-24","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"valganciclovir","drugSlug":"valganciclovir","fdaApproval":"2001-03-29","patentExpiry":"Dec 11, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"exclusivity":[{"code":"M-301","date":"Jul 13, 2026"},{"code":"NCE","date":"Oct 22, 2025"},{"code":"M-301","date":"Jul 13, 2026"},{"code":"NCE","date":"Oct 22, 2025"},{"code":"PED","date":"Apr 22, 2026"},{"code":"PED","date":"Apr 22, 2026"},{"code":"PED","date":"Jan 13, 2027"},{"code":"PED","date":"Jan 13, 2027"}],"genericName":"remdesivir","indications":{"approved":[{"name":"Disease caused by Severe acute respiratory syndrome coronavirus 2","source":"DrugCentral","snomedId":840539006,"regulator":"FDA"}],"offLabel":[{"name":"Coronavirus infection","source":"DrugCentral","drugName":"remdesivir"}],"pipeline":[]},"currentOwner":"Gilead Sciences Inc","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"acyclovir","brandName":"acyclovir","genericName":"acyclovir","approvalYear":"1982","relationship":"same-class"},{"drugId":"idoxuridine","brandName":"idoxuridine","genericName":"idoxuridine","approvalYear":"1963","relationship":"same-class"},{"drugId":"vidarabine","brandName":"vidarabine","genericName":"vidarabine","approvalYear":"1976","relationship":"same-class"},{"drugId":"ganciclovir","brandName":"ganciclovir","genericName":"ganciclovir","approvalYear":"1989","relationship":"same-class"},{"drugId":"famciclovir","brandName":"famciclovir","genericName":"famciclovir","approvalYear":"1994","relationship":"same-class"},{"drugId":"valaciclovir","brandName":"valaciclovir","genericName":"valaciclovir","approvalYear":"1995","relationship":"same-class"},{"drugId":"cidofovir","brandName":"cidofovir","genericName":"cidofovir","approvalYear":"1996","relationship":"same-class"},{"drugId":"penciclovir","brandName":"penciclovir","genericName":"penciclovir","approvalYear":"1996","relationship":"same-class"},{"drugId":"valganciclovir","brandName":"valganciclovir","genericName":"valganciclovir","approvalYear":"2001","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":["COVID-19"],"enrollment":1500,"completionDate":"2030-07-31"},{"nctId":"NCT04365725","phase":"","title":"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-05-05","conditions":["COVID-19"],"enrollment":84,"completionDate":"2020-06-12"},{"nctId":"NCT07013474","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-07-14","conditions":["COVID-19 Infection"],"enrollment":300,"completionDate":"2027-05-06"},{"nctId":"NCT06817889","phase":"PHASE2","title":"Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-12-23","conditions":["Hematopoietic and Lymphatic System Neoplasm","Autoimmune Disease","Respiratory Syncytial Virus Infection"],"enrollment":60,"completionDate":"2027-11-30"},{"nctId":"NCT05587894","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-27","conditions":["COVID-19","Immunodeficiency"],"enrollment":256,"completionDate":"2027-06-30"},{"nctId":"NCT05911906","phase":"PHASE4","title":"An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.","status":"COMPLETED","sponsor":"University of Derby","startDate":"2024-10-08","conditions":["SARS-CoV-2 Infection","COVID-19"],"enrollment":73,"completionDate":"2025-09-17"},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":["COVID-19"],"enrollment":3800,"completionDate":"2027-01"},{"nctId":"NCT07406217","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients","status":"RECRUITING","sponsor":"Calmy Alexandra","startDate":"2023-04-27","conditions":["COVID-19","Immunodeficiency"],"enrollment":256,"completionDate":"2026-06-30"},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":["Lactating Women on Select DOI","Breastfed Infants of Mothers on Select DOI"],"enrollment":1600,"completionDate":"2027-07-31"},{"nctId":"NCT04746183","phase":"PHASE1,PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":["Covid19"],"enrollment":600,"completionDate":"2026-07-31"},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":["Covid19"],"enrollment":473,"completionDate":"2022-11-20"},{"nctId":"NCT06729593","phase":"PHASE3","title":"Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":["Covid19"],"enrollment":87,"completionDate":"2022-11-20"},{"nctId":"NCT07197164","phase":"PHASE2","title":"Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients","status":"RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-09-01","conditions":["COVID - 19","Renal Transplant","SARS CoV 2 Infection"],"enrollment":15,"completionDate":"2027-02-28"},{"nctId":"NCT05013632","phase":"","title":"COVID-19 International Drug Pregnancy Registry","status":"RECRUITING","sponsor":"Pregistry","startDate":"2021-12-01","conditions":["Covid19"],"enrollment":2000,"completionDate":"2027-09-30"},{"nctId":"NCT06683937","phase":"","title":"Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-01","conditions":["Immunocompromised Patients","SARS-CoV-2 Disease"],"enrollment":300,"completionDate":"2026-06-01"},{"nctId":"NCT06873633","phase":"PHASE2","title":"Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV","status":"RECRUITING","sponsor":"PENTA Foundation","startDate":"2025-07-16","conditions":["Respiratory Syncytial Virus (RSV)"],"enrollment":120,"completionDate":"2027-02"},{"nctId":"NCT04865237","phase":"NA","title":"SARS-CoV-2 Human Challenge Characterisation Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2021-03-06","conditions":["Covid19","SARS-CoV Infection","Corona Virus Infection","Coronavirus","COVID-19"],"enrollment":36,"completionDate":"2022-07-11"},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":["Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome"],"enrollment":5000,"completionDate":"2027-09"},{"nctId":"NCT06860282","phase":"PHASE1","title":"A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects","status":"COMPLETED","sponsor":"Heronova Pharmaceuticals","startDate":"2022-12-26","conditions":["COVID-19","Coronavirus Pneumonia"],"enrollment":63,"completionDate":"2023-03-27"},{"nctId":"NCT04784559","phase":"PHASE3","title":"Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection","status":"TERMINATED","sponsor":"PharmaMar","startDate":"2021-06-04","conditions":["COVID-19 Infection"],"enrollment":205,"completionDate":"2023-03-01"},{"nctId":"NCT04790240","phase":"PHASE1,PHASE2","title":"Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)","status":"RECRUITING","sponsor":"All Natural Medicine Clinic, LLC","startDate":"2025-01-01","conditions":["Covid19 Virus Infection"],"enrollment":100,"completionDate":"2027-05-30"},{"nctId":"NCT05780437","phase":"PHASE3","title":"AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-02-10","conditions":["COVID-19"],"enrollment":1455,"completionDate":"2023-06-09"},{"nctId":"NCT05553743","phase":"","title":"Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2014-03-27","conditions":["Breastfeeding","COVID-19 Infection","COVID-19 Vaccine","Remdesivir","Antibiotics"],"enrollment":5000,"completionDate":"2040-03"},{"nctId":"NCT06792214","phase":"PHASE4","title":"Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2025-01-03","conditions":["SARS CoV-2 Post-Acute Sequelae"],"enrollment":118,"completionDate":"2027-01"},{"nctId":"NCT04847622","phase":"","title":"Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2021-02-12","conditions":["Covid19"],"enrollment":451,"completionDate":"2021-04-30"},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":["COVID-19"],"enrollment":120,"completionDate":"2024-06-17"},{"nctId":"NCT04575064","phase":"PHASE2,PHASE3","title":"An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY","status":"WITHDRAWN","sponsor":"Professor Dr. Bernd Mühlbauer","startDate":"2020-06-29","conditions":["SARS-CoV-2 Infection","COVID-19","Moderate and Severe COVID-19"],"enrollment":0,"completionDate":"2022-11"},{"nctId":"NCT06610643","phase":"NA","title":"Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-21","conditions":["COVID-19","SARS-CoV-2","Immunocompromised"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":["Corona Virus Infection"],"enrollment":1552,"completionDate":"2023-09-25"},{"nctId":"NCT05038488","phase":"PHASE2","title":"Phase 2a MIB-626 vs. Placebo COVID-19","status":"COMPLETED","sponsor":"Metro International Biotech, LLC","startDate":"2021-10-26","conditions":["Covid19","Stage 1 Acute Kidney Injury"],"enrollment":42,"completionDate":"2023-08-17"},{"nctId":"NCT05882331","phase":"NA","title":"Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19","status":"COMPLETED","sponsor":"Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases","startDate":"2021-01-01","conditions":["COVID-19"],"enrollment":7,"completionDate":"2024-08-06"},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":["Community-acquired Pneumonia, Influenza, COVID-19"],"enrollment":20000,"completionDate":"2028-02"},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":["SARS-CoV-2 Infection (COVID-19)"],"enrollment":2200,"completionDate":"2025-12-31"},{"nctId":"NCT04351503","phase":"","title":"A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-04-09","conditions":["SARS Coronavirus (SARS-CoV-2) Infection"],"enrollment":126586,"completionDate":"2022-07-31"},{"nctId":"NCT05060705","phase":"PHASE2","title":"\"Efesovir\" (FS-1) for COVID-19, Phase 2","status":"NOT_YET_RECRUITING","sponsor":"Scientific Center for Anti-infectious Drugs, Kazakhstan","startDate":"2025-12","conditions":["Covid19"],"enrollment":62,"completionDate":"2026-11"},{"nctId":"NCT04970719","phase":"PHASE3","title":"Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2021-07-10","conditions":["COVID-19 Pneumonia"],"enrollment":0,"completionDate":"2021-12"},{"nctId":"NCT04681040","phase":"","title":"Risk Stratification of COVID-19 Using Urine Biomarkers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2020-09-15","conditions":["Covid19","Urine","Biomarker","Acute Respiratory Failure With Hypoxia"],"enrollment":964,"completionDate":"2024-03-25"},{"nctId":"NCT05239988","phase":"","title":"Observational Study in COVID-19 Patients Treated With Remdesivir","status":"COMPLETED","sponsor":"Fadoi Foundation, Italy","startDate":"2021-11-24","conditions":["Hospitalization"],"enrollment":1004,"completionDate":"2022-06-30"},{"nctId":"NCT05780541","phase":"PHASE3","title":"PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-15","conditions":["COVID-19"],"enrollment":58,"completionDate":"2023-07-14"},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":["COVID-19","Hospitalized COVID-19 Patients"],"enrollment":1000,"completionDate":"2025-12-30"},{"nctId":"NCT04431453","phase":"PHASE2,PHASE3","title":"Study of Remdesivir in Participants Below 18 Years Old With COVID-19","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-07-21","conditions":["COVID-19"],"enrollment":59,"completionDate":"2023-02-10"},{"nctId":"NCT05780424","phase":"PHASE3","title":"BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-16","conditions":["COVID-19"],"enrollment":353,"completionDate":"2022-10-10"},{"nctId":"NCT05780463","phase":"PHASE3","title":"MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-06-11","conditions":["COVID-19"],"enrollment":485,"completionDate":"2023-06-08"},{"nctId":"NCT05780281","phase":"PHASE3","title":"VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-16","conditions":["COVID-19"],"enrollment":367,"completionDate":"2022-10-04"},{"nctId":"NCT05780268","phase":"PHASE3","title":"LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":["COVID-19"],"enrollment":314,"completionDate":"2021-02-01"},{"nctId":"NCT04713176","phase":"PHASE3","title":"Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-02-02","conditions":["Severe COVID-19"],"enrollment":240,"completionDate":"2022-12-09"},{"nctId":"NCT04593940","phase":"PHASE3","title":"Immune Modulators for Treating COVID-19","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2020-10-15","conditions":["Covid19"],"enrollment":1971,"completionDate":"2022-03-05"},{"nctId":"NCT04321993","phase":"PHASE2","title":"Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","status":"UNKNOWN","sponsor":"Lisa Barrett","startDate":"2020-04-17","conditions":["COVID-19"],"enrollment":363,"completionDate":"2024-04"},{"nctId":"NCT05407597","phase":"PHASE2,PHASE3","title":"Inhibition of Bradykinin in COVID-19 Infection With Icatibant","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2022-05-16","conditions":["SARS CoV 2 Infection"],"enrollment":32,"completionDate":"2023-07-07"},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":["Covid19"],"enrollment":2753,"completionDate":"2023-07-14"},{"nctId":"NCT04727775","phase":"","title":"Antiviral Drugs on the Treatment of SARS-CoV-2","status":"COMPLETED","sponsor":"Astana Medical University","startDate":"2020-12-01","conditions":["Complication of Medical Care","Pneumonia, Viral"],"enrollment":150,"completionDate":"2023-07-25"},{"nctId":"NCT05502081","phase":"PHASE4","title":"Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients","status":"COMPLETED","sponsor":"Mansoura University Hospital","startDate":"2022-09-02","conditions":["COVID-19"],"enrollment":265,"completionDate":"2022-12-28"},{"nctId":"NCT04756128","phase":"PHASE2","title":"Impact of Colchicine and Low-dose Naltrexone on COVID-19","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2021-01-25","conditions":["Covid19"],"enrollment":142,"completionDate":"2021-12-12"},{"nctId":"NCT04391309","phase":"PHASE2","title":"COVID-19 and Anti-CD14 Treatment Trial","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-12","conditions":["Coronavirus Disease 2019 (COVID-19)","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)"],"enrollment":49,"completionDate":"2022-02-04"},{"nctId":"NCT04582266","phase":"","title":"PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-31","conditions":["COVID-19"],"enrollment":54,"completionDate":"2022-04-13"},{"nctId":"NCT04988035","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-03","conditions":["COVID-19"],"enrollment":201,"completionDate":"2022-04-23"},{"nctId":"NCT04583969","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":["COVID-19"],"enrollment":527,"completionDate":"2022-04-22"},{"nctId":"NCT04583956","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":["COVID-19"],"enrollment":214,"completionDate":"2021-09-13"},{"nctId":"NCT04745351","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-03-31","conditions":["COVID-19"],"enrollment":249,"completionDate":"2022-05-24"},{"nctId":"NCT05151094","phase":"","title":"Registry of Hospitalized Patients in University Hospital Dubrava Respiratory Center","status":"UNKNOWN","sponsor":"University Hospital Dubrava","startDate":"2021-04-01","conditions":["Covid19","Thrombosis","Bleeding","Sepsis","Mechanical Ventilation Complication","Inflammatory Response"],"enrollment":6000,"completionDate":"2026-01-01"},{"nctId":"NCT04314817","phase":"","title":"Adverse Events Related to Treatments Used Against Coronavirus Disease 2019","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2020-03-17","conditions":["Coronavirus","Iatrogenic Disease","Acute Kidney Injury","ARDS, Human"],"enrollment":1000,"completionDate":"2023-01-01"},{"nctId":"NCT04672564","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients","status":"TERMINATED","sponsor":"Shenyang Tonglian Group CO., Ltd","startDate":"2021-03-30","conditions":["Coronavirus Disease 2019"],"enrollment":93,"completionDate":"2022-05-09"},{"nctId":"NCT05187793","phase":"PHASE3","title":"Study of Efficacy of Different Treatment Regimens of Olokizumab","status":"UNKNOWN","sponsor":"R-Pharm","startDate":"2021-07-08","conditions":["COVID-19"],"enrollment":198,"completionDate":"2023-04"},{"nctId":"NCT05226533","phase":"PHASE2","title":"Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-03-31","conditions":["COVID-19"],"enrollment":1,"completionDate":"2022-12-21"},{"nctId":"NCT04401410","phase":"PHASE1","title":"Anti-SARS Cov-2 T Cell Infusions for COVID 19","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2020-11-04","conditions":["SARS-CoV 2","Viral Infection","COVID 19"],"enrollment":4,"completionDate":"2021-10-12"},{"nctId":"NCT04854837","phase":"","title":"Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis","status":"COMPLETED","sponsor":"Semmelweis University","startDate":"2021-04-12","conditions":["Covid19","End Stage Renal Failure on Dialysis"],"enrollment":45,"completionDate":"2022-09-30"},{"nctId":"NCT04962347","phase":"","title":"Real World Study of COVID-19 in a Flyover Region","status":"COMPLETED","sponsor":"Tulane University","startDate":"2021-10-14","conditions":["Covid19"],"enrollment":1800,"completionDate":"2022-10-18"},{"nctId":"NCT04978051","phase":"PHASE2","title":"Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection","status":"COMPLETED","sponsor":"Sebastian Videla","startDate":"2021-04-12","conditions":["COVID-19 Pneumonia"],"enrollment":73,"completionDate":"2022-03-17"},{"nctId":"NCT04404608","phase":"","title":"Etiology of Lymphopenia in Covid19 Infection","status":"COMPLETED","sponsor":"Dr Medhat Khafagy","startDate":"2020-06-01","conditions":["Lymphopenia"],"enrollment":172,"completionDate":"2021-12-01"},{"nctId":"NCT04978259","phase":"PHASE4","title":"SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)","status":"UNKNOWN","sponsor":"Clinical Urology and Epidemiology Working Group","startDate":"2021-07-24","conditions":["Covid19"],"enrollment":202,"completionDate":"2023-12-31"},{"nctId":"NCT04640168","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 4 (ACTT-4)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-02","conditions":["COVID-19"],"enrollment":1010,"completionDate":"2021-06-18"},{"nctId":"NCT04977960","phase":"PHASE2","title":"Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2022-09","conditions":["COVID-19 Acute Respiratory Distress Syndrome"],"enrollment":180,"completionDate":"2023-12"},{"nctId":"NCT05045937","phase":"","title":"Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19","status":"UNKNOWN","sponsor":"Patrick Robinson","startDate":"2022-05-01","conditions":["Covid19","COVID-19 Pneumonia","COVID-19 Respiratory Infection","COVID-19 Acute Bronchitis"],"enrollment":1000,"completionDate":"2024-05-01"},{"nctId":"NCT04980534","phase":"NA","title":"Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip","status":"COMPLETED","sponsor":"Catalysis SL","startDate":"2021-01-08","conditions":["Covid19","COVID-19 Pneumonia","COVID-19 Respiratory Infection","Viral Infection","Respiratory Tract Infections","Infection, Coronavirus","SARS-CoV2 Infection"],"enrollment":80,"completionDate":"2021-09-15"},{"nctId":"NCT04546581","phase":"PHASE3","title":"Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-10-08","conditions":["COVID","COVID-19","SARS-CoV-2","SARS (Severe Acute Respiratory Syndrome)"],"enrollment":593,"completionDate":"2021-05-21"},{"nctId":"NCT05279391","phase":"NA","title":"Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19","status":"UNKNOWN","sponsor":"Democritus University of Thrace","startDate":"2020-10-25","conditions":["COVID-19 Severe Respiratory Failure"],"enrollment":150,"completionDate":"2023-12-31"},{"nctId":"NCT04492475","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 3 (ACTT-3)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":["COVID-19"],"enrollment":969,"completionDate":"2020-12-21"},{"nctId":"NCT04280705","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial (ACTT)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-21","conditions":["COVID-19"],"enrollment":1062,"completionDate":"2020-05-21"},{"nctId":"NCT04401579","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 2 (ACTT-2)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-05-08","conditions":["COVID-19"],"enrollment":1033,"completionDate":"2020-07-31"},{"nctId":"NCT04539262","phase":"PHASE1,PHASE2","title":"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-09-14","conditions":["COVID-19"],"enrollment":156,"completionDate":"2021-03-22"},{"nctId":"NCT05024006","phase":"NA","title":"Public Health Emergency: SOLIDARITY TRIAL Philippines","status":"COMPLETED","sponsor":"University of the Philippines","startDate":"2020-04-23","conditions":["Covid19"],"enrollment":1314,"completionDate":"2021-04-17"},{"nctId":"NCT04302766","phase":"","title":"Expanded Access Remdesivir (RDV; GS-5734™)","status":"NO_LONGER_AVAILABLE","sponsor":"U.S. Army Medical Research and Development Command","startDate":"","conditions":["Coronavirus Disease 2019"],"enrollment":0,"completionDate":""},{"nctId":"NCT02818582","phase":"PHASE2","title":"GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-07-01","conditions":["Ebola"],"enrollment":38,"completionDate":"2020-08-31"},{"nctId":"NCT04409262","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-06-16","conditions":["COVID-19 Pneumonia"],"enrollment":649,"completionDate":"2021-03-08"},{"nctId":"NCT05222113","phase":"","title":"OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA","status":"COMPLETED","sponsor":"Bernadette Dian Novita, MD.,PhD","startDate":"2021-08-01","conditions":["Duration of Hospitalization","Clinical Manifestation of COVID-19"],"enrollment":87,"completionDate":"2021-09-25"},{"nctId":"NCT05184127","phase":"PHASE2","title":"Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19","status":"COMPLETED","sponsor":"National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia","startDate":"2021-04-27","conditions":["COVID-19"],"enrollment":156,"completionDate":"2021-09-07"},{"nctId":"NCT05185284","phase":"PHASE3","title":"Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2021-08-11","conditions":["COVID-19"],"enrollment":217,"completionDate":"2021-12-30"},{"nctId":"NCT04501952","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2020-09-18","conditions":["COVID-19"],"enrollment":584,"completionDate":"2021-05-06"},{"nctId":"NCT05083000","phase":"PHASE1","title":"Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2021-08-16","conditions":["COVID-19 Respiratory Infection"],"enrollment":24,"completionDate":"2022-03-31"},{"nctId":"NCT03719586","phase":"PHASE2,PHASE3","title":"Investigational Therapeutics for the Treatment of People With Ebola Virus Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-11-21","conditions":["Ebola Virus"],"enrollment":681,"completionDate":"2020-08-18"},{"nctId":"NCT04385719","phase":"PHASE2","title":"Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy","status":"COMPLETED","sponsor":"Makerere University","startDate":"2021-05-05","conditions":["Ebola","HIV/AIDS"],"enrollment":24,"completionDate":"2021-07-16"},{"nctId":"NCT04596839","phase":"PHASE2","title":"Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Dr. Md. Alimur Reza","startDate":"2020-09-04","conditions":["Covid19"],"enrollment":60,"completionDate":"2021-04-30"},{"nctId":"NCT04859244","phase":"PHASE1","title":"First-in-Human Study of Orally Administered GS-441524 for COVID-19","status":"COMPLETED","sponsor":"Copycat Sciences LLC","startDate":"2021-01-01","conditions":["COVID-19"],"enrollment":1,"completionDate":"2021-08-01"},{"nctId":"NCT04869579","phase":"PHASE2","title":"Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.","status":"UNKNOWN","sponsor":"CHRISTUS Health","startDate":"2021-08-15","conditions":["Covid19"],"enrollment":100,"completionDate":"2021-12-15"},{"nctId":"NCT04345419","phase":"PHASE2,PHASE3","title":"Remdesivir Efficacy in Coronavirus Disease","status":"COMPLETED","sponsor":"Tanta University","startDate":"2020-06-16","conditions":["COVID"],"enrollment":200,"completionDate":"2020-12-01"},{"nctId":"NCT04904783","phase":"NA","title":"Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study","status":"UNKNOWN","sponsor":"Mahatma Gandhi Institute of Medical Sciences","startDate":"2021-06-01","conditions":["COVID-19","Pneumonia"],"enrollment":20,"completionDate":"2021-12-31"},{"nctId":"NCT04944082","phase":"PHASE4","title":"Remdesivir- Ivermectin Combination Therapy in Severe Covid-19","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-07-01","conditions":["Covid19"],"enrollment":60,"completionDate":"2021-12-31"},{"nctId":"NCT04647669","phase":"PHASE3","title":"World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments","status":"UNKNOWN","sponsor":"The University of The West Indies","startDate":"2021-06-01","conditions":["Covid19"],"enrollment":100,"completionDate":"2021-12-31"},{"nctId":"NCT04871633","phase":"NA","title":"Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2020-08-01","conditions":["COVID-19"],"enrollment":66,"completionDate":"2020-12-30"},{"nctId":"NCT04853901","phase":"PHASE3","title":"Remdesivir Efficacy In Management Of COVID-19 Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-07-27","conditions":["Covid19"],"enrollment":77,"completionDate":"2021-03-01"}],"_emaApprovals":[{"date":"2020-03-07","status":"Authorised","company":"Gilead Sciences Ireland UC"}],"genericFilers":[],"latestUpdates":[{"url":"https://s29.q4cdn.com/585078350/files/doc_financials/2025/q4/GILD-Q425-FY25-Earnings-Press-Release-10-February-2026.pdf","date":"2026-04-07","type":"news","title":"[PDF] gilead sciences announces fourth quarter and full year 2025 ...","source":"s29.q4cdn.com"},{"url":"https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2796682:0-gild-2025-revenue-and-eps-rose-on-hiv-and-liver-drugs-2026-outlook-strong-despite-veklury-decline/","date":"2026-04-07","type":"news","title":"GILD: 2025 revenue and EPS rose on HIV and liver drugs; 2026 ...","source":"www.tradingview.com"},{"url":"https://www.pharmaceutical-technology.com/news/gilead-expects-6-of-hiv-sales-growth-in-2026-with-800m-yeztugo-target/","date":"2026-04-07","type":"news","title":"Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo ...","source":"www.pharmaceutical-technology.com"},{"url":"https://www.gilead.com/news/news-details/2022/fda-approves-veklury-remdesivir-for-the-treatment-of-non-hospitalized-patients-at-high-risk-for-covid-19-disease-progression","date":"2026-04-07","type":"news","title":"FDA Approves Veklury® (Remdesivir) for the Treatment of Non ...","source":"www.gilead.com"},{"url":"https://investors.gilead.com/news/news-details/2023/FDA-Approves-Veklury-Remdesivir-for-COVID-19-Treatment-in-Patients-With-Severe-Renal-Impairment-Including-Those-on-Dialysis/default.aspx","date":"2026-04-07","type":"news","title":"FDA Approves Veklury® (Remdesivir) for COVID-19 ...","source":"investors.gilead.com"}],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Veklury"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Veklury"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"333266","NDDF":"018308","UNII":"3QKI37EEHE","CHEBI":"CHEBI:145994","VANDF":"4039395","INN_ID":"10478","RXNORM":"2284718","UMLSCUI":"C4726677","chemblId":"CHEMBL5280654","ChEMBL_ID":"CHEMBL4065616","KEGG_DRUG":"D11472","DRUGBANK_ID":"DB14761","PUBCHEM_CID":"121304016","SNOMEDCT_US":"870518005","IUPHAR_LIGAND_ID":"10715","MESH_SUPPLEMENTAL_RECORD_UI":"C000606551"},"formularyStatus":[],"originalProduct":{"form":"INJECTION","route":"INTRAVENOUS","company":"Gilead Sciences, Inc.","brandName":"Veklury","isOriginal":true,"marketingStatus":"UNAPPROVED DRUG OTHER"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"2020-","companyName":"Gilead Sciences","relationship":"Original Developer"},{"period":"2020","companyName":"Gilead Sciences Ireland UC","relationship":"EMA Licensee"},{"period":"2020","companyName":"Gilead Sciences K.K.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"tmax":"0.67–0.68 hours (remdesivir); 1.51–2.00 hours (GS-441524); 0.75 hours (GS-704277)","halfLife":"1 hour (remdesivir); 27 hours (GS-441524 metabolite); 1.3 hours (GS-704277 metabolite)","clearance":"","excretion":"Remdesivir: 10% urine, metabolism is major route; GS-441524: 49% urine, 0.5% feces; GS-704277: 2.9% urine via glomerular filtration and active tubular secretion","metabolism":"CES1 (80%), Cathepsin A (10%), CYP3A (10%); GS-441524 not significantly metabolized; GS-704277 metabolized via HINT1","proteinBinding":"88–93.6% (remdesivir); 2% (GS-441524); 1% (GS-704277)","bioavailability":"","volumeOfDistribution":""},"publicationCount":4568,"therapeuticAreas":["Metabolic"],"_revenueScrapedAt":"2026-04-08 13:58:46.177491+00","atcClassification":{"source":"DrugCentral","atcCode":"J05AB16","allCodes":["J05AB16"]},"biosimilarFilings":[],"originalDeveloper":"Gilead Sciences Inc","commercialAnalysis":{"text":"Veklury (remdesivir) by Gilead Sciences has experienced a decline in sales, with product sales excluding Veklury increasing 4% year-over-year to $28.0 billion for full-year 2025 [1]. This decline is partially offset by higher sales of HIV and Liver Disease products, as stated in Gilead's fourth-quarter and full-year 2025 financial results [1]. Despite this, Veklury remains a significant contributor to Gilead's revenue, with $1.2 billion in revenue in 2025 [2].\n\nThe competitive landscape for Veklury is intense, with several competitors emerging in the market. However, Gilead's strong portfolio of HIV and Liver Disease products, including Biktarvy and Descovy, continues to drive growth and offset the decline in Veklury sales [1]. The company's recent launch of Yeztugo, a twice-yearly HIV prevention therapy, is expected to contribute to future growth, with analysts predicting 433% year-over-year growth [3].\n\nKey upcoming catalysts for Veklury include the potential for label expansions and the emergence of pipeline competitors. However, Gilead's strong pipeline and recent launches are expected to mitigate these risks and drive continued growth [1]. The company's 2026 guidance projects continued growth, with new launches and ongoing risks from regulatory and market pressures [2].\n\nOverall, Veklury's market position and revenue trajectory are influenced by the company's strong portfolio of HIV and Liver Disease products. While the competitive landscape is intense, Gilead's recent launches and pipeline are expected to drive continued growth and mitigate risks [1, 2, 3].\n\nReferences:\n[1] Gilead Sciences, Inc. (2026) [PDF] gilead sciences announces fourth quarter and full year 2025 financial results [Source: s29.q4cdn.com]\n[2] GILD: 2025 revenue and EPS rose on HIV and liver drugs; 2026 outlook strong despite Veklury decline [Source: www.tradingview.com]\n[3] Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target [Source: www.pharmaceutical-technology.com]","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://s29.q4cdn.com/585078350/files/doc_financials/2025/q4/GILD-Q425-FY25-Earnings-Press-Release-10-February-2026.pdf","date":"","title":"[PDF] gilead sciences announces fourth quarter and full year 2025 ...","source":"s29.q4cdn.com"},{"url":"https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2796682:0-gild-2025-revenue-and-eps-rose-on-hiv-and-liver-drugs-2026-outlook-strong-despite-veklury-decline/","date":"","title":"GILD: 2025 revenue and EPS rose on HIV and liver drugs; 2026 ...","source":"www.tradingview.com"},{"url":"https://www.pharmaceutical-technology.com/news/gilead-expects-6-of-hiv-sales-growth-in-2026-with-800m-yeztugo-target/","date":"","title":"Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo ...","source":"www.pharmaceutical-technology.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"date":"2026 Mar 6","pmid":"41901743","title":"Therapeutic Drug Monitoring of GS-441524 in Cats with Feline Infectious Peritonitis: Pharmacokinetic Variability and Implications for Dose Optimization.","journal":"Pathogens (Basel, Switzerland)"},{"date":"2026 Mar 18","pmid":"41893449","title":"Successful Treatment of Persistent and Relapsing COVID-19 with Ensitrelvir in a Patient with Obinutuzumab-Induced Long-Term B-Cell Depletion: A Case Report.","journal":"Reports (MDPI)"},{"date":"2026 Mar","pmid":"41889454","title":"Outcome of and Risk Factors for Mortality in Pediatric Coronavirus Disease 2019 Encephalitis During the 2022 Omicron Wave in Taiwan: A National Retrospective Study.","journal":"Open forum infectious diseases"},{"date":"2026 Mar 15","pmid":"41887113","title":"Discovery of orally bioavailable N-acylated remdesivir derivatives with potent broad-spectrum antiviral activity.","journal":"Bioorganic chemistry"},{"date":"2026 Mar 24","pmid":"41876770","title":"In silico evaluation of FDA-approved antivirals and corticosteroids against SARS-CoV-2.","journal":"Scientific reports"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Gilead Sciences Inc","companyId":"gilead","modality":"Small molecule antiviral","firstApprovalDate":"2020","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2020-03-07T00:00:00.000Z","mah":"Gilead Sciences Ireland UC","brand_name_local":"","application_number":""},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2020-05-07T00:00:00.000Z","mah":"Gilead Sciences K.K.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-10-22T00:00:00.000Z","mah":"GILEAD SCIENCES INC","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2020-10-22T00:00:00.000Z","mah":"GILEAD SCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2020-10-22T00:00:00.000Z","mah":"GILEAD SCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2020-10-22T00:00:00.000Z","mah":"GILEAD SCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2020-10-22T00:00:00.000Z","mah":"GILEAD SCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2020-10-22T00:00:00.000Z","mah":"GILEAD SCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-12-19T00:00:00.000Z","mah":"GILEAD SCIENCES INC","brand_name_local":null,"application_number":"NDA214787"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"regulatorySummaries":{"US_FDA_approval_10979":{"country_code":"US","agency":"FDA","entity_type":"approval","entity_id":"10979","summary_short":"GILEAD SCIENCES INC received FDA marketing authorisation for Veklury on 2024-12-19 under NDA214787.","summary_long":"GILEAD SCIENCES INC received marketing authorisation for Veklury from the FDA on 2024-12-19. The application number for this approval is NDA214787. The marketing authorisation holder is GILEAD SCIENCES INC, and the drug's indication is listed in the labelling.","key_points":["Veklury received marketing authorisation from the FDA on 2024-12-19.","The marketing authorisation holder is GILEAD SCIENCES INC.","The application number for this approval is NDA214787."],"citations":[{"source":"https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214787"}],"generated_at":"2026-05-18T08:23:36.990Z"}},"trialStats":{"total":23,"withResults":13},"validation":{"fieldsValidated":7,"lastValidatedAt":"2026-04-20T08:34:39.998229+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}